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ABSTRACT
 The management and outcomes of patients with coronary heart disease (CHD) have improved considerably 
in Portugal in the last three decades. However, important challenges and opportunities remain to achieve the 
optimal delivery and assessment of care, particularly to vulnerable groups; namely women, patients with 
a lower socioeconomic position, and patients from the interior and rural regions. The lack of availability of 
disaggregated data, and complexity of their interpretation due to the interplay of multiple patient and/or 
health system level factors determining different CHD results, makes the task of assessing inequalities in 
CHD management and outcomes in Portugal a stimulating and useful challenge.
The specific objectives of this work were: 1) to describe time trends in death rates, absolute number of 
deaths and years of life lost from CHD among men and women in Portugal, by region, during the period 
1981–2012; 2) to analyse sex differences in conservative versus invasive management of patients with acute 
coronary syndrome (ACS) in 10 hospitals with different characteristics; 3) to assess differences by sex in 
management and outcomes (30-day mortality) of patients with acute myocardial infarction (AMI), by the 
application of standard quality indicators (QIs); 4) to analyse sex differences in presenting symptoms of ACS; 
5) to assess the proportion of patients with a first episode of ACS who reported chest pain, medical care 
seeking and performance of exams because of the pain; and to identify determinants of seeking medical 
advice and referral to electrocardiogram (ECG).
Different sources of data were used. We performed a secondary analysis of data of population at risk 
and number of deaths from CHD between 1981 and 2012, disaggregated by sex, age and region, which was 
provided by Statistics Portugal. To analyse the regional variation in CHD mortality trends, we used joinpoint 
regression analysis to calculate the annual percent change in age-standardised mortality rates, and the 
Global Burden of Disease method to obtain years of life lost (YLL) due to premature mortality for CHD.
The remaining data were provided by two cohort studies of patients consecutively discharged with 
a type 1 ACS: the EURHOBOP study, retrospective and multinational, performed in seven countries, and 
within Portugal, in 10 hospitals covering different regions, from North to South, and including both coastal 
and interior regions; and the EPIHeart study, prospective and performed in two northern Portuguese 
hospitals, one in the coast and one in the interior.
Within the EURHOBOP study, which included patients admitted between 2008 and 2010, we analysed, by 
review of medical records, performance of coronary angiography, reperfusion and revascularisation by sex in 
2941 Portuguese patients with an ACS.
The EPIHeart study comprised 939 patients and was assembled between August 2013 and December 
2014. Detailed information was collected through questionnaires and review of medical records. Within the 
4EPIHeart study, twenty QIs for the key aspects of the AMI care pathway were calculated for 771 patients; 
clinical presentation by sex was evaluated in 873 patients through a face-to-face interview; and reported 
chest pain within the preceding six months of the event and health system resources seeking behaviour and 
utilisation were analysed in 690 patients with a first episode of ACS.
In Portugal, between 1981 and 2012, relative declines of CHD mortality indicators were different by 
geographic region. Consistent decreases in mortality rates were only observed in the Centre, Lisbon and 
North, smaller declines were observed in Alentejo, and later declines, after 2003, in Algarve and Madeira. 
Across the country, the YLL from CHD decreased from 1981 to 2012 (mainly after 2000), with the lowest 
decreases in Alentejo and the highest in Madeira. Lisbon and the North were the two geographic regions 
with the lowest YLL. In most regions, greater declines in mortality rates were observed among women 
compared to men.
We found that women diagnosed with ST elevation myocardial infarction (STEMI) or ACS with left bundle 
branch block, but not with non-ST elevation acute coronary syndrome (NSTEACS), had a lower probability when 
compared with men to be submitted to coronary angiography (adjusted odds ratio [OR] 1.64, 95% confidence 
interval [95% CI] 1.11–2.44). There was no difference in the performance of reperfusion and revascularisation 
by sex among those managed invasively, for the whole spectrum of ACS presentation.
The application of QIs showed that specific evidence-based management strategies for AMI patients 
need increased implementation in clinical practice, namely the assessment of ischemic and bleeding risk 
using GRACE and CRUSADE prognostic tools, and the use of fondaparinux in eligible patients. Through the 
use of time dependent QIs, we found that fewer eligible women with AMI received timely reperfusion than 
men, corroborating previous findings. We also found differences in long term secondary prevention; fewer 
women with AMI were discharged on dual antiplatelet therapy, on high intensity statins and were referred 
to cardiac rehabilitation than men. Women received recommended interventions at a whole (59.6% vs 
65.2%, p<0.001) less often compared with men, and also had a higher mean GRACE 2.0 risk score adjusted 
30-day mortality (3.0% vs 1.7%, p<0.001), which was inversely associated with the composite QI (OR 0.08, 
95% CI 0.01-0.64) for the highest performance tertile compared with the lowest).
A distinct clinical presentation between women and men suffering an ACS may contribute to differences 
in management and outcomes. Chest pain was reported by 82% of patients, with no differences in frequency 
or location between sexes. Women were more likely to feel pain with an intensity higher than 8/10, and 
this association was stronger for patients under 65 years old (interaction p=0.028), and referred pain 
particularly to typical and atypical locations simultaneously. The multiple symptoms cluster, which was 
characterized by a high probability of presenting with all symptoms, was almost four-fold more prevalent 
in women (OR 3.92, 95% CI 2.21–6.98) than in men, and was associated with a higher 30-day mortality rate 
adjusted for the GRACE 2.0 risk score (4.9% vs 0.9% for the two other clusters, p<0.001). 
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Chest pain in the six months preceding the index ACS was reported by 61% of patients, 43% sought the 
health care system, mainly the public sector, less than half of them had an ECG performed, and in nearly 
40% the pain was attributed to a problem of the heart. Patients with hypertension were more likely (OR 2.13, 
95% CI 1.29-3.51) to seek the health care system because of preceding chest pain, while former smokers 
(OR 0.52, 95% CI 0.28-0.99) and patients from the upper middle/upper social class (OR 0.16, 95% CI 0.05-
0.48) were less likely to do so. Electrocardiogram was performed more frequently by men (OR 2.56, 95% CI 
1.11-5.87), patients with a health subsystem (OR 3.88, 95% CI 1.11-13.53) and patients from the northeastern 
region (OR 9.07, 95% CI 4.07-20.24); and less frequently by patients with cognitive impairment (OR 0.37, 95% 
CI 0.15-0.92) and those who were employed (OR 0.36, 95% CI 0.14-0.97).
In conclusion, inequalities in CHD in Portugal are present at different levels, in acute and long term 
management and in outcomes; according to region, sex/gender and socioeconomic position. Opportunities 
and insights for intervention to improve diagnosis, management and outcomes throughout the CHD 
continuum in different vulnerable groups were identified. Policies, programmes and practices will only 
successfully reach the most vulnerable, if data are available to identify, not only where the inequalities are, 
but importantly what are their underlying mechanisms. Additionally, there is a complex interplay between 
patient and health system characteristics, present throughout the whole CHD pathway of care, from 
perception of need to benefiting from care.
6
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RESUMO
Nas últimas três décadas houve uma melhoria significativa na abordagem e resultados da doença 
coronária em Portugal. Continuam, no entanto, a existir desafios e oportunidades para melhorar a qualidade 
do tratamento e da monitorização, particularmente de grupos vulneráveis como as mulheres, doentes de 
grupos socioeconómicos desfavorecidos e de regiões rurais ou do interior. A avaliação das desigualdades 
na abordagem e resultados da doença coronária em Portugal é um desafio estimulante e útil, em virtude de 
limitações relacionadas com a disponibilidade de dados desagregados e da complexidade de interpretação 
dos resultados, que são consequência da interação de múltiplos fatores ao nível do doente e/ou do sistema.
Os objetivos específicos deste trabalho foram: 1) descrever a evolução da taxa de mortalidade, número de 
óbitos e anos de vida perdidos por doença coronária em homens e mulheres em Portugal, por região, para o 
período compreendido entre 1981 e 2012; 2) analisar as diferenças por sexo na abordagem conservadora versus 
invasiva de doentes com síndrome coronária aguda (SCA) em 10 hospitais com distintas características; 3) 
avaliar as diferenças por sexo na abordagem e resultados (mortalidade aos 30 dias) de doentes com enfarte 
agudo do miocárdio (EAM), através da aplicação de indicadores de qualidade predefinidos; 4) analisar as 
diferenças por sexo na apresentação clínica da SCA; 5) avaliar a proporção de doentes com o primeiro episódio 
de SCA com dor torácica prévia ao evento, procura de cuidados médicos e realização de exames devido à dor; 
e identificar determinantes de procura de aconselhamento médico e de pedido de eletrocardiograma (ECG).
Foram usadas diferentes fontes de dados. Foi realizada uma análise secundária de dados da 
população em risco e número de óbitos por doença coronária entre 1981 e 2012, desagregados por sexo, 
idade e região, disponibilizados pelo Instituto Nacional de Estatística. Para analisar a variação regional 
na evolução da mortalidade por doença coronária, usámos análise de regressão joinpoint para calcular 
a variação percentual anual da taxa de mortalidade padronizada para a idade. O número de anos de vida 
perdidos por mortalidade precoce devido a doença coronária foi calculado através do método do estudo 
Global Burden of Disease.
Os restantes dados foram obtidos através de dois estudos de coorte que incluíram doentes 
consecutivos com o diagnóstico de alta de SCA tipo 1: o estudo EURHOBOP, retrospetivo e multinacional, 
realizado em sete países, e em Portugal em 10 hospitais em diferentes regiões, de Norte a Sul e incluindo 
regiões do litoral e do interior; e o estudo EPIHeart, prospetivo e realizado em 2 hospitais do norte de 
Portugal, um no litoral e um no interior.
Com dados do estudo EURHOBOP, que incluiu doentes internados entre 2008 e 2010, analisámos a 
realização de angiografia coronária, reperfusão e revascularização por sexo em 2941 doentes Portugueses 
com SCA, informação obtida através da revisão dos registos médicos.
8O estudo EPIHeart incluiu 939 doentes entre agosto de 2013 e dezembro de 2014. Através de questionários 
e revisão de registos médicos foi recolhida informação detalhada. Com dados do estudo EPIHeart, foram 
calculados 20 indicadores de qualidade relativos aos principais componentes da abordagem do EAM para 
771 doentes; a apresentação clínica por sexo foi avaliada em 873 doentes através de uma entrevista; a 
presença de dor torácica nos seis meses anteriores ao evento e o comportamento relacionado com a 
procura e utilização de recursos do sistema de saúde foram avaliados em 690 doentes com um primeiro 
episódio de SCA, através da aplicação de outro questionário.
Em Portugal, entre 1981 e 2012, a redução relativa dos indicadores de mortalidade por doença 
coronária foi diferente por região. As regiões do Centro, Lisboa e Norte foram as únicas com diminuição 
consistente das taxas de mortalidade; o Alentejo apresentou menores reduções das taxas e no Algarve 
e na Madeira, o declínio foi mais tardio, após 2003. Em todo o país, os anos de vida perdidos por doença 
coronária diminuíram entre 1981 e 2012 (sobretudo após 2000), o Alentejo teve as menores reduções 
e a Madeira as maiores. Os anos de vida perdidos foram menores nas regiões de Lisboa e do Norte. Na 
maioria das regiões, as mulheres apresentaram reduções maiores na mortalidade por doença coronária 
do que os homens.
A probabilidade de realizar angiografia coronária foi menor nas mulheres com EAM com 
supradesnivelamento de ST ou com SCA com bloqueio completo de ramo esquerdo, mas não nas com 
SCA sem supradesnivelamento de ST, em comparação com os homens (odds ratio [OR] ajustado 1,64 
intervalo de confiança a 95% [IC 95%] 1,11-2,44). No subgrupo de doentes abordados de forma invasiva, 
não foi observada diferença na proporção de reperfusão e revascularização entre homens e mulheres, 
independentemente do tipo de SCA.
A aplicação dos indicadores de qualidade mostrou que há necessidade de promover a implementação 
na prática clínica de estratégias específicas de abordagem de doentes com EAM, nomeadamente a 
avaliação da estratificação do risco isquémico e hemorrágico usando as ferramentas prognósticas GRACE 
e CRUSADE e a utilização do fondaparinux nos doentes elegíveis. Através da utilização de indicadores 
de qualidade dependentes do tempo observámos que a reperfusão atempada nas mulheres com EAM 
elegíveis foi menos frequente do que nos homens, corroborando os resultados prévios. Também foram 
observadas diferenças na prevenção secundária de longo prazo; a proporção de mulheres com EAM que 
tiveram alta com dupla antiagregação e com estatinas de alta intensidade, e que foram referenciadas 
para reabilitação cardíaca foi menor em relação à observada para os homens. As mulheres receberam 
menos intervenções no global do que os homens (59,6% vs 65,2%, p<0,001) e apresentaram também uma 
maior mortalidade aos 30 dias ajustada para o score GRACE 2,0 (3,0% vs 1,7%, p<0,001), negativamente 
associada ao indicador de qualidade composto (OR 0,08 IC 95% 0,01-0,64 para o tercil de performance 
mais elevado comparado com o mais baixo).
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Uma apresentação clínica distinta entre mulheres e homens com SCA pode contribuir para diferenças na 
abordagem e nos resultados. Do total de doentes, 82% referiu dor torácica, não se observaram diferenças 
na frequência ou localização da dor entre mulheres e homens. As mulheres apresentaram dor com 
intensidade superior a 8/10, esta associação foi mais forte em doentes com menos de 65 anos de idade (p 
de interação=0,028), e dor referida, particularmente para localizações típicas e atípicas simultaneamente, 
mais frequentemente do que os homens. O cluster de múltiplos sintomas, caracterizado por elevada 
probabilidade de apresentar todos os sintomas, foi quase 4 vezes mais prevalente em mulheres do que 
em homens (OR 3,92 IC 95% 2,21-6,98) e associou-se a uma maior mortalidade aos 30 dias ajustada para 
o score de risco GRACE 2,0 (4,9% vs 0,9% para os dois restantes clusters, p<0,001).
Do total de doentes, 61% declararam ter tido dor torácica nos seis meses anteriores ao SCA índice, 
43% procuraram o sistema de saúde, principalmente o setor público, menos de metade destes realizaram 
ECG e em aproximadamente 40% a dor foi atribuída a um problema do coração. Os doentes hipertensos 
apresentaram maior probabilidade (OR 2,13 IC 95% 1,29-3,51) e os ex-fumadores (OR 0,52 IC 95% 0,28-
0,99) e doentes de classes sociais média alta/alta (OR 0,16 IC 95% 0,05-0,48) menor de procurar o sistema 
de saúde devido à dor torácica prévia ao SCA. O ECG foi realizado mais frequentemente em homens (OR 
2,56 IC 95% 1,11-5,87), em doentes com um subsistema de saúde (OR 3,88 IC 95% 1,11-13,53) e da região 
nordeste (OR 9,07 IC 95% 4,07-20,24); e menos frequentemente em doentes com deterioração cognitiva 
(OR 0,37 IC 95% 0,15-0,92) e com emprego (OR 0,36 IC 95% 0,14-0,97).
Concluindo, existem desigualdades na doença coronária em Portugal a diferentes níveis, na 
abordagem aguda e de longo prazo e nos resultados; por região, sexo/género e grupo socioeconómico. 
Foram identificadas oportunidades e dados para delinear estratégias para intervir no sentido de 
melhorar o diagnóstico, abordagem e resultados ao longo do continuum da doença coronária em 
diferentes grupos vulneráveis. Para que os grupos mais vulneráveis beneficiem de políticas, programas e 
práticas é fundamental existirem dados que permitam perceber onde estão as desigualdades e quais os 
mecanismos que lhe estão subjacentes. Há uma interface complexa entre as características do doente e 
do sistema de saúde, presente ao longo de todo o processo de abordagem da doença coronária, desde 
a perceção da necessidade até ao benefício do tratamento.
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1.1 Coronary heart disease
1.1.1 Cardiovascular risk factors
Epidemiological research on coronary heart disease (CHD) began with aetiological observational studies 
in the late 1940s; by the end of the 1960s, the concept of cardiovascular risk factors and the power of 
observational studies were well established [1,2]. Several modifiable variables associated with an increased risk 
of cardiovascular disease (CVD) were identified: elevated arterial blood pressure, elevated blood cholesterol, 
tobacco smoking, a sedentary lifestyle and diabetes [1,3-7]. The multifactorial origin of the disease tailored 
preventive research; the effect of multifactorial intervention strategies was studied at the population level 
and in high-risk people [8-10]. Controlled trials at the community level [11,12] and demonstration projects [13-
15] were also important to understand that differences in incidence of CHD between intervention and control 
groups were the result of the extent of differences achieved in cardiovascular risk profile [16].
INTERHEART [17], a large international case-control study evaluated the association between  various 
risk factors and acute myocardial infarction (AMI), by geographic region, ethnic origin, sex and age. 
Consistently in women and men, across all geographic regions and ethnic groups of the world, nine easily 
measured risk factors (smoking, raised Apolipoprotein B/Apolipoprotein A1 ratio, history of hypertension, 
diabetes, abdominal obesity, psychosocial factors, lack of daily consumption of fruits and vegetables, 
regular alcohol consumption, and a lack of regular physical activity) accounted for more than 90% of the 
risk of an AMI (population attributable risks: 90% in men and 94% in women).
Genetic factors contribute importantly to the risk of CHD, mostly in younger individuals [18], and in 
the past decade, there has been major progress in this area [19]. Results from the Framingham Offspring 
Study strengthened the role of heritability in the risk of CHD, by finding an age-specific incidence of CHD 
increase of more than two-fold after adjustment for conventional CHD risk factors in participants with a 
family history of premature disease [20]. The tools applied in genetic epidemiology, namely genome-wide 
association studies complemented by bioinformatic approaches have identified associations between 
several human traits and diseases; for CHD, 62 loci have been identified thus far, explaining 15% of the 
disease’s heritability [19,21,22]. Several CHD loci show substantial pleiotropy, more than one-third of the 
CHD loci showed an association with traditional cardiovascular risk factors and almost one-half of the 
CHD loci showed a strong or suggestive association with other diseases or traits [22]. The genetic basis 
of CHD derives from the cumulative effect of multiple common and small effect size risk alleles rather 
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than from rare variants with large effects on CHD risk [19]. More research is needed to understand the 
mechanisms by which these loci affect CHD risk.
Primary prevention management is based on the assessment of total cardiovascular risk. Proposed risk 
charts to evaluate total cardiovascular risk, for example the Systemic COronary Risk Evaluation (SCORE) 
[23], take conventional major cardiovascular risk factors into account. Other risk factors may be relevant 
for assessing total cardiovascular risk, mainly when the individual’s risk is close to a decisional threshold. 
Family history of premature CVD, socioeconomic position (SEP), social isolation or lack of social support, 
body mass index, or central obesity are among the modifiers considered to have reclassification potential 
[23]. Although genetic risk scores can improve CHD risk prediction beyond traditional risk factors, they 
are still not used in clinical practice [24-26].
The understanding of CHD causality is further complicated by the vast network of connections between 
characteristics of individuals, their lifestyles, and extrinsic social, economic and political context, which we 
will attempt to disentangle in this thesis.
1.1.2 Atherosclerosis
Coronary atherosclerosis is a complex, long lasting and continuously evolving inflammatory disease 
characterized by remodelling of the coronary arteries. In the 1980s, several insights of the pathogenesis 
of atherosclerosis were available [27]. During this time, the major components of atherosclerotic plaque 
considered were deposited lipids derived largely from the lower-density lipoproteins of the blood, and 
modified arterial smooth muscle cells with their synthesized connective tissue products. Endothelial 
dysfunction has been described, as was the role of other cells in addition to platelets to the progression 
of atherosclerotic plaque, including activated monocytes and monocyte-derived macrophages, injured 
endothelial cells and smooth muscle cells [27].
In the 1990s, the hypothesis that atherosclerosis lesions result from an excessive fibroproliferative 
response to various forms of insult to the endothelium and smooth muscle of the artery wall was 
advocated and evidence supported the idea that atherosclerosis could be reversed [28]. The endothelial 
cell, at this time, was considered a barrier gatekeeper and its important role in the vascular homeostasis 
had not yet been described. The following two decades were profitable to the study of mechanisms 
involved in the initiation and progression of atherosclerotic plaques. Evidence derived from cell 
biology and physiology, followed by biochemistry, pharmacology and bioengineering changed the 
understanding of the vital role of the vascular endothelium, and endothelial dysfunction is nowadays 
considered a pathogenic sine qua non for atherosclerotic CVD [29]. Endothelial dysfunction involves 
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impaired vasodilator capacity, mediated by nitric oxide [30] but also disturbances in antithrombotic, 
profibrinolytic, anti-inflammatory and antioxidant properties of the normal endothelium [31].
Life history of an atherosclerotic lesion
The earliest changes that are detectable in an atherosclerotic lesion are focal permeation, trapping 
and physicochemical modification of circulating lipoprotein particles in the subendothelial space [32]. 
This is the onset of the pathogenic sequence that originates foam cells (the hallmark of early fatty streak 
lesions), which involves the selective recruitment of circulating monocytes from the blood into the intima, 
its differentiation into macrophages and the internalization of modified lipoproteins [32,33]. Activated 
endothelium and macrophages elaborate multiple chemokines and growth factors that activate smooth 
muscle cells, promoting their proliferation and synthesis of extracellular matrix components within the 
intimal layer, creating a fibromuscular plaque. Progressive structural remodelling originates lesions with a 
fibrous cap, overlying a lipid-rich necrotic core. The edges of these complex plaques contain inflammatory 
cells, that intervene in the modulation of the endothelial pro-inflammatory phenotype, promoting the 
structural instability of the plaque [34]. These unstable or vulnerable plaques may trigger an acute 
clinical event, caused by atherothrombotic occlusion because of rupture, with luminal release of the 
highly thrombogenic contents of the necrotic core. Superficial intimal erosions without plaque rupture, a 
consequence of endothelial cell apoptosis and consequent localized endothelial denudation with thrombus 
formation [35], can also trigger an acute clinical event, namely an acute coronary syndrome (ACS) [36]. 
Characteristics of plaques prone to these superficial erosions have already been described. They contain 
abundant smooth muscle cells and proteoglycans, and few macrophages, and they are associated with 
regions of disturbed blood flow [35]. On the other hand, stable lesions have a thick fibrous cap, less lipid 
and inflammatory cell content, and typically do not precipitate atherothrombotic events, but can cause 
ischemic symptoms by reduction of the vessel lumen.
There are still several unknowns related to plaque progression and triggering of acute events. 
Findings from clinical, imaging and pathological studies have challenged commonly held notions of the 
pathophysiological features of atherosclerosis [36]. Evidence suggests the possibility of plaque rupture 
without forming an occlusive thrombus and provoking little consequences, and of mild erosions leading to 
occlusive thrombus [37]. Additionally, multiple atherosclerotic plaques, at different stages of pathobiologic 
evolution, can coexist in an individual [37].
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1.1.3 Clinical presentation
In Europe, CVD is responsible for more than four million deaths each year, accounting for 45% of all 
deaths (49% and 40% of all deaths in women and men, respectively) [38]. CHD and cerebrovascular disease 
are the most common causes of CVD deaths. The proportional decreases in age-standardised death rates 
over 10 years (to the latest year available), varied between European countries, ranging in men from 25.2% 
in Austria to 49.7% in Luxembourg, and in women from 25.3% in Italy to 42.9% in Portugal [38]. This is the 
result of effective primary and secondary prevention measures implemented mainly in the management 
of AMI and stroke [39]. Consequently, the initial presentations of CVD in contemporary practice have 
changed in comparison with the latter part of the last century, and the majority are heart failure, angina, 
transient ischemic attack and peripheral artery disease [39].
In particular, CHD presentation is a continuum, characterized by transition from unstable to stable 
syndromes or vice-versa, without a clear boundary [40]. Even reversible myocardial demand/supply 
mismatch episodes, related to transient ischaemia or hypoxia that causes minute troponine release below 
the threshold for AMI, have prognostic implications [41,42]. Stable CHD is characterized by episodes of 
reversible myocardial demand/supply mismatch, related to ischaemia or hypoxia and commonly associated 
with transient chest pain (angina pectoris). Stable CHD is usually caused by exercise, emotion or other 
stress, but may also occur spontaneously. Stable CHD also includes the stabilized and often asymptomatic 
phases after an ACS [40]. A careful medical history remains the cornerstone of the diagnosis of stable 
CHD. Prediction tools have been developed to assist in the diagnosis of chest pain. In primary care, a 
validated prediction rule [43], containing five determinants [age/sex (male≥55 years, female≥65 years); 
known vascular disease; patient assumes pain is of cardiac origin; pain is worse during exercise and pain 
is not reproducible by palpation: one point for each determinant], has been proposed to be a useful tool for 
general practitioners to rule out CHD in patients presenting with chest pain [40]. More research is needed 
to validate its use in clinical practice.
Unstable angina is defined as myocardial ischaemia at rest or minimal exertion in the absence of 
cardiomyocyte necrosis. The application of the universal definition of myocardial infarction together with 
the use of contemporary troponin assays, reduced the proportion of patients with unstable angina to 
the benefit of patients with non-ST elevation AMI (NSTEMI) (4% absolute and 20% relative increase) 
[44,45]. Furthermore, the relative incidences of NSTEMI and ST elevation myocardial infarction (STEMI) 
are increasing and decreasing, respectively [46].
Patients with symptoms suggestive of ischemia and a left bundle branch block (LBBB) present an 
important diagnostic and therapeutic challenge. The three electrocardiographic criteria proposed 
by Sgarbossa and colleagues [47] are the most validated tool to assess the diagnosis of STEMI in 
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patients with LBBB. These criteria have high specificity but low sensitivity, compromising its utility in 
clinical practice [48]. Prompt and accurate identification of STEMI in the presence of LBBB remains 
difficult [49] and is of paramount importance because very proximal coronary occlusion is required to 
involve the septal perforating arteries that supply the proximal left bundle branch [50]. The key is to 
rapidly distinguish patients with LBBB without STEMI from those with STEMI, to avoid inappropriate 
management by emergent coronary angiography or fibrinolysis for the former group, and guarantee 
adequate and timely reperfusion therapy for the latter group [49]. To reduce false catheterization 
laboratory activation and inappropriate fibrinolytic therapy, and to avoid denying reperfusion therapy 
to patients who benefit, a group proposed a diagnosis and triage algorithm incorporating the Sgarbossa 
criteria to quickly and accurately identify, among patients presenting with chest pain and new or 
presumably new LBBB, those with acute coronary artery occlusion [49]. Further studies are needed to 
validate this approach.
With contemporary ACS assessment strategies, including the widespread use of coronary angiography 
in management of patients with ACS, a novel syndrome arose, termed myocardial infarction with non-
obstructed coronary arteries (MINOCA), defined as obstructions below 50% on angiography [51,52]. 
MINOCA can account for about 10% of all AMI cases, according to data from the Can Rapid risk stratification 
of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA 
Guidelines (CRUSADE) registry [53]. There are different aetiological entities leading to MINOCA [54], 
which can present as both myocardial infarction type 1 and type 2, according to the universal definition of 
myocardial infarction [55].
Increasingly recognized are also patients presenting with the syndrome of symptoms and signs 
suggesting ischemic heart disease, not AMI, but found to have no obstructed coronary arteries (less than 
50% diameter stenosis) [56,57]. Ischemia and No Obstructive Coronary Artery Disease (INOCA) was the 
term proposed to describe these patients’ presentation [58].
Considering these recent proposed syndromes, figure 1 depicts the biological and clinical progression 
features of CHD, adapted from the scheme proposed by Labarthe DR [59].
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1.1.4 Diagnostic approaches
Location and/or extent of atherosclerotic lesions and ischemia are amenable to investigation through 
several invasive and non-invasive methods, anatomical and/or functional. Indications for diagnosis strategy, 
particularly for suspected CHD will mainly depend on the evaluation of risk and clinical presentation.
The diagnosis and risk stratification of patients with ACS, both with non-ST elevation ACS (NSTEACS) 
or STEMI, is objectively proposed by cardiology societies and is relatively consensual, depending on risk 
predictors, presenting symptoms, electrocardiogram (ECG) and biomarkers measurement [45,46]. Yet, 
for the chronic stable phase of CHD, recommendations for diagnostic test indication and exam selection 
are not so consensual if we compare current practice guidelines on the management of stable CHD 
[40,60,61]. For stable CHD, the European Society of Cardiology (ESC) guidelines propose a Bayesian 
approach to the selection and interpretation of non-invasive cardiac tests. This approach uses clinicians’ 
pre-test probability of disease along with results of diagnostic tests to generate individualized post-test 
disease probabilities for a given patient [40]. The pre-test probabilities of stable CHD proposed by these 
guidelines are based on the Diamond-Forrester score, and depend on the prevalence of the disease in the 
population studied, as well as on clinical features (including the presence of cardiovascular risk factors) 
of an individual, by age and gender; and on the nature of symptoms [62]. For patients with low pre-test 
Figure 1.  Biological and clinical progression features of CHD (adapted from Labarthe DR) [59].
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probability of stable CHD (<15%), no further investigation is needed to exclude the diagnosis; for those 
with an intermediate pre-test probability of disease (15-85%), non-invasive testing should be performed to 
establish the diagnosis. The diagnosis of CHD is established for patients with a high pre-test probability 
of disease (>85%), who should proceed directly to risk stratification [40].
Several anatomical or functional non-invasive tests for diagnosing (and stratifying) CHD are widely 
available, including exercise stress test, stress echocardiography, nuclear stress testing, coronary 
computerized tomography angiography (CTA), and stress cardiac magnetic resonance, each with varying 
accuracy, cost and availability [63]. Multi-detector CTA has good diagnostic accuracy in the detection of 
significant coronary artery stenosis in patients with low to intermediate risk, who present with acute chest 
pain [64]. On the other hand, CTA is sensitive to heart rate, body weight and the presence of calcification. 
A strategy of initial CTA, as compared with functional testing, did not improve clinical outcomes of patients 
with suspected CHD over a median follow-up of 2 years [56]. The best diagnostic approaches by non-
invasive test for stable CHD remain largely a work in progress; however, globally, their performance for 
likelihood of diagnosis of CHD is good, and only rarely is a coronary angiography necessary for the sole 
purpose of diagnosing suspected CHD in stable patients [40].
1.1.5 Management (primary and secondary prevention)
A central principle in CHD management is that the first lifetime diagnosis signals the failure of primary 
prevention and the need to initiate secondary prevention of recurrent or related CHD events. Prevention 
strategies for CHD in the current generation of adults are in fact, at least in part, a postponement of events. 
Premature deaths and disability adjusted life years (DALYs) can be prevented and are accompanied by an 
increase in the prevalence of CHD in the elderly and in the very old, and in other manifestations of end-stage 
CVD, such as heart failure, chronic kidney disease, atrial fibrillation and vascular dementia. The prevention of 
the development of total cardiovascular risk may only be achieved by primordial prevention from childhood 
onwards [2].
Guidelines from recognized organisations, namely from the ESC [65], the American Heart Association 
(AHA) [66], the American College of Cardiology (ACC) [67], the National Institute of Health and Care 
Excellence (NICE) [68], among others, summarize evidence and expert opinion, and provide graded 
recommendations for evaluation and management of CHD patients.
In Europe, significant efforts have been made to develop and disseminate guidelines for the management 
of CHD, both for primary and secondary prevention settings (Figure 2). 
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a) Primary prevention
CHD prevention is defined as a coordinated set of actions, at the population or at individual level, aimed 
at eliminating or minimizing the impact of CHD and its related disabilities [69].
CVD primary prevention, through implementation of lifestyle changes or use of medication, is cost 
effective [23].
The SCORE system estimates the 10 year risk of a first fatal atherosclerotic event and because it is 
based on a large pooled dataset of 12 European prospective studies, it captures the heterogeneity across 
Europe in terms of baseline CVD risk [70]. The calculation of total cardiovascular risk, through the SCORE 
chart, should be systematic for individuals at increased cardiovascular risk, namely those with risk factors 
or comorbidities that increase CVD risk; and may be considered in men above 40 years of age and in 
women above 50 years of age or post-menopausal with no known cardiovascular risk factors [23]. Risk 
categories obtained through the application of risk scores assist physicians in decisions with individual 
people. However, and applying Rose’s theory of distribution of risk in a population [71], although individuals 
at the highest levels of risk gain most from risk factor interventions, most deaths and morbidity in a 
population come from those at lower levels of risk, simply because they are more numerous compared to 
high-risk individuals. Management strategies of high-risk subgroups should be complemented by actions 
targeting low-risk populations, namely public health measures to encourage a healthy lifestyle and to 
reduce population levels of cardiovascular risk factors [71].
Current risk factor goals and target levels for important cardiovascular risk factors according to ESC 
guidelines are presented in table 1. 
Figure 2.  The most recent ESC Guidelines for management of patients with CHD 
(primary and secondary prevention settings).
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Risk factor intervention at the individual level is defined for each major cardiovascular risk factor, 
and includes lifestyle interventions for all [23]. The benefit of risk factor-lowering therapy depends on 
the risk factor level itself and on the total cardiovascular risk.
For blood pressure, although several classes of drugs are available [thiazide and thiazide-like diuretics 
(chlorthalidone and indapamide), beta-blockers, calcium antagonists, angiotensin converting enzyme 
inhibitors, angiotensin receptor blockers], which can adequately lower blood pressure and reduce the risk 
of cardiovascular death and morbidity, benefits of treatment are mainly driven by blood pressure reduction 
per se and not by the type of drug, and most patients with indication for medication need combination 
treatment. Dyslipidaemic and diabetogenic effects of some beta-blockers and thiazides has questioned 
their role as first-choice blood pressure-lowering drugs, particularly in hypertensive patients with multiple 
Table 1. Risk factor goals and target levels for important cardiovascular risk factors 
(adapted from ESC guidelines) [23].
 
 
  
Smoking No exposure to tobacco in any form. 
Diet Low in saturated fat with a focus on wholegrain products, vegetables, fruit 
and fish. 
Physical activity 
 
At least 150 minutes a week of moderate aerobic physical activity (30 minutes 
for 5 days/week) or 75 minutes a week of vigorous aerobic physical activity 
(15 minutes for 5 days/week) or a combination thereof. 
Body weight Body mass index 20–25 kg/m2. Waist circumference <94 cm (men) or <80 cm 
(women). 
Blood pressure 
 
<140/90 mmHg if <60 years old. Systolic blood pressure: 150 - 140 mmHg if 
>60 years old with initial values ≥160 mmHg 
Lipids LDL (Low 
density lipoprotein 
cholesterol) is the 
primary target 
 
HDL (High density 
lipoprotein 
cholesterol) 
Very high-risk: 70 mg/dL, or a reduction of at least 50% if the baseline is 
between 70 and 135 mg/dL.  
High-risk: <100 mg/dL, or a reduction of at least 50% if the baseline is 
between 100 and 200 mg/dL.  
Low to moderate risk: <115 mg/dL. 
No target, but >40mg/dL in men and >45 mg/dL in women indicate lower risk. 
 
Triglycerides No target but <150 mg/dL indicates lower risk and higher levels indicate a 
need to look for other risk factors. 
Diabetes Hemoglobin A1c <7%. 
Risk factors Goals and targets
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metabolic risk factors and conditions that increase the risk of new onset diabetes mellitus [72,73].
Low density lipoprotein cholesterol (LDL) reduction is the key point of treatment and, although several 
lipid-lowering drugs are available, statins are the first drugs of choice in patients with dyslipidaemia 
[23,72], due to its effectiveness in reducing cardiovascular morbidity and mortality, and the need for 
coronary artery interventions [74,75].
Although the use of antiplatelet therapy in primary prevention is still controversial, proved by changes 
in position of the ESC in the last decade [76], most recent European guidelines [23] do not support the 
use of this class of drugs in primary prevention. This is due to the conclusion that the number of primary 
serious cardiovascular events prevented is offset by the increased risk of major bleeding [77,78]. Ongoing 
primary prevention trials, in patients with diabetes mellitus [79,80], in individuals with advanced age [81] 
and in individuals with moderate risk [82], prove that the scientific community considers this is not yet a 
solved research question. Interestingly, data analysing current practice patterns of prophylactic aspirin 
utilisation showed that its use is in the opposite direction of current recommendations, with patients at 
low risk for CVD using aspirin more frequently than patients at high risk [83].
Several drugs for diabetes mellitus management have been introduced, but metformin is still 
recommended as the first-line therapy, if tolerated and not contra-indicated [23].
Globally, simplifying the treatment regimen of cardiovascular risk factors to the lowest acceptable level is 
recommended, as is continuous adherence monitoring [23].
b) Stable CHD
Prognostic assessment is an important part of the management of patients with stable CHD. The goal 
is to correctly identify patients with severe disease who may have outcome benefit with a more aggressive 
investigation and potentially with intervention, namely revascularisation; but also to avoid unnecessary 
invasive and non-invasive tests, and revascularisation procedures in patients with less severe disease and 
good prognosis [40]. And here stands the difficult task.
After establishing the diagnosis of stable CHD, optimal medical therapy should be instituted and 
stratification for risk of subsequent events should be performed. Risk stratification depends on clinical 
evaluation, on assessment of ventricular function by resting echocardiography and, in most patients, on 
non-invasive assessment of ischaemia/coronary anatomy; usually these variables of risk stratification 
are obtained during the process of stable CHD diagnosis [40].
Patients with a predicted annual mortality ≥3% are defined as high event risk patients [40] and may 
directly benefit from coronary angiography and eventually revascularisation. The remaining patients 
should be managed with optimal medical therapy, with those remaining symptomatic despite treatment 
eventually benefiting from referral to an invasive approach [40].
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Optimal medical therapy of stable CHD encompasses lifestyle modification, control of cardiovascular 
risk factors, evidence-based pharmacological therapy and patient education. Pharmacological 
management has two main goals, relief of angina symptoms and prevention of the occurrence of 
cardiovascular events. Several classes of drugs are available for relief of angina symptoms [40]. Beta-
blockers and/or calcium channel blockers are the first-line treatment; the addition of one of the second-
line drugs (long-acting nitrates, ivabradine, nicorandil or ranolazine) is the next step. All patients should 
also be prescribed short-acting nitrates [40]. For event prevention, low-dose aspirin and statins are 
recommended in all stable CHD patients; clopidogrel is an alternative in the case of aspirin intolerance. 
For patients with stable CHD and concomitant heart failure, hypertension or diabetes, angiotensin 
converting enzyme inhibitors or angiotensin receptor blockers are recommended [40].
The decision to proceed to a revascularisation of a patient with stable CHD will depend on many clinical, 
anatomical, technical and environmental factors that should be discussed within a Heart Team. The large 
number of possible combinations of these factors is responsible for the lack of absolute revascularisation 
recommendations for patients with stable CHD. The severity of obstructive coronary artery stenosis, the 
amount of related ischaemia, left ventricular systolic function and the expected benefit for prognosis and/
or symptom relief are factors to take into account in this decision [40]. Nevertheless, there is still a gap 
in evidence as to what is the real benefit from myocardial revascularisation of patients with stable CHD.
c) Acute coronary syndromes
Non-ST elevation acute coronary syndrome (NSTEACS)
The selection of the best acute management approach for patients with NSTEACS greatly depends 
on risk stratification. For prognosis estimation of patients with ACS, established ischaemic and bleeding 
risk scores are superior to clinical assessment alone [84], and should therefore be part of the initial 
management of patients with NSTEACS [45]. The Global Registry of Acute Coronary Events (GRACE) 
risk score provides accurate stratification of ischaemic risk both at admission and at discharge [85]. The 
updated GRACE risk score 2.0 has better discrimination and is easier to use than the previous score, and it 
performed equally well acutely and over the long term [86]. Age, systolic blood pressure, pulse rate, serum 
creatinine, Killip class at presentation, cardiac arrest at admission, elevated cardiac biomarkers and ST 
deviation are used for the GRACE 2.0 risk calculation. If the Killip class or serum creatinine values are not 
available, a modified score can be calculated by adding renal failure and use of diuretics, respectively [86]. 
Bleeding risk is another part of the risk assessment of NSTEACS. The CRUSADE bleeding risk score [87] 
is recommended for patients undergoing coronary angiography [45]. This score includes baseline patient 
characteristics (i.e. female gender, history of diabetes, history of peripheral vascular disease or stroke), 
admission clinical variables (i.e. heart rate, systolic blood pressure, signs of heart failure) and admission 
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laboratory values (i.e. haematocrit, calculated creatinine clearance) to estimate the patient’s likelihood of 
an in-hospital major bleeding event [87].
The acute inpatient medical treatment of NSTEACS includes pharmacological treatment of ischaemia, 
antiplatelet inhibition, anticoagulation, initiation of secondary prevention drug therapy, and decision 
between conservative vs invasive treatment; and thereafter time and type of revascularisation [45].
The European guidelines updated the risk criteria to decide referral and time to coronary angiography 
among patients with NSTEACS. For patients with at least one very-high-risk criterion (recurrent or 
ongoing chest pain refractory to medical treatment; haemodynamic instability or cardiogenic shock; 
life-threatening arrhythmias or cardiac arrest; mechanical complications of AMI; acute heart failure; 
recurrent dynamic ST-T wave changes, particularly with intermittent ST-elevation), an immediate, 
within two hours from hospital admission, invasive strategy with intent to perform revascularisation is 
recommended, irrespective of ECG or biomarker findings [45]. An early invasive strategy (defined as 
coronary angiography within 24 hours of hospital admission) is recommended for patients with a high-
risk profile, defined as at least one high-risk criterion (rise or fall in cardiac troponin compatible with AMI; 
dynamic ST- or T-wave changes, symptomatic or silent; GRACE score >140) [45]. This recommendation is 
based on two meta-analyses of randomised trials, a retrospective analysis of the Acute Catheterization 
and Urgent Intervention Triage strategy (ACUITY) trial, and on a beneficial effect of early intervention in 
a high-risk subgroup (GRACE >140) of patients, observed in The Timing of Intervention in Acute Coronary 
Syndromes (TIMACS) trial [88-91]. Both meta-analyses concluded that there is insufficient evidence either 
in favour of or against an early invasive approach in the NSTEACS population, considering benefit for the 
hard endpoints of mortality, nonfatal AMI or major bleeding, but only a reduction in secondary outcomes, 
particularly refractory ischaemia. The invasive strategy (defined as coronary angiography within 72 hours 
of hospital admission) is recommended for patients with at least one intermediate risk criterion (diabetes 
mellitus, renal insufficiency defined as estimated glomerular filtration rate below 60 ml/min/1.73 m2, left 
ventricular ejection fraction below 40% or congestive heart failure, early post-infarction angina, prior 
percutaneous coronary intervention (PCI), prior coronary artery bypass graft surgery (CABG), GRACE risk 
score >109 and <140); recurrent symptoms or known ischaemia on non-invasive testing [45]. Patients with 
no symptom recurrence and none of the very high, high or intermediate risk criteria are to be considered 
at low risk of ischaemic events, and a non-invasive stress test (preferably with imaging) for inducible 
ischaemia is recommended before deciding on an invasive strategy [45].
Considering these recommendations, coronary angiography followed, if indicated, by revascularisation 
is indicated for most patients with NSTEACS. The time and selection of the revascularisation modality 
depend on numerous factors, namely clinical presentation, comorbidities, risk stratification, presence 
of high-risk features specific for a revascularisation modality, frailty, cognitive status, estimated life 
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expectancy, and functional and anatomic severity as well as the pattern of coronary arteries lesions [45].
ST elevation myocardial infarction (STEMI)
The primary goal in treating patients with STEMI is rapid restoration of coronary arterial flow and 
reperfusion. In the 1980s, fibrinolysis was the only means to accomplish this. Over the last two decades, 
primary PCI has become the preferred reperfusion strategy if performed on time by skilled operators [46].
In STEMI patients, the main limitation to referral to reperfusion therapy is the time of presentation after 
symptom onset. For patients with the clinical presentation of STEMI within 12 hours of symptom onset and 
with persistent ST-segment elevation or LBBB, early mechanical or pharmacological reperfusion should be 
performed. Whether PCI is also beneficial in patients presenting more than 12 hours after symptom onset 
is more controversial. Patients with clinical and/or electrocardiographic evidence of ongoing ischaemia 
benefit more than asymptomatic patients. In patients who present more than 48 hours after symptom 
onset, and are stable and without signs of ischaemia, routine PCI is not recommended [46]. This timeframe 
recommendation was extended from 24 hours [92] to 48 hours in the 2017 guidelines [46], according to 
the results of a randomized clinical trial of approximately 350 patients, that showed improved myocardial 
salvage and 4 year survival in asymptomatic patients without persistent symptoms 12-48 hours after 
symptom onset treated with primary PCI, compared with those with conservative treatment [93,94].
International guidelines recommend primary PCI generally within 90 minutes of first medical contact, 
preferably within 60 minutes if patients present at a primary PCI capable hospital. Fibrinolysis is 
recommended if PCI cannot be performed within 120 minutes from first medical contact. After a successful 
fibrinolysis, a routine early PCI strategy, preferably within 2 to 24 hours, is indicated [46,95]. There still 
is a large debate on the time delay that is acceptable before deciding on fibrinolysis, or instead in a 
combination of the two reperfusion modalities, due to the lack of contemporaneous data to set the limit 
to choose PCI over fibrinolysis [46,96]. Significant delays may negate the benefit of primary PCI over 
fibrinolysis. The total ischaemic time, time from symptom onset until effective reperfusion, is influenced 
by patient and health care system delays. Preventing these delays in STEMI patients means reducing 
mortality and morbidity [97]. This involves identifying barriers to access, which may occur in many steps 
of this complex chain, in the perception of need and health system seeking behaviour of the patient, the 
pre-hospital logistics of care including pre-hospital triage, ambulance services and networks between 
non-PCI and PCI capable hospitals, and treatment strategies. To prevent delays, the process of monitoring 
of care is also important [98]. Several challenges and opportunities exist throughout this process of care to 
improve quality. Considering the monitoring phase, different definitions of STEMI delays used for evaluating 
performance limit benchmarking and interpretation of delay determinants [46,99]. 
Despite acknowledging the challenge and diagnostic uncertainty of LBBB, the 2012 ESC guidelines 
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recommended emergent reperfusion therapy for this subgroup of patients [92]. In the 2013 American STEMI 
guidelines, the recommendation to treat patients with new or presumably new LBBB as STEMI equivalent was 
removed [95]. This conceptual change was supported by arguments related with the subjective definition 
of “new LBBB” when no ECG is available for comparison, the low frequency of LBBB at AMI presentation, 
the possibility of other diagnosis besides STEMI, the increased risk of complications from inappropriate 
approaches, namely false catheterization laboratory activation or inappropriate fibrinolytic therapy [95]. The 
most recent European guidelines for management of patients with STEMI go in the opposite direction of 
the American guidelines, supporting that patients with LBBB, regardless of whether the LBBB is previously 
known, should be managed in a way similar to STEMI patients. This position is grounded on the lack of 
sufficient diagnosis acuity of the complex electrocardiographic algorithms to assist in the diagnosis of 
transmural AMI in patients with LBBB.  These guidelines also support a primary PCI strategy to patients 
with right bundle branch block and persistent ischaemic symptoms, considering that it also may be difficult 
to detect transmural ischaemia in patients with chest pain and right bundle branch block [46]. The debate 
around these recommendations will continue.
MINOCA and INOCA
No clinical practice management guidelines exist for the management of the heterogeneous group 
of patients with MINOCA or INOCA, although working groups critically reviewed available literature and 
current practices, and suggested research directions to develop evidence-based therapies [58,100]. 
According to the position of these working groups, extrapolation from some studies support the role of 
some drug classes to target coronary microvascular dysfunction, namely statins, angiotensin converting 
enzyme inhibitors, aspirin and antianginal agents. However, there is a lack of appropriately designed 
clinical outcome trials to support evidence-based therapeutic strategies for these specific groups of 
patients [58,100].
d) Long-term management of patients with acute coronary syndromes
The long-term management of patients with NSTEACS and STEMI, according to the most recent 
European guidelines is summarised in table 2 [23,45,46]. Drug therapy and participation in a well-structured 
cardiac rehabilitation programme, classes and levels of recommendation are presented for patients with 
NSTEACS and STEMI, without contraindication for each specific class of drugs and for exercise-based 
cardiac rehabilitation.
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Table 2.  Long-term management of patients with acute coronary syndromes (drug therapy and cardiac rehabilitation).
  NSTEACS STEMI  
 Recommendation Class Level Class Level Comment 
Drug class       
Low dose aspirin  I A I A Indefinitely 
P2Y12 inhibitor  I A I A  
Dual antiplatelet 
therapy 
     Duration depends on type 
of stent, concomitant oral 
anticoagulation and is not   
a solved research question  
 Aspirin+ticagrelor  I B I A  
 Aspirin+prasugrel  I B I A Prasugrel if PCI 
 Aspirin+clopidogrel  I B - - Clopidogrel if ticagrelor or 
prasugrel not feasible or if 
oral anticoagulation 
High-intensity statin All patients and as 
early as possible 
LDL target <70 
mg/dl or a 50% 
reduction 
I A I A If LDL cholesterol 
≥70mg/dL despite a 
maximally tolerated dose of 
statin, ezetimibe should be 
added[101] (IIa)  
ACEI Patients with 
systolic 
dysfunction, or 
heart failure, or 
diabetes 
I A I A LVEF≤40% specifically 
defined for NSTEACS       
For NSTEACS also 
hypertension                     
For STEMI also anterior 
infarction 
 All patients - - IIa A  
 
ARB 
 
For those who are 
intolerant to ACEI 
 
I 
 
A 
 
I 
 
B 
 
Preferably valsartan in 
STEMI 
Beta-blockers Heart failure or 
LVEF ≤40% 
I A I A  
 All patients - - IIa A  
Aldosterone 
antagonists 
In patients with 
systolic dysfunction  
and either heart failure  
or diabetes
 
I A I B Preferably eplerenone     
For NSTEACS: LVEF≤35% 
For STEMI: LVEF≤40% 
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; LDL, low density lipoprotein; LVEF, left ventricular ejection 
fraction; NSTEACS, non-ST elevation acute coronary syndrome; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction.
 
Exercise-based 
cardiac 
rehabilitation 
program 
 I A I A To improve patient 
outcomes 
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1.2 Health care quality assessment and improvement
Quality of care is difficult to define and implies the characterisation of several domains, which represent 
attributes or properties of the process of care itself, but also of goals or objectives of that process, defined 
by the medical care system and by the larger society of which it is a part [102]. The definition of health 
care quality proposed by the Institute of Medicine is widely accepted: “the degree to which health services 
for individuals and populations increase the likelihood of desired health outcomes and are consistent with 
current professional knowledge” [103]. Its specific aims are the following:
Effectiveness: relates to providing care processes and achieving outcomes as supported by scientific 
evidence to all who could benefit, and refraining from providing services to those not likely to benefit 
(avoiding underuse and overuse).
Efficiency: relates to maximizing the quality of a comparable unit of health care delivered or unit of health 
benefit achieved for a given unit of health care resource used.
Equity: relates to providing health care of equal quality to those who may differ in personal characteristics 
other than their clinical condition or preferences for care, such as gender, ethnicity, geographic location, 
and socioeconomic position.
Patient centeredness: relates to meeting patient needs and preferences, and providing education 
and support.
Safety: relates to avoiding actual or potential harm.
Timeliness: relates to obtaining needed care while minimising delays.
Quality of care is not a unitary concept, as relevant dimensions and values can be defined differently, 
according to time and setting. The selection of dimensions to define quality of health care will impact 
the approaches and methods employed in its assessment. Hence, although the sense of quality of care is 
intuitive, it is difficult to develop an operational definition, and valid and reliable measures.
Avedis Donabedian is widely recognised as one of the most important figures in health care quality 
research. He gave an important contribution to define and disseminate approaches and methods of 
assessment, and proposed, what are still today considered, the three types of indicators of quality of health 
care. Evaluating whether high quality care is provided can be performed by examining what the outcomes 
of care are, by measuring the actual process of care and/or by assessing the structure of the setting 
in which care is provided [102]. Advantages and limitations of these outcome, process and structure 
indicators of quality of care can be identified.
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Outcome indicators
The outcome of medical care, in terms of recovery, restoration of function and survival, has been 
frequently used as an indicator of health services quality, because of its advantages: accepted validity, 
stability and objectivity. However, there are some limitations to take into account, one very relevant is the 
fact that outcomes will depend not only on the degree to which evidence based medicine has been applied 
in the instances under study, but also on the power of medical science itself to achieve certain results 
under any given set of conditions. Furthermore, other factors besides medical care may influence outcome, 
and have to be taken into account if valid conclusions are to be drawn. One of the major factors affecting 
post-treatment status is pre-treatment status [104]. Noteworthy is also the fact that long periods of time, 
sometimes decades, must elapse before relevant outcomes manifest after intervention, so this lag of time 
should be considered to appraise the results of care. Another limitation of outcome measures for quality 
improvement purposes is that they may not provide insights into why there were poor outcomes and 
what needs to be changed to yield better outcomes. Finally, not all outcome indicators are unmistakable 
and easy to measure as mortality, examples of outcome indicators more difficult to measure are patient 
attitudes and satisfactions, social restoration, and physical disability and rehabilitation [102]. The important 
role of these outcome indicators collectively referred as health-related quality of life measures [105] has 
been increasingly recognised, proved by the development of a repository of patient reported outcome 
measures, The Patient Reported Outcomes Measurement Information System (PROMIS) [106].
Process indicators
Process indicators are not interested in the power of medical technology to achieve results, but in 
whether what is known to be “good” medical care has been applied. These indicators pretend to answer 
whether medicine is properly practiced; such measures are used because research has demonstrated a 
link between those processes and important outcomes.
Disadvantages of process indicators include the fact that it is difficult to relate many processes of care 
with outcomes. Links between outcome and process are more likely when the patient group is well defined 
by a medical condition and/or demographic characteristics, when there is a well understood physiologic, 
biochemical, or psychological mechanism that links medical intervention with outcome, and when the 
outcomes are targeted for the medical condition. Another shortcoming is related to the complexity of the 
process of care for several conditions, a multitude of actions take place across the pathway of care, and 
it is difficult to develop and use enough measures to form a comprehensive assessment. Although it is 
increasingly recognised that it is not adequate to simply assess individual processes of care, but rather 
groups of processes that need to occur to lead to a better outcome [107], the interpretation of results in 
terms of what needs to be changed is more difficult.
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Structure indicators
This third approach to quality assessment is related with studying the settings in which health care 
takes place and the instrumentalities of which it is the product [102]. Structure indicators include material 
resources (facilities, equipment), human resources (number of personnel and their qualifications) and 
organisational structure (medical staff organisation, level of reimbursement) [102]. Another important 
aspect of structure is organisational culture, including the priority given to quality and leadership, and 
policies and procedures for maximizing the quality of care [108]. One of the major allure of structure 
measures is that they are fairly concrete and usually accessible to evaluate. It is relatively easy to 
determine whether a hospital has a cardiac catheterization laboratory available 24 hours a day. However, 
the relationship between structure and process, or structure and outcome is often not well established, 
because it is very complex [109] and weak [110].
This framework developed by Avedis Donabedian, and providing a valuable conceptualisation of 
outcome, process and structure as essential domains for evaluating medical care quality, was determinant 
in directing the investments in health care quality measurement and improvement.
Questions related with sources of data, sampling, methods of analysis and interpretation of quality 
measures are a current topic. The recognition of the importance of availability; standardisation of 
measures for specific care settings and clinical conditions; of broad multistakeholder engagement in the 
development of measures were important to identify solutions to controversial issues, including adequacy 
of risk adjustment and strategies to link cost and quality, as well as set new directions of research.
The hierarchical structure evaluation criteria for the endorsement of standard measures for health care 
quality set by the National Quality Forum in the United States of America, which was established in 1999, is 
a good example of the relevance of the quality improvement goal to define quality measures. The National 
Quality Forum evaluation criteria measures include: importance to measure and report (first must-pass) are 
related with the level of evidence for the measures and the existence of an opportunity for improvement. 
Scientific acceptability of the measurement properties (second must-pass) are related with the reliability 
and validity of the measure. Usability and use are related with accountability and improvement. Feasibility 
is related with implementation of the measures without undue burden and captured with electronic data. 
Also included is the need to assess related and competing measures [111].
Accurate data collection for quality assessment implies identifying patients with the specified 
disease, evaluating the severity of their condition to determine whether they are appropriate candidates 
for the performance measure, doing appropriate risk adjustment and measuring the process or outcome 
of care to compare with accepted standards [112]. Risk adjustment is particularly a challenge; although 
a range of biostatistical techniques is available to account for variability due to patient factors, much 
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variability remains unexplained [112].
Measures are being developed to increasingly take advantage of the best data available for measurement, 
which include the use of clinical data registries, electronic health records (standardised data from laboratory 
results, imaging results and patient vital signs), and the ability to link these data and track patients 
using multiple registries. Denmark is a remarkable example. A 10-digit personal identification number 
is allocated to each Dane from birth to death and used in all medical databases, allowing unambiguous 
linkage between various registries [113] and therefore the creation of a network of more than 60 publicly 
financed nationwide clinical quality databases [114]. These registries contain systematically collected data 
related to clinical observations, diagnostic procedures, treatments and outcomes within the context of 
patient pathways of specific diseases or health-related interventions [115]. Clinical quality databases are 
required to fulfil a set of national criteria regarding organisation, functionality, data safety and reporting 
to be approved. Questions related with data validity, namely completeness and other issues related with 
quality of data are also objectively addressed [114]. Authors highlight the potentials of this approach 
to quality improvement, namely the following advantages: population-based studies on large cohorts of 
patients usually with fairly complete data and complete follow-up; collection of data independently of the 
research question, minimising risk of some types of bias such as recall bias and the impact of a decision 
on diagnosis and therapy through awareness of an ongoing study; unique data source in studies of long-
term health; lower cost; more detailed clinical data than the central health registries and better control for 
confounding [114].
Currently, in Nordic countries, registry data can be used in legally approved research without obtaining 
informed consent. Concerns are being raised about the requirement for individual patient informed consent 
before data can be collected or used, considering positions advocated by the European Commission [116] 
and by the World Medical Association [117]. To maximise the potential of these clinical quality databases 
for research purposes, there are several technical, legal, educational and financial challenges [114].
1.2.1 Access to health care
Access is an important concept to the study of the organisation, financing and delivery of health care 
services. Access to health care is defined as access to a service, a provider or an institution, thus defined 
as the opportunity or ease with which consumers or communities are able to use appropriate services 
in proportion to their needs [118]. Access to health care has been the subject of much study and battle 
of frameworks; seen from the beginning as a multi-dimensional concept, still today, the definition of 
dimensions and operational measuring lacks consensus.
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Andersen developed one of the most important and cited theory of access, “the behavioural model of 
health services use” [119]. The key item noticed by Andersen and colleagues was that earlier concepts 
of use of health care focused on 2 major alternative dimensions: the characteristics of the population vs. 
the characteristics of the delivery system. They also noted that access could be measured using service 
and outcomes of the use process. The biological imbalance of individuals was termed “need” and was also 
considered an important component of the core conceptualisation. The overall framework included causal 
links and pathways between and among the elements, labeled “predisposing” (generally characteristics of 
individuals) or “enabling” (system or structural characteristics) that led to an outcome.
The Penchansky conceptualisation of access focused on the interaction of key elements that determined 
use of services [120]. Penchansky suggested the concept of “fit” between the patient’s needs and the 
system’s ability to meet those needs. He suggested that this fit could be measured across five dimensions: 
availability, which is the volume of physician and other health care services; accessibility, the spatial or 
geographic relationship between the providers of health care and the users of care; accommodation, 
describes the organisation and content of the health care system as it relates to the ease with which 
people can use care (clinic hours, waiting time and length of time waiting for an appointment); affordability, 
the financial ability of the population to use the care provided by the system and the perception of value 
on the part of patients; and acceptability, which represents the attitudes of the users of health care toward 
the providers, and vice versa.
Frenk extended the work of Penchansky, to suggest that “fit” was a process of adjustment between the 
population and the health care delivery system [121]. Frenk also noted the internal problem of using terms 
which have not been clearly defined but are used interchangeably (access, accessibility, availability).
All these frameworks highlighted the central role of health system characteristics with regards to 
facilitating or impeding the use of services by potential users, and were in line and influenced by the 
conceptual framework for evaluating quality of medical care proposed by Donabedian [102].
More recently, the concept of access was revisited by Levesque and colleagues [122], who tried to 
draw the different steps in the sequence that a patient will experience through the process of care, which 
represent crucial transitions, where barriers or facilitators to access can be revealed. Levesque and 
colleagues defined access to health care as “the opportunity to identify health care needs, to seek health 
care services, to reach, to obtain or use health care services, and to actually have a need for services 
fulfilled”. These authors subdivided, at the system level, the dimension of accessibility into five sub-
dimensions (approachability, acceptability, availability/accommodation, affordability and appropriateness) 
and identified, at the population level, five corresponding abilities of populations to interact with the 
dimensions of accessibility, to generate access (ability to perceive, ability to seek, ability to reach, ability 
to pay and ability to engage).
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The ultimate goal of disaggregating access into broad dimensions and sub-dimensions, that is, to 
identify its specific determinants, is to obtain more operational measures for its evaluation. But this is still 
a difficult task that raises the question about if they are sufficiently distinct to be measured and studied 
separately. Independently of how these dimensions are labelled and defined, they surely represent closely 
related phenomena, and should be taken into account in the design, analysis and interpretation of health 
care research.
1.2.2 Quality indicators in acute coronary syndrome
Despite the advances in primary and secondary prevention, namely some revolutionary in technology 
with respect to ACS, important challenges and opportunities remain in the optimal delivery of care to this 
patient population. Adherence to recommended guidelines has been convincingly associated with significant 
improvement in survival [123], but is still suboptimal [124]. The use of evidence-based ACS treatments is 
less than ideal, particularly for certain high-risk populations, namely older and female patients [125], non-
white patients [126], patients from lower SEP [127-129], and patients from certain geographic regions [130]. 
Opportunities to quality improvement exist, which imply the existence of operational indicators of quality 
assessment for ACS.
Quality indicators (QIs) are developed for each condition of interest in most instances by the use of 
general consensus statements or guidelines as a basis. However, guidelines are not quality of care indicators; 
guidelines suggest diagnostic or therapeutic interventions for most patients in most circumstances, its 
use is left to the discretion of the physician. In contrast, QIs in addition to stating an explicit diagnostic or 
therapeutic action to be performed, must also define how to identify patients for whom a specific action 
should be taken. Thus, health care providers, researchers and payers identified a need to link development 
of guidelines with development of QIs [112].
Considering the conceptual framework of quality of health care, it is not surprising that there is not a 
unique and universal standardised set of QIs for ACS. In 2015, the Spanish Society of Cardiology and the 
Spanish Society of Thoracic and Cardiovascular Surgery organized a task force to define outcome and 
process indicators of hospital cardiology practice [131,132]. More recently, the ESC/ Acute Cardiovascular 
Care Association (ACCA) proposed a set of QIs for the management of AMI [133], based on the ESC 
guidelines [45,92]. They comprise 7 domains across 20 QIs including the evaluation of key aspects of the 
AMI care pathway and include structure, process and outcome indicators. The relevance of time dependent 
QIs, of risk stratification assessment, of the need to gather appropriate clinical detail, for example the need 
to consider the specific type and doses for some drugs, and of composite QIs are strengthened in this 
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proposal. These indicators were validated using data from the National Health Service of England and Wales 
(Myocardial Ischaemia National Audit Project [MINAP]) and showed the potential to improve care and reduce 
unwarranted variation in death from AMI [134], serving as a conceivably useful tool to improve benchmarking 
and to study inequalities. The 2017 version of the ESC guidelines for the management of STEMI patients [46] 
recommend a set of QIs to measure and compare the quality of health service provision, based on the ESC/
ACCA proposal [133].
A comprehensive approach to quality assessment and improvement should be made at four levels of 
analysis: national, regional, institutional and individual, as suggested by Leatherman [135].
There are several examples of quality of care assessment and improvement initiatives for CHD, performed at 
different levels. In the United States of America, the Guidelines Applied in Practice program from the ACC [136], 
and the Get With The Guidelines program from the AHA [137] were developed to increase the use of evidence-
based medical therapies for patients with ACS in the acute phase of the illness, at hospital discharge and at 
long-term follow-up. In Europe, several initiatives were also developed to increase the use of CHD guidelines. 
The EURopean Hospital Benchmarking by Outcomes in acute coronary syndrome Processes (EURHOBOP) 
study intended to provide the European Community with valid standardised and adjusted benchmarking tools 
that allow European hospitals to monitor their outcomes in key procedures used in CHD [138]. The European 
Heart Health Strategy (EuroHeart) I [139], by strengthening cross-sector cooperation and determining areas 
of policies and public health interventions which can contribute to prevent avoidable deaths and disability 
across Europe, ultimately served the propose of increasing adherence to guidelines, and included one package 
specifically drawn to improve awareness, diagnosis and treatment of cardiovascular disease in women.
Several strategies for hospitals to encourage maximal utilisation of evidence-based interventions for ACS 
care have been described, including separate standardised order sheets [140], quality of care teams to do 
real time surveillance and ensure that guideline-based therapies are not omitted in patients unless specific 
contraindications [141], and evaluation and report of performance to quality metrics on a regular basis [142]. 
Patient information and discharge forms improve health literacy and are an opportunity for the patient and 
family to ask any questions they may have regarding the patient’s diagnosis, prognosis, severity of disease, 
risks and benefits of the newly prescribed medications, and follow-up plans. Lifestyle modifications, such as 
healthy eating and smoking cessation, should be included in the patient discharge forms [124].
Despite being used within and across several health care systems, there is a lack of strong scientific 
evidence supporting the many different quality improvement and patient safety strategies, namely 
dissemination of clinical guidelines, auditing and accreditation [114].
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1.2.3 Importance of registries to the evaluation of adherence to recommended guidelines
a) CRUSADE
The CRUSADE registry, developed in 2001, has been used to evaluate guideline adherence and to 
increase the practice of evidence-based medicine in NSTEACS (including unstable angina). In 2007, 
approximately 200,000 patients were enrolled [143]. The CRUSADE database provided important 
observations on guideline adherence. The database was used to evaluate the usage of early invasive and 
conservative approaches; recipients of the early invasive approach were younger, more frequently male 
and white, more likely to be under the care of a cardiologist, and less likely to have heart failure or impaired 
renal function [144].
b) GRACE
The GRACE registry was a multinational study conducted between 1999 and 2009 to assess patient 
characteristics, clinical outcomes, and derive predictive risk scores in patients with ACS. Main GRACE 
involved 123 hospitals in 14 countries in North and South America, Europe, Australia, and New Zealand. 
GRACE 2 (expanded GRACE) comprised 154 hospitals in Europe, North and South America, Asia, 
Australasia, and China [145].
By identifying missed opportunities, GRACE analyses were critical to improve the quality of care of ACS 
patients. One example was the observation that modern reperfusion strategies were not offered to nearly 
30% of eligible patients with STEMI in 2002, particularly to the elderly, those with atypical presenting 
symptoms and those with previous coronary bypass surgery [146]. Rates of reperfusion of eligible STEMI 
patients in 2008 were clearly improved [147].
GRACE also provided strong evidence that adherence to performance measures in the use of 
medications, both in-hospital and at discharge, is associated with mortality reduction [148], and identified 
opportunities to improve quality of care in vulnerable populations of ACS, including those with diabetes, 
heart failure and women [149-151].
c) EUROASPIRE
In nine European countries in 1995 and 1996, a survey was developed to describe clinical practice, 
namely secondary prevention of CHD [152], the European Action on Secondary and Primary Prevention 
by Intervention to Reduce Events (EUROASPIRE) I. The EUROASPIRE II (1999 to 2000), III (2006 to 2007) 
and IV (2012 to 2013) surveys were conducted in the same geographical areas and selected hospitals 
in each country, and included consecutive patients (≤70 years) after CABG, PCI, or ACS. According to 
comparisons of results of these surveys, lifestyle habits have deteriorated over time with increases in 
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obesity, central obesity and diabetes, and stagnating rates of persistent smoking. Although blood pressure 
and lipid management improved, they were still not optimally controlled [153].
d) CICD
The Chronic Ischaemic Cardiovascular Disease (CICD) registry was created to characterize CICD in 
terms of demographic characteristics, clinical profiles management and outcomes, and to identify inter-
regional differences and potential gaps between actual treatment and evidence-based recommendations 
in a European contemporary environment.
The CICD-Pilot survey, an international prospective observational longitudinal registry in CHD and/or 
peripheral artery disease patients with a 3-year follow-up, aimed to validate the structure, performance, 
feasibility and quality of the data set, with the intention of extending the survey to other participating 
European countries into a long-term registry. Portugal was one of the Southern European countries 
participating in the CICD-Pilot [154].
From April 2013 to December 2014, 2420 consecutive CICD patients with NSTEACS (n=755) and chronic 
stable CHD (n=1464), or with peripheral artery disease (n=201), were enrolled. According to the results of 
the CICD-Pilot registry, the implementation of guideline recommended therapies has improved since the 
previous surveys. However, important heterogeneity exists in the clinical profile and treatment modalities 
in the different cohorts of patients enrolled with a broad spectrum of CICDs.
e) Portuguese registries
The National Cardiology Data Collection Centre (Centro Nacional de Coleção de Dados em Cardiologia), 
was created in 2002 by the Portuguese Society of Cardiology, to provide logistic support for joint national 
studies, including technical, data management and human resources. This data centre gives support to 
two continuous registries, the National Registry of Acute Coronary Syndromes and the National Registry 
of Interventional Cardiology, which were established in January 2002; to periodic registries on metabolic 
syndrome (the VALSIM study, beginning in 2006) and on hypertension and dyslipidemia (beginning in 
2005); and to the ESC’s Euro Heart Surveys [155].
These registries showed that the implementation of guideline recommended therapies for ACS and 
outcomes have improved in Portugal in the last two decades and also identified issues requiring further 
interventions [156,157].
These observational data enabled the identification of an important gap between recommendations 
and clinical practice, and identified groups of patients with CHD deserving further investigation to 
assess and understand these inequalities in management, namely women, older patients, patients of 
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low SEP, patients of minority ethnic groups, patients from certain geographical regions, and those with 
comorbidities, including diabetes, heart failure and renal failure. Opportunities to improve quality of care 
of these vulnerable populations with CHD were identified.
1.3 Health inequalities, “the causes of the causes”
Health inequalities are systematic disparities in health or in the major determinants of health between 
distinct populations or groups, defined by a large variety of constructs, including age, gender, SEP, ethnicity 
and geographic region. Inequalities in health systematically put groups of people who are already socially 
disadvantaged at further disadvantage with respect to their health [158]. Inequalities have important 
impacts on the accessibility and effectiveness of cardiovascular disease preventive measures [159].
The Black Report [160] (Report of the Working Group on Inequalities in Health), published in 1980 by 
the United Kingdom Department of Health and Social Security, showed an unequal distribution of ill-health 
and death among the British population, and suggested that these inequalities have been widening rather 
than diminishing since the establishment of the National Health Service in 1948. The Report concluded 
that these inequalities were driven by social inequalities influencing health (income, education, housing, 
diet, employment, and conditions of work), increasing the interest of researches and public policy on 
health inequality. This report also showed that the provision of free services to all citizens at the time 
of need did not reduce differences in mortality risk between people in more and less advantaged social 
circumstances. Access to health care itself was not sufficient to reduce health inequality, mainly due to 
two main reasons, one is the relevant role of social environment and lifestyles in health, the other is the 
fact that most common causes of mortality and disability in developed societies, namely CHD, involves 
longstanding processes, diagnosed and treated late in the natural long period course of the disease [161].
A socioeconomic explanation of health inequalities is relevant to all countries in the world. The model 
of socioeconomic determinants of health [162], developed in 2007 by Solar and Irwin for the Commission 
on Social Determinants of Health, is a conceptual framework that goes beyond the immediate causes 
of disease. Applied to the study of inequalities in CHD, it serves to trace individual “agentic” level or 
the societal “structural” level determinants of cardiovascular health, which interplay between them. 
Understanding inequalities in management and outcomes is therefore a complex task, because it involves 
the quantification of different factors and at different levels. This socioeconomic model traces the roots of 
health and disease beyond health services to determinants at the macro level, namely public, social and 
economic politics, cultural and societal norms and values, which influence at the individual level gender, 
education, occupation, income, ethnicity/race and other SEP indicators. These individual socioeconomic 
characteristics have impact in health by determining health literacy, psychosocial factors and behaviours, 
which can favour or protect against disease risk factors and also influence attitudes toward health and 
health service interactions. The practical implication for this conceptual framework is that measures 
undertaken to reduce health inequalities should not only target the system level of access, but also the 
patient level, and the general population, with its several dimensions [162].
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The concept of health inequality is sometimes used with ambiguity, we use the term as descriptive in 
nature, of variations in health by groups, without assuming a moral judgment of unfairness. By contrast 
the term “inequity” applies to health variations that being unnecessary and avoidable are judged to 
be unfair or unjust, and therefore unacceptable. The term ‘inequity’ has therefore a moral and ethical 
dimension [118]. Equity in health relates to allocating means unequally, based on the notion that different 
subpopulations have different needs and it is concerned with creating equal opportunities for health, 
bringing health differentials down to the lowest possible level. Equality means making the same offer 
accessible to all people regardless of potentially different needs level [118]. A long and complex debate 
exists about equality, equity and justice in health [163].
When health inequalities emerge, it is complex to conclude to which extent they are inequities [118,158]. 
The answer to the question of which inequalities are inequities varies according to place and time. Margaret 
Whitehead, by proposing seven main determinants of health differences and by identifying those that are 
unfair, gave a good contribution to this discussion (Table 3) [118].
Table 3.  Seven main determinants of health differences proposed by Whitehead [118].
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Inequ lities
Inequities
Monitoring inequality was considered an emerging priority for health post-2015 [164]. The World Health 
Organisation developed initiatives related to health inequality monitoring at the global and/or national 
level, which improved availability of disaggregated data [165]. Sustainable Development Goals cannot 
be accomplished without addressing inequality, and the goal is “leaving no-one behind” [166]. Health 
inequality monitoring entails collecting, analysing, interpreting and reporting health disaggregated data. 
With the World Health Organisation’s Health Equity Monitor database, between 2014 and 2016, the Health 
Equity Assessment Toolkit software was developed [167]. This application allows for the assessment of 
inequalities within a country using over 30 reproductive, maternal, newborn and child health indicators, 
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and five dimensions of inequality (economic status, education, place of residence, subnational region and 
child’s sex, where applicable).
1.3.1 Determinants of inequalities in coronary heart disease by vulnerable group 
a) SEX AND GENDER
Both biological and social/cultural factors are important for women’s and men’s health status. A dichotomous 
view of the concepts of sex and gender pretended to capture separately those factors. Unlike one’s biological 
sex, gender was considered the social and cultural construction of masculinity and femininity [168]. The 
American Psychological Association stated that “sex is biological; use it when the biological distinction is 
prominent”, while “gender is cultural and is the term to use when referring to men and women as social 
groups” [169]. In 2001, the Institute of Medicine defined the concepts similarly: sex was classified according 
to reproductive organs and functions assigned by the chromosomal complement, and gender as a person’s 
self-representation as male or female, or how that person is responded to by social institutions on the basis 
of the individual’s gender presentation [170].
The terms sex and gender employed in biomedical publications are frequently misused [171], it is not so 
simple to separate biology from social/cultural factors. More recently, the concepts of “sex” and “gender” 
meant for gender researchers within medicine were explored. They concluded that “sex is more than 
biology”, concepts of “sex” and “gender” should be looked beyond a dichotomous view, because they are 
intertwined [172]. To compare differences between women and men in papers of this thesis, we used the 
term “sex”, considering that “sex is more than biology”.
Sex and gender gap in CVD research
The first inequality is the sex and gender gap in CVD research. Besides sex and gender differences 
across most areas of heart disease, women are still underrepresented in cardiovascular research, namely 
in the field of CHD. The EuroHeart project revealed a high underrepresentation of women in randomized 
clinical trials. Since 2006, the percentage of women enrolled in trials ranged between 15% and 60%, but 
only 50% (31 trials) reported an analysis of the results by sex/gender [173]. It is accepted that one priority 
of research is the need for more explanatory sex and gender specific cardiovascular research [174] to be 
able to adapt existing guidelines for better cardiovascular health in women.
Burden
CHD was perceived as a disease predominantly affecting males, which promoted a knowledge gap with 
Introduction  |  39
impact on physicians and also on patients, contributing for suboptimal care for at-risk women [175]. In fact, 
women and men are about equally affected by the still main cause of death across Europe, 20% of females 
and 19% of males dye from CHD in Europe [38]. To strengthen that sex-specific CVD research is a priority 
is the fact that, in some settings, the decline in mortality from CHD does not extend to younger women (49 
and under), in whom the rate of change has reversed in the last 20 years, indicating a future plateau and 
possible reversal of previous improvement in CHD mortality rates [176].
Pathophysiology
One of the major sex differences in CHD is in the pathophysiology. Women have higher probability 
of non-obstructive CHD, and of coronary plaque erosion and distal embolization, microemboli and 
dysfunction of the microvascular coronary system [177], mainly women at younger ages [178]. In fact, 
the role of microvascular dysfunction leading to subendocardial ischaemia without coronary obstructive 
disease seems to be greater in women than in men [179]; MINOCA and INOCA are more frequent 
among women [52,58,180]. Inflammatory and thrombotic processes are involved in the progression of 
atherosclerotic disease in men and women, while the role of endogenous oestrogen status in delaying the 
onset of atherosclerosis in women is not definitively clarified [181]. Furthermore, inflammatory diseases, 
which may be more involved in the progression of atherosclerosis in females, are more prevalent in older 
women compared with men [182].
Cardiovascular risk factors
Although CVD risk factors are the same in women and men, once CHD has developed, women tend to 
have a higher burden of risk factors, when compared to age-matched male patients [183]. Additionally, 
although overall prevalences of traditional cardiovascular risk factors are higher in men, which largely 
explains the lower ACS prevalence among women at younger ages [184], there is substantial sex/gender 
related variability in their relative weighting and in the associated outcomes [185]. Elderly hypertensive 
women and young female smokers are particular at risk subsets [186-188]; as are female diabetic patients. 
According to a meta-analysis of prospective cohort studies, the relative risk for fatal CHD associated with 
diabetes is 50% higher in women than in men [189]. Although women with diabetes have more classical 
cardiovascular risk factors than men; excess risk factor clustering only partially explains how diabetes 
eliminates the “female advantage” of a predominately lower CHD prevalence and outcome risk [190]. 
The prevalence of hypercholesterolaemia is lower in women compared with men, but above 65 years 
of age, mean low-density lipoprotein-cholesterol is higher among women [191]. High-density lipoprotein 
cholesterol values in men are generally lower than those of women at all ages, but sex/gender differences 
in high-density lipoprotein values diminish with advancing age [175]. Hypertriglyceridaemia and low high-
40
density lipoprotein cholesterol seem to be more important risk factors of CVD for women than men [7].
Psychosocial factors strongly influence the development of CHD, particularly among women [192]. 
Besides traditional psychosocial factors (e.g. depression), factors associated with responsibilities at home 
or multiple roles have an important deleterious impact on CHD risk and prognosis in women [192,193]. 
Women have a lower SEP more often, and a lower social support is associated with worse health status 
and more depressive symptoms over the first year of AMI recovery, particularly for women [194]. Men 
and women experience different barriers to lifestyle change, display distinct dietary patterns and levels 
of physical exercise, and are subject to different psychosocial factors. Their different socio-cultural 
preferences impact sustained adherence to healthy behaviour [195]. A group-based psychosocial 
intervention program for women with CHD may prolong lives independently of other prognostic factors 
[196]. Behavioural factors have been addressed in guidelines for CVD prevention, but a more gender 
specific approach is still lacking [23]. 
Traditional risk factors underestimate the CHD risk in women, non-classic risk factors were proposed 
to improve risk stratification, namely C-reactive protein, whose mean levels are higher in women compared 
to men [197]. The hypothesis is that of a synergism between inflammation and other traditional risk factors 
to speed up the development of CHD in women (4).
The lower perceived risk of CVD despite a similar calculated risk for women versus men is one of the 
main factors associated with a lower adherence to CVD preventive recommendations [198]. According to 
the EUROASPIRE III results, women are less likely than men to achieve blood pressure, cholesterol and 
glycated haemoglobin targets after a coronary event, despite similarities in medication exposure. This gap 
did not narrow between 1994 and 2007 [199].
Clinical presentation and diagnoses approaches
Women have a similar or slightly higher prevalence of angina across countries that differ widely in AMI 
mortality, despite men having a universal excess of fatal AMI [200]. There is a widespread understanding that 
women with CHD present with symptoms that are different from those in men. However, current evidence 
supports that the same symptoms during an ACS episode occur, though available data are not consistent 
regarding the proportion presenting with different symptom combinations [201-203]. Sex/gender specific 
research of ACS presentation is therefore a priority [204].
Significant sex/gender bias has been identified in the use of investigations in stable CHD [205]. In women, 
the accuracy of most non-invasive diagnostic investigations for CHD is diminished compared with men [206], 
as is coronary angiography, which is considered the gold standard to detect CHD if obstructive, and therefore 
less suited for middle aged women [207]. The use of more advanced non-invasive imaging modalities such 
as resonance perfusion imaging or computed tomographic angiography, as well as intracoronary imaging 
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techniques, has the potential of being better suited to the detection of CHD in female patients [46,174].
Acute coronary syndrome
Differences in outcomes of therapeutic strategies in NSTEACS low-risk patients were observed 
between men and women, the benefit in mortality of an early invasive strategy was only observed for men 
[208,209]. Additionally, an increased risk of adverse clinical outcomes was observed for women with ACS 
undergoing an early invasive strategy and coronary revascularisation compared with men [210].
Analyses of sex/gender based differences in outcomes after ACS have revealed conflicting results. 
In STEMI, female sex (especially young women) is associated with higher in-hospital mortality but not 
with long-term mortality [211]. Other studies showed that in STEMI, 30-day mortality was higher among 
women, whereas in NSTEMI and unstable angina mortality was lower among women, but after additional 
adjustment for clinical differences at presentation and angiographic disease severity, 30-day mortality 
among women was not significantly different than among men, regardless of ACS type [212]. The 
increased mortality might be explained by the fact that women with ACS are generally older with more 
clustering of risk factors, differences in treatment and in vascular flow [174]. Furthermore, although rates 
of vascular complications in women have decreased in the last two decades with the development of 
less aggressive anticoagulation regimens, weight-adjusted heparin dosing, and the availability of smaller 
sheath sizes suitable for the smaller newer third and fourth-generation devices; women undergoing 
PCI (primarily through the femoral artery) continue to have a two-fold increased risk of bleeding and 
vascular complications compared with men, even after adjusting for differences in baseline and procedural 
characteristics [213]. Women with bleeding complications have a 75% increased risk of death, AMI, or 
stroke during their index hospitalisation after controlling for both clinical and procedural differences [213]. 
Thus, therapies that reduce bleeding complications after PCI may be particularly beneficial to female 
patients, and may help to narrow the mortality gap between men and women. One useful strategy, that has 
proved to reduce bleeding, is the use of radial instead of femoral access [214].
Furthermore, obstructive CHD has been the focus of therapeutic strategies [197], therefore benefiting 
more male patients.
But not all is biology, feminine roles and personality traits were associated with higher rates of recurrent 
ACS and major adverse cardiac compared with masculine characteristics, independently of female sex [215].
b) SOCIOECONOMIC POSITION
Socioeconomic position (social class, social stratification, social or socioeconomic status are often used 
interchangeably) is a common and intuitive concept in health research. However, there are several socioeconomic 
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indicators and ways to measure them, which indicate the complexity of the construct [216].
Krieger and colleagues [217] discussed in detail concepts and methodologies to measure socioeconomic 
inequalities in health. Socioeconomic position refers to the social and economic factors that influence 
what positions individuals or groups hold within the structure of a society, and is related to numerous 
exposures, resources and susceptibilities that may affect health [217]. Different socioeconomic indicators 
measure different, often related aspects of socioeconomic stratification. According to aims, settings and 
time frames, and also whether SEP is the exposure of interest or a potential confounding/mediating factor, 
one or another will be more or less suitable for research [216]. Several socioeconomic indicators besides 
gender exist: education, income, occupation based measures, subjective social class, housing characteristics 
and geographic region are examples of indicators measuring life course SEP of the individual, each having 
advantages and limitations [216,218]. Considering the complexity of the socioeconomic construct, particularly 
when SEP is a potential confounding factor, a single measure of SEP will not encompass the entirety of the 
effect of SEP on health. Multiple SEP indicators or composite measures will be needed to avoid residual 
confounding by unmeasured socioeconomic circumstances [219] and also to deal with the time varying 
exposure nature of SEP [220].
The inverse association between SEP and health status is particularly evident in the case of CHD. 
However, the underlying mechanisms by which social inequalities impair cardiovascular health are complex 
and not well understood [221].
There is an accepted association between SEP and CV risk factors, namely with hypertension [222], 
tobacco smoking [223], physical inactivity [224] and obesity [225]. The influence of SEP on cardiovascular 
risk factors is different between women and men [226]. To analyse results of studies on this subject, the 
setting, timeframe and the SEP indicators used should be taken into account.
Part, but not all SEP differences in CHD risk are accounted for by associated differences in risk factors 
prevalences; growing evidence supports a role for social cognitions for this association [221,227]. Differences 
in incidence of CHD between patients with different SEP are explained not only by cardiovascular risk 
factors, but also by psychosocial work environment and social support [228].
Even in settings with universal health care systems, SEP had effects on access to invasive cardiac 
procedures following an AMI [229], and this socioeconomic gradient is not explained by geography and 
service supply [230].
Patients from lower SEP are less likely to change risk behaviours (smoking cessation, cardiac 
rehabilitation, medication adherence, diet and physical activity) following an AMI [231]. The excess CHD 
mortality and morbidity rates among persons with low SEP were considerable in developed settings [232], 
and seem to have persisted over time [233]. The inverse relationship of SEP with CHD risk, management 
and outcomes probably lies in a complex interaction of genes, environment and behaviour.
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1.4 The Portuguese context
According to the recently published health system review report [234], health inequalities remain a 
general problem in Portugal. As per this report, health inequalities in Portugal are mainly related to gender 
and geographic location [234].
Portugal (including the two archipelagos of Azores and Madeira) has a population of 10.3 million 
people, has a democratic regimen since 1974, and is a member of the European Community since 1986 
and of the Euro Zone since 1999. Portugal is divided into municipalities and parishes, which have their 
own level of elected government. Mainland Portugal is conceptually divided in five regions (North, Centre, 
Lisbon, Alentejo and Algarve), but regional authorities have no real decisional power and the government 
nominates their leaders [234].
The average life expectancy at birth in Portugal was 81.3 years in 2014 (European Union in 2014: 80.9 
years). According to data from 2014, Portuguese women are expected to live 6.4 years longer than men, 
whereas the EU average is 5.5 years. Increasing life expectancy, the decline in fertility rates and the 
decrease of those aged 15–64 years are causing a “double ageing” effect in Portugal, which will pose a 
huge nearby challenge to the health system [234].
1.4.1 The Portuguese health care system
In 1946, the first social security law was launched, health care was provided for the employed population 
and their dependents through social security and sickness funds. After 1974, a process of health services 
was progressively restructured and in 1979 the National Health Service (NHS) was established [235]. 
The NHS is a universal system, financed mainly through taxation. The Portuguese health system has 
three co-existing and overlapping systems: the NHS (with the aim of being “universal, comprehensive 
and almost free”); special health insurance schemes for particular professions or sectors called the health 
subsystems (covering approximately 16% of the population) [236]; and private voluntary health insurance 
(covering about 26% of the population) [237].
Regional health administrations were introduced in 1993 and are responsible for management at the 
regional level, although with financial responsibilities limited to primary care because hospital budgets 
are defined centrally. The autonomous Azores and Madeira have broad powers for their own health care 
planning and management. Public and private expenditure in the NHS account for approximately 66% 
and 35% of total health expenditure, respectively [234].
In May 2011, the economic crisis led Portugal to sign a Memorandum of Understanding with the 
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International Monetary Fund, the European Commission and the European Central Bank [238,239]. A set 
number of measures in the health sector were therefore implemented, aimed at increasing cost-containment, 
improving efficiency and increasing regulation [240].
Resources and provision of health services
In Portugal in 2014, there were 225 hospitals, 113 of which belonged to the NHS, with a total capacity 
of 34,522 beds. There were 442.6 physicians per 100,000 population (above the European Union average 
of 349.6) and 637.8 nurses per 100,000 population (below the European Union average of 864.3). Health 
workers and health equipment are concentrated in the major urban centres and along the coast, leaving 
the interior underserved. Despite the universal and comprehensive nature of the NHS, for example the 
lack of all medical specialties in hospitals located outside great metropolitan areas like Lisbon, Porto 
and Coimbra represents geographical gaps in provision. The distribution of health resources, including 
health workers, does not seem to take into consideration the characteristics of the population, for example 
municipalities with a higher ageing index, and therefore higher health needs, are not those concentrating 
more resources, in part because those municipalities are not very densely populated [241].
The NHS predominantly provides primary care and acute hospital care. Although with public funding 
to a considerable extent, dental consultations, diagnostic services, renal dialysis and rehabilitation are 
more commonly provided in the private sector. The reorganisation of Portuguese primary care was started 
in 2007, with the creation of Family Health Units. Hospitals provide secondary and tertiary care, and are 
grouped into Hospital Centres covering a given geographical area [234].
In Portugal, public hospitals provide treatment for the majority of acute coronary events [242]. According 
to the cardiology referral net that was updated in 2015 [243], there are 38 public hospitals with human 
and technical resources to provide structured care for patients with ACS, of which 16 have catheterisation 
laboratory facilities. A coronary fast track system was implemented at the national level, with the aim of 
increasing the proportion of STEMI patients submitted to reperfusion, namely through primary PCI. This 
fast track system is organized to diagnose ACS, to identify the subgroup of patients with STEMI by enabling 
the performance and analysis of ECG, to provide immediate care, and to assist in transport to the appropriate 
hospital. The National Institute for Medical Emergencies (INEM) is responsible for the coordination and 
functioning of an integrated medical emergency system in Portugal, and is crucial to the coronary fast track 
functioning. INEM provides medical aid at the scene; assists transportation of patients to the appropriate 
hospital; and ensures the coordination between various participants in the system [234].
Nevertheless, a description of the cardiology resources at the national level hides a heterogeneous 
geographic distribution. Cardiologists are concentrated in Lisbon and in the North, regions where 42.4% 
and 34.1% of the total number of Cardiologists work, respectively. Additionally, in 2013, the number of 
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catheterisation laboratory rooms per inhabitant varied from 1/743,306 in Alentejo to 1/311,947 in Lisbon. 
For example, in the northeastern region of Portugal, an interior and rural region, several subregions have 
only access within a maximum of 60 minutes to one basic emergency department, while the coastal regions 
have several emergency departments, basic, intermediate and with intensive care facilities accessible 
within the acceptable maximum distance, considering the importance of rapid access to the appropriate 
health service of patients with ACS [243].
1.4.2 Coronary heart disease in Portugal
Burden
In terms of CVD disease, Portugal is a low-risk country (the age-adjusted 2012 CVD mortality cut-offs 
in those 45 –74 years of age are less than 225/100,000 in men and less than 175/100,000 in women) [23].
According to the latest available data from Statistics Portugal [244], diseases of the circulatory system 
were the main cause of death in 2015. In 2015, CHD [International Classification of Diseases (ICD) 10: 
I20-I25] accounted for 6.7% of mortality in the whole country (7.5% for men and 6.0% for women), but with 
differences by region, ranging from 9.8% in Azores to 3.7% in Viseu, Dão, Lafões and Coimbra regions. 
The sex ratio for death due to CHD was 124.4 male deaths per 100 female deaths. For CHD, the age 
standardised mortality rate was 37.1 deaths per 100,000 inhabitants (52.6 for men and 24.4 for women); the 
adjusted rate of potential years of life lost (YLL) was 182.6 per 100,000 inhabitants (317.7 for men and 59.7 
for women); and the average number of potential YLL 11.1 (11.6 for men and 9.2 for women) [244].
In Portugal, in recent decades a dramatic decrease in CVD mortality and YLL was observed, with a 
parallel transition towards cancer, with women having the highest burdens of disease from CVD until later 
than men [245].
In 2015, CHD was responsible for the loss of 1,272 DALYs per 100,000 males and of 571 DALYs per 100,000 
females, being within the group of European countries with the lowest age-standardised DALYs rate for 
CHD [246]. Results of evaluation of the burden of CHD by region in Portugal in 2013, revealed that age-
standardised DALYs rates per 1000 population ranged from 7.3 in the Northern and Central regions to 11.8 in 
the Algarve in men, and from 2.6 in the Northern region to 4.6 in Lisbon in women [247].
Inequalities in risk factors, management and treatment
Important insights about relative contributions of different primary and secondary prevention measures 
to the decline in CHD mortality in Portugal were given by Pereira and colleagues [248], with the application 
of the IMPACT CHD Policy Model. This model was able to explain 92% of the estimated decrease in number 
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of deaths. Approximately 42% of the decrease in CHD mortality explained by the model was attributable to 
population risk factor reductions, mainly blood pressure (27% in men and 60% in women) and total cholesterol 
(14% in men and 5% in women), and smoking in men (11%). However, these reductions were partially offset 
by adverse trends in diabetes (18% in men and 2% in women) and obesity (6% in men and 5% in women), 
and smoking in women (2%). In the last decades, there was a decrease in blood pressure levels, observed in 
middle-aged and older adults, while among young adults, the levels remained approximately constant [249]. 
Self-reported diabetes and overweight/obesity increased in both sexes; and smoking prevalence increased 
only among women [248,250-252].
No systematic and comprehensive information about trends in risk factors by Portuguese region or SEP 
is available. However, cross-sectional studies on some cardiovascular risk factors support inequalities in 
their distribution by Portuguese region [253,254] and SEP [255,256]. According to results of an ecological 
study, using aggregated statistics on hospital admissions and mortality from CHD between 2000 and 2007, 
and regional data on demography, economics and health care resources, an inner/coastal pattern in the 
geographic distribution of incidence and mortality from CHD was clear even after adjustment for age, gender, 
economic development and health resources distribution [257].
According to the IMPACT model, approximately 50% of the decrease in CHD mortality explained was 
attributable to increased uptake of treatments, including initial treatments after an AMI (10%) [248]. In recent 
decades, an improvement in secondary prevention of ACS was observed in Portugal. There was an increase 
in the use of recommended pharmacological therapy for secondary prevention, during hospitalisation and 
at hospital discharge, after an ACS [258]; the proportion of mixed ACS patients treated with fibrinolysis 
decreased and the use of PCI increased, while the use of CABG did not change [259]. Between 2002 and 
2013, there was a three-fold increase in primary angioplasty rates per million population, with no statistically 
significant differences in age and sex distribution by year of analysis [260]. Between 2010 and 2015, a two-
fold increase in primary angioplasty was observed at the national level, no information is given about trends 
by sex, age or region [156].
According to results obtained from the Portuguese interventional cardiology database, from the period 
between 2002 and 2012, women with STEMI treated by primary PCI had a greater risk factor burden, were 
less frequently revascularised within six hours of symptom onset, and had a 1.7 times higher risk of in-hospital 
death compared with men. After risk adjustment, in-hospital mortality was similar between women and men 
with STEMI treated by primary PCI [261]. 
There are also known differences in distribution of structure and process quality indicators for CHD at the 
geographic level, namely the number of patients submitted to primary PCI, the mean time delay to coronary 
angiography, and the number of patients admitted through the coronary fast track system [243,262].
No adequate systematic monitoring of disaggregated data by group prone to inequality is available in 
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what concerns trends in secondary prevention of CHD in Portugal.
Portuguese goals to deal with inequalities
The department of quality in health of the National Health System was created to promote and 
disseminate the improvement of the health institutions quality, proving efforts to develop this area in 
Portugal [263]. The current National Health Plan, which was extended until 2020, defines strategies for 
improving citizens’ empowerment and tackling health inequalities, through involvement of social and 
private sectors, and the development of intersectoral and multidisciplinary approaches [264]. The current 
plan sets four main axes: health citizenship, equity and adequate access to health care, health quality, and 
health policies.
The National Strategy for Quality in Health 2015–2020, in line with the European Union Health 
Programme 2014–2020, defines several priorities, including improving organisational and clinical practice 
quality; increasing the adoption of practice guidelines in clinical practice; strengthening patient safety; 
strengthening clinical research; continuous monitoring of quality and safety; disseminating comparable 
performance data; improving quality and accreditation of health care providers; providing transparent 
information to citizens and citizens’ empowerment [234]. However, the health policy-making process is 
not systematically evaluated; health impact assessments have not been institutionalised in Portugal, nor 
have specific guidelines on this subject been produced [234].
The information infrastructure of the health system in Portugal is extensive, with electronic platforms 
that store different kinds of health information, used for different purposes. Limitations related to effective 
connection of different platforms and challenges concerning patient privacy and the legal basis for 
connecting patient data exist in the monitoring and reporting of the health system performance, and in 
the use of these data for research purposes.
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Independently of differences in patient and system level determinants of health care between and 
within countries, tackling inequalities in health status is a worldwide target priority [165], and a task 
particularly important and challenging for Portugal [234]. Cardiovascular science advances over the past 
two centuries have been remarkable, and today, a huge focus is set to improve the implementation of 
well-established consensus in this field in routine clinical practice. The continuum of CHD presentation, 
the effective and safe diagnoses and therapeutic approaches available and the current organisation of 
health systems in developed countries create several opportunities to improve the quality of care of these 
patients, which encompasses reducing inequalities. To study inequalities in management and outcomes 
of patients with CHD in Portugal, we used two frameworks to address the complex process of care of this 
disease, particularly of ACS: the model of socioeconomic determinants of health proposed by Solar and 
Irwin [162], and the model of access to health care proposed by Levesque [122]. Departing from the clinical 
knowledge of the disease, the use of these conceptual frameworks was structural to guide the objectives, 
select data sources, groups of patients, variables of exposure, outcomes and confounding; and also to 
analyse and interpret results (Figure 3).
2. OBJECTIVES
Figure 3.  Conceptual framework to study inequalities in CHD in Portugal (adapted from the model of socioeconomic determinants 
of health proposed by Solar and Irwin [162], and from the model of access to health care proposed by Levesque [122]).
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The specific objectives of this thesis are depicted in figure 4 and are the following:
1.  To describe time trends in death rates, absolute number of deaths and years of life lost from coronary 
heart disease among men and women in Portugal, by region, during the period 1981–2012 (Paper 1).
2.  To analyse sex differences in conservative vs invasive management of acute coronary syndrome in 10 
hospitals with different characteristics (Paper 2).
3.  To assess differences by sex in management and outcomes (30-day mortality) of patients with acute 
myocardial infarction, by the application of standard quality indicators (Paper 3).
4.  To analyse sex differences in presenting symptoms of acute coronary syndrome (Paper 4).
5.  To assess the proportion of patients with a first episode of acute coronary syndrome who reported 
chest pain, medical care seeking and performance of exams because of the pain; and to identify determi-
nants of seeking medical advice and referral to electrocardiogram (Paper 5).
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We started our research by assessing differences in outcomes from CHD at the geographical level and 
separately in men and women. Departing from assessing inequalities at the regional level, we then moved 
to the individual level, analysing differences in management and its relation with outcomes between women 
and men hospitalised with an ACS. Considering that different diagnostic accuracy of symptoms by sex 
may be one possible determinant of delayed diagnosis, of management and of attainment of the maximal 
benefit of treatment, we decided to characterise differences by sex in clinical presentation of ACS. We 
then moved backward, towards potential missed opportunities to intervene before the ACS phase.
Figure 4.  Schematic depiction of the specific objectives.
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Background: Information is scarce about the geographic variation in time trends of mortality from coronary heart
disease (CHD).We aimed to describe trends in death rates, absolute number of deaths and years of life lost (YLL)
due to CHD among men and women in Portugal, by region, from 1981 to 2012.
Methods: The age-standardized mortality rates from CHD were estimated by sex and region. We used joinpoint
regression analysis to calculate the annual percent change (APC) inmortality and to identify points of significant
change in the trend. The YLL due to prematuremortality for CHDwere computed using the Global Burden of Dis-
ease method.
Results: The age-adjusted mortality from CHD decreased between 1981 and 2012, both in men and women, but
with significantly different APC by region. Smaller declines in rates were observed in Alentejo (men: APC 1993–
2012:−2.4%; women: APC 1991–2012:−2.4%). The greatest decline was observed in Madeira between 2003
and 2012, in men (APC:−7.6%) and women (APC:−9.7%). The decline in rates in Algarve started only after
2003, whereas it was consistent from 1981 in the North and started in the 1990s in most other regions. A de-
crease in the number of deaths was only observed after 2000. The YLL from CHD decreased from 1981 to 2012,
mainly after 2000.
Conclusions: In Portugal, between 1981 and 2012, relative declines of CHDmortality indicators were different by
geographic region. Consistent decreases in mortality rates were only observed in the Centre, Lisbon and North,
the most populated and urbanized regions.
© 2016 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Cardiovascular diseases (CVD) are themost common cause of death.
In 2012, almost half of non-communicable disease deaths worldwide
were caused by CVD (17.5 million deaths), more than double the num-
ber of deaths caused by cancers [1,2]. CVD are responsible for close to
half of all deaths in Europe (over 4 million deaths per year), with coro-
nary heart disease (CHD) accounting for 20% of all deaths in Europe an-
nually (nearly 1.8 million deaths) [2]. Themost up-to-date data on CVD
still show disparities in the death rates between European countries,
with Central and Eastern Europe having higher rates than Northern,
Southern and Western Europe [2]. Within-country CVD mortality in-
equalities have been reported in several European countries, by region,
socioeconomic characteristics and country of birth [3–5].
CVD and CHD death rates have been consistently falling across most
but not all European countries; the timing and magnitude of this de-
crease also vary [2]. CHD mortality trends may also be different by de-
mographic groups, with young adults, especially women, experiencing
smaller decreases in CHD mortality rates in the two last decades [6].
Specific indicators such as years of life lost are needed to capture prema-
ture mortality due to CHD.
In Portugal, the age-adjusted mortality from CVD, in 2011, was
174.7/100,000 among men and 126.8/100,000 among women, and the
age-adjusted mortality rates from CHD are among the lowest in
Europe [2]. There was a decrease in the age-adjusted mortality from
CVD between 1980 and 2010 [7], and also from CHD [2], but there is
no information about the magnitude of these trends by region. Differ-
ences in health status by geographic region, namely in less populated
and less urban regions, are among the sizeable inequalities identified
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in the Portugal health system performance assessment in 2010, con-
ducted by the World Health Organization [8]. This report states that it
is difficult to assess and monitor the extent of the health inequalities
in Portugal, due to the lack of a monitoring system of health indicators
by target population groups, owing, at least in part, to a narrow inter-
pretation of the data confidentiality law. A recent ecological study
showed geographic variation in hospital admissions and in-hospital
mortality of patients admitted with ischemic heart disease in Portugal
from 2000 to 2007, with the interior regions showing higher rates, not
fully explained by socio-demographic, economical and health resource
factors [9]. It is of interest to expand this observation to a longer period
and to consider total mortality, in addition to in-hospital mortality.
We aimed to describe time trends in death rates, absolute number of
deaths and YLL from CHD among men and women in Portugal, by re-
gion, during the period 1981–2012.
2. Methods
2.1. Sources of data
Estimates of population at risk aswell as the number of deaths fromCHD [Internation-
al Classification of Diseases 9th revision clinical modification, (ICD 9 CM) 410–414] were
obtained from official statistics [10,11].
All data were obtained from 1981 to 2012 for each sex in age groups (b1, 1–4, 5-year
age groups to 80–84 and ≥85 years), by region [Nomenclature of Territorial Units for Sta-
tistics (NUTS II): Alentejo, Algarve, Azores, Centre, Lisbon, Madeira and North].
2.2. Trends in mortality rates
We calculated age-standardized mortality rates per 100,000 by the direct method,
using the European standard population (2013 revision) as reference [12].
To calculate the annual variation in mortality and to identify points of significant
change in the log-linear slope of the trend (joinpoints) [13] we performed a joinpoint re-
gression analysis, using Joinpoint® version 3.4 from the Surveillance Research Program of
the US National Cancer Institute. The analysis starts with the minimum number of
joinpoints, with no joinpoints corresponding to a straight line, testing if one or more
joinpoints significantly improve model fit. We set the minimum number of years before
the first, after the last and between consecutive joinpoints as five. The best fitting models
for the trends are presented formen andwomen by region. The estimated annual percent
change (APC) in mortality for each period was calculated taking the calendar year as the
independent variable and assuming a Poisson distribution.
2.3. Years of life lost
The years of life lost (YLL) due to premature mortality for CHD, by sex and age group,
in each geographic region, were computed using the Global Burden of Disease method
[14], by multiplying the number of deaths at each age by the life expectancy at the age
at which death occurs. We considered the recommended standard life expectancy at
birth of 80 years for men and 82.5 years for women. The average age at death was set to
the mid-point of each five-year age group, except for the oldest group in whom it was as-
sumed to be87.5 years [14].We applied a 3% time discount rate to assign lessweight to the
YLL corresponding to the periods more distant from the time of death than to those refer-
ring to the first years after death, an age-weighting parameter to weight YLL in the very
young and the older ages less than other ages (Global Burden of Disease standard value
is 0.04) and an age weighting correction constant so that the introduction of age-
weights did not alter the total number of YLL (Global Burden of Disease standard value
is 0.1658) [14]. The total YLL for each gender and region was obtained by summing the
YLL of all age groups. Moving averages (over 3 years) for YLL were calculated.
3. Results
3.1. Trends in mortality rates
In Portugal, the age-adjusted mortality rates from CHD decreased
between 1981 and 2012, both in men and women, though with differ-
ent patterns by geographic region, both in magnitude and year of de-
cline onset.
In Portugal, amongmen, age-standardizedmortality rates decreased
from 195.6/100,000 in 1981 to 86.7/100,000 in 2012; and among
women, from 108.0/100, 000 to 50.0/100,000, in the same period.
Among men, Azores and Alentejo were the two regions with the
highest standardized mortality rates in 1981 (326.5/100,000 and
250.3/100,000), respectively and also in 2012 (174.9/100,000 and
157.6/100,000, respectively). In the remaining regions, the standardized
mortality rates were similar among regions in 1981, ranging from
171.1/100,000 in Algarve to 186.4 in Lisbon, while in 2012 the North
showed a lower standardized mortality rate than all other regions
(66.4/100,000). Among women, Azores and Alentejo were also the
two regions with the highest standardized mortality rates both in
1981 (148.4/100,000 and 164.6/100,000, respectively) and in 2012
(97.4/100,000 for both regions). In the remaining regions, themortality
rates in 1981 ranged from 87.1/100,000 in the Algarve to 139.7/100,000
in Madeira, while the North ranked again as the region with the lowest
mortality rate in 2012 (32.6/100,000) (Fig. 1).
When analysing the decreases in standardized mortality rates over
the study period, in the whole country 1993 and 2003 mark inflexion
points for progressively steeper declines in rates among men, with
APC ranging from −0.7% in 1981–1993 to −5.1% in 2003–2012.
Among women, inflexion points were observed in 1992 and 2003,
with APC ranging from−0.2% in 1981–1992 to−5.5% in 2003–2012
(Table 1).
Among men, the decline in rates in Algarve and Madeira started
later, only after 2003, whereas it was consistent from 1981 in the
North and started in the nineties in the other regions. Among women,
Algarve also started to experience a decrease in rates only after 2004,
whereas the North and Centre had consistent decreases in rates from
1981, and from the nineties in the remaining regions, except for Madei-
ra where a fluctuating pattern was observed (Table 1, Fig. 1).
Among men, smaller relative declines in CHD mortality rates were
observed in Alentejo and in the Centre region (APC 1993–2012:
−2.4% and −3.3%, respectively), while among women the region
with the smallest decline was Alentejo (APC 1991–2012: −2.4%)
(Table 1, Fig. 1). The greatest relative decline was observed in Madeira
for the period 2003 to 2012, both in men (APC:−7.6%) and in women
(APC:−9.7%) (Table 1, Fig. 1).
The declines in mortality rates had similar magnitude over time be-
tween men and women, when analysing the country as a whole. How-
ever, in most regions, greater declines were observed among women
compared to men, with larger sex differences in the Centre (APC:
−5.7% vs−3.3%; women vs men), followed by Madeira (APC:−9.7%
vs−7.6%) and the North (APC:−6.2% vs−4.3%) (Table 1).
3.2. Number of deaths and YLL
Although the decrease in the age-adjustedmortality rates from CHD
started in the nineties in themajority of the Portuguese regions, the de-
crease in the number of deaths was only observed after 2000 (Fig. 2).
All over the country, the YLL from CHD were significantly higher in
men. The YLL from CHD decreased from 1981 to 2012, both among
men and women, ranging from a 23.9% decrease in Alentejo to a 64.5%
decrease in Madeira, among men, and from a 4.8% decrease in Alentejo
to a 57.8% decrease in Madeira, among women (Table 2). This decrease
was mainly observed after the year 2000, and Lisbon and the North
were the two geographic regions with lowest YLL, both in men and
women, during the majority of the period studied (YLL in 2012,
among men: 7.09/1000 population in Lisbon and 4.43/1000 population
in the North; and among women: 4.91/1000 population in Lisbon and
2.70/1000 population in the North) (Table 2, Fig. 2).
4. Discussion
CHDmortality rates decreased in Portugal over the last 30 years, but
with geographic disparities, meaning that cardiovascular health in-
equalities persisted in the country throughout this period. Azores and
Alentejo started with the highest rates in 1981, and despite the de-
crease, still showed higher rates in 2012, although the difference from
the other regions was attenuated. The North, on the other hand, had a
mortality rate that was dissimilar to other regions, which began to di-
verge early in the nineties but maintaining the lowest rates until 2012.
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The YLL fromCHDalso decreased from1981 to 2012 and the decrease in
the number of deaths was only observed after 2000. The CHDmortality
trends in Portugal are similar to those observed in other developed
countries of the world, namely in Western Europe [15]. This decline
has generally been described at the national level, which masks any
existing differences between socioeconomic groups or geographic
regions.
From 1981 to around 2000 the increase in the population size and
the older age structure [11] exceeded the contribution of decrease in
rates to a lower mortality burden, explaining an increase in the number
of deaths due to CHD until 2000. The higher YLL from CHD in men is in
accordance with the fact that the difference of CHD risk by sex is signif-
icantly larger in young people. Lisbon and the North are the two regions
with the youngest population, explaining the lowest YLL observed [16].
The inequalities in CHD mortality trends by Portuguese region are
dependent on two main domains, namely 1) the prevalence of cardio-
vascular risk factors and 2) health-care related factors, including the dis-
tribution and quality of health resources, access to the services and
patterns of use of health care [17]. These factors are related not only
with socioeconomic conditions, but also with lifestyle choices,
Fig. 1. Time trends in age standardized (European population) mortality rates for coronary heart disease, by sex and region, 1981–2012.
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structured by cultural forces, often operating in opposite directions. For
instance, in Portugal, those forces promote the Mediterranean diet and
at the same time smoking among women [17].
The contribution of the reduction in risk factors to the decline of Por-
tuguese CHDmortality from 1995 to 2008 was estimated to be 42% and
the increase in the uptake of treatments contributed approximately 50%
[17]. Previous studies have analysed trends in the prevalence or means
of cardiovascular risk factors in Portugal [18–20]. In the last decades
there was a decrease in blood pressure levels, observed in middle-
aged and older adults, while among young adults the levels remained
approximately constant [18]. Self-reported diabetes and overweight/
obesity, on the other hand, increased in both sexes; while smoking
prevalence increased only among women [17,19–21]. These estimates,
very important to understand the main determinants of the CHD mor-
tality decline in Portugal, certainly conceal different proportions across
geographic regions.
There is no systematic and comprehensive information available
about trends in risk factors by Portuguese regions, but cross-sectional
studies on some cardiovascular risk factors distribution by Portuguese
region convey relevant information. According to the AMALIA study
[22], which included 38,893 individuals, with regional, gender and
age-group distribution representative of the Portuguese population, be-
tween October 2006 and February 2007, Azores, one of the regionswith
the highest standardizedmortality rate over the last three decades, was
the region with the highest prevalence of self-reported hypertension
(35.6%), hypercholesterolemia (25.6%), diabetes (15.4%) and over-
weight/obesity (77.7%). Algarve, Madeira and the North were the re-
gions with the lowest prevalence of hypercholesterolemia (15.6, 15.8
and 15.9%, respectively); Algarve and the North had also the lowest
prevalence of hypertension (18.3 and 19.3%, respectively) and diabetes
(9.1 and 6.5%, respectively). The North had the lowest prevalence of
overweight/obesity (41.3%). Algarve was the region with the highest
self-reported prevalence of smoking (20.3%), and Madeira and the Cen-
tre region the lowest (11.9 and 12.8%, respectively). According to the
VALSIM study [23], carried out between April 2006 and November
2007, there were significant regional variations in the prevalence of
metabolic syndrome, adjusted for gender and age: residents in the Al-
garve or in Lisbon and Tagus Valley had lower prevalence [odds ratio
(OR) (95% confidence interval): 0.78 (0.66–0.92) and 0.83 (0.77–
0.91), respectively], while residents in the North or Centre regions had
higher prevalence (OR (95% confidence interval): 1.11 (1.01–1.21)
and 1.08 (1.002–1.16), respectively). After adjusting for gender and
age, thehigher prevalence in Alentejo residentswasno longer observed,
probably due to its elderly population. Considering a possible different
individual's global risk of developing CHD profile by region and there-
fore a probable different need of risk-factor lowering treatment for
CHD primary prevention within Portugal, data on time trends of differ-
ent drugs utilization by region, namely statins and blood pressure low-
ering agents, would help to compare CHD risk level and risk-factor
lowering treatment, analysing the importance of evidence based treat-
ment in the reduction of CHDmortality by region. If regionswith a faster
reduction in CHDmortality showed a larger increase in risk-factor low-
ering treatment, a positive effect of these agents on CHDmortality and a
risk-based prescription would be supported; however if a “discordant”
relation (slower reduction in mortality accompanied by a larger in-
crease in prescription) was observed, which was already observed
with statins in other settings [24], other factors apart from the actual
risk of the patients would emerge as an explanation. Available data do
not allow the quantification of time trends in cardiovascular risk factors
by region, which would help to better understand the determinants of
Table 1
Annual percent change (95% confidence intervals, CI) in coronary heart disease mortality rates, by sex and region, 1981–2012.
Men Women
Perioda Mortality rateb APC, % (95% CI)c Perioda Mortality rateb APC, % (95% CI)c
Portugal
1981–1993 195.6 −0.7 (−1.2 to−0.1) 1981–1992 108.0 −0.2 (−1.0 to 0.6)
1993–2003 180.7 −2.6 (−3.4 to−1.8) 1992–2003 105.6 −2.1 (−2.9 to−1.4)
2003–2012 139.2 −5.1 (−5.9 to−4.3) 2003–2012 83.3 −5.5 (−6.4 to−4.6)
Alentejo
1981–1993 250.3 0.1 (−1.0 to 1.2) 1981–1987 164.6 −3.3 (−6.7 to 0.2)
1993–2012 252.4 −2.4 (−3.0 to−1.9) 1987–1991 134.4 4.9 (−4.5 to 15.3)
1991–2012 163.0 −2.4 (−2.9 to−2.0)
Algarve
1981–2003 171.1 −0.7 (−1.4 to 0.0) 1981–2004 87.1 −0.4 (−1.2 to 0.4)
2003–2012 148.0 −5.4 (−7.8 to−2.9) 2004–2012 79.8 −6.5 (−10 to−2.8)
Azores
1981–1998 326.5 1.2 (0.4 to 1.9) 1981–1998 148.3 1.8 (0.7 to 3.0)
1998–2012 397.1 −5.7 (−6.7 to−4.7) 1998–2012 202.0 −5.1 (−6.5 to−3.7)
Centre
1981–1993 186.3 −0.8 (−1.8 to 0.2) 1981–2003 101.8 −1.2 (−1.6 to−0.8)
1993–2012 168.9 −3.3 (−3.8 to−2.8) 2003–2012 78.0 −5.7 (−7.7 to−3.8)
Lisbon
1981–1990 186.4 0.7 (−0.7 to 2.2) 1981–1991 116.0 0.9 (−0.2 to 2.0)
1990–2004 198.8 −1.9 (−2.6 to−1.3) 1991–2004 126.7 −2.2 (−2.9 to−1.5)
2004–2012 151.3 −6.2 (−7.5 to−4.9) 2004–2012 94.9 −6.3 (−7.7 to−5.0)
Madeira
1981–2003 194.3 −0.4 (−1.4 to 0.6) 1981–1986 139.7 −8.2 (−15.2 to−0.7)
2003–2012 177.0 −7.6 (−11.6 to−3.4) 1986–2003 90.9 0.8 (−0.5 to 2.1)
2003–2012 104.6 −9.7 (−12.8 to−6.5)
North
1981–1993 185.5 −1.5 (−2.5 to−0.5) 1981–2003 100.7 −2.5 (−3.2 to−1.7)
1993–2012 153.8 −4.3 (−4.8 to−3.8) 2003–2012 58.1 −6.2 (−9.0 to−3.3)
a Periods with constant log-linear trend identified in the joinpoint analysis.
b Mortality rate (/100,000), estimated age-standardized mortality rate at the beginning of the respective period.
c APC, annual percent change; 95% CI, 95% confidence interval.
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the different patterns of coronary disease mortality declines observed,
we expect that these differences are partly explained by anunequal pre-
vention and control of risk factors per region.
The National Health Service (NHS) provides universal coverage, fi-
nanced mainly through taxation, which should ensure avoidance of in-
equalities, at least in access to care. Treatment of CHD in Portugal should
therefore be equitable and based on clinical need, and not dependent on
age, sex, race, region of residence and other socio-economic factors. In-
deed the majority of acute coronary events are treated in public hospi-
tals, but long-term care of patients is also carried out by other
providers, both public and private [25]. Besides theNHS, the Portuguese
health care system has two other coexisting and overlapping players:
special public and private insurance schemes for certain professions
(health subsystems) and private voluntary health insurance. Public pro-
vision is particularly responsible for primary and hospital care. Special-
ist consultations and diagnostic services, among other treatments, are
commonly provided also in the private sector, less accessible to the gen-
eral population [26]. Despite the NHS' supposed universal coverage, the
geographic distribution of health resources is heterogeneous [25]. Al-
garve and Alentejo are the regions with the lowest number of hospital
beds (2.1 and 2.2 per 1000 inhabitants in 2010, respectively). Azores
and Alentejo are the regions with the lowest physician workforce, ap-
proximately 2 doctors per 1000 inhabitants, about half the number at
the national level [27]. Additionally there are several access indicators,
Fig. 2. Time trends in years of life lost and in number of deaths for coronary heart disease, by sex and region, 1981–2012.
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directly related to CHDoutcomes,with clear differences by region. Some
of these indicators have improved in the last years at the national level,
namely the number of patients submitted to primary percutaneous cor-
onary intervention (primary PCI), that increased by 37.0% from 2009 to
2013, the mean delay time to coronary angiography, that decreased
from 22.3 days in 2009 to 13.7 days in 2013, or the number of patients
admitted through the coronary fast-track system that increased by
80.5% from 2009 to 2013. However, at the region level, these improve-
ments were not of the same magnitude. Considering specific cardiac
procedures, in 2013, Alentejo was the region with the lowest number
of patients submitted to primary PCI (170.9 per million of inhabitants)
and with the highest mean delay time after a coronary angiography is
indicated (30 days). Lisbon and the Algarve were the regions with the
highest number of patients submitted to primary PCI (506.4 and 429.5
per million of inhabitants, respectively); and Algarve and the North
were the regions with the lowest mean delay time after a coronary an-
giography is indicated (2 and 8.2 days, respectively). Additionally the
coronary fast-track system was not implemented at the same time in
the different Portuguese regions, with Alentejo being the region with
the latest implementation [25]. Despite the increase in theuse of recom-
mendedpharmacological therapy for secondary prevention after anACS
during hospitalization and at hospital discharge over the last two de-
cades in Portugal [28], there is no information on trends of utilization
of these drugs in this group of patients by region. Treatment with
invasive proceduresmay be dependent on access determinants, namely
access to catheterization laboratories, but the prescription of pharmaco-
logical treatment during hospitalization and at discharge only depends
on the medical decision. It would be important to evaluate variation in
trends of utilization of pharmacological therapy for secondary preven-
tion of ACS by region, and to understand their role in the different pat-
terns of decrease in mortality observed. All these data suggest that the
factors that determine the observed trends, even in regions with similar
CHD mortality trends, play through different causality pathways. Un-
derstanding the specific pathways operating in each region has the po-
tential to further reduce the burden of CHD.
Considering the five main patterns of CHD mortality trends at
country level recently proposed, Portugal was included in a pattern
characterized by the lowest age-standardized mortality rate and with
a consistent decrease throughout the period of analysis [29]. The Centre,
Lisbon and the North regions, where most of the population lives, a
young and more educated population that lives predominantly in
urban areas [16], were closest to this same pattern, while the remaining
regionsweremore similar to a pattern characterized by higher rates ob-
served until later, after 2000. This difference shows inequalities in car-
diovascular health by region.
When analysing the CHD mortality trends by sex, we found greater
declines among women. The most consistent sex differences in adult
global mortality are attributed to CHD, which is the most common vas-
cular condition with consistently greater age-adjusted mortality rates
and risks in men than women, across different countries [2]. Lower
CHDmortality rates amongwomen are explained by a better risk factor
profile, even though there is evidence of higher in-hospital mortality
after a cardiovascular event and lower access to evidence-based second-
ary prevention [30]. The smaller sex difference in CVD mortality after
midlife has traditionally been related to postmenopausal oestrogen de-
ficiency in women [31], but it might also be explained by the decelera-
tion of the age-related increase in male specific mortality in midlife,
whereas women's mortality rates steadily increase with age, with no
significant or particular change at menopause [32]. The fact that greater
declines were observed among women might be the result of effective
primary and/or secondary prevention measures implemented among
this group. Despite the slight increase in the prevalence of smoking
among women, changes in the major cardiovascular risk factors in
Portugal contributed significantly more to the CHD decrease among
women than among men (58% vs 29%), with greater differences by
sex observed in the decrease in the mean population systolic blood
pressure (6.5 mmHg inmen and 12.4mmHg inwomen), that were es-
timated to have prevented or postponed 40% of deaths in men and 72%
in women [17]. Interestingly, the effect of antihypertensive treatment
was small, similar in men and women, and therefore this difference
was mainly attributable to lifestyle changes [17]. The greater declines
in CHD mortality among women are also in accordance with a recent
study showing improvements in sex-differences in dischargemedications
of patients admitted with acute coronary syndromes in Portugal, after
adjusting for the potential confounding effect of age, co-morbidities, and
contraindications [33].
5. Limitations
The key factor to correctly interpret these results is good-quality
data on mortality, dependent on the coverage, accuracy of diagnosing
causes of death and correct coding. Portuguese mortality data have
high coverage and the underlying cause of death is certifiedby amedical
practitioner. Nevertheless there is still a high proportion of deaths (17%)
coded as ill-defined causes [34] and validation studies are needed to
better measure the accuracy of causes of death diagnosis.
Although we used ICD-9, which has considerably less detail than
ICD-10,we aremeasuring CHD as a large group,without needing specif-
ic codes, which minimizes errors, even considering changes in coding
rules and revisions done during the period of the study.
6. Conclusion
Despite the large decrease in age-adjusted mortality and in the YLL
from CHD observed in Portugal, between 1981 and 2012, relative
declines and the respective periods were different by geographic region.
Recognition of these inequalities clearly underlies the need to implement
an objective and systematic approach to monitor cardiovascular risk fac-
tor prevalence and proportion of control, and uptake of evidence-based
treatments, both during acute events and in more stable phases, by re-
gion. Good quality data on determinants of CHD incidence and mortality
by region are essential to define specific targets for intervention.
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Summary
Background:	 Real-	world	 data	 from	 different	 levels	 of	 hospital	 specialisation	would	
help	to	understand	if	differences	in	management	between	women	and	men	with	acute	
coronary	syndrome	(ACS)	are	still	a	priority	target.	We	aimed	to	identify	sex	inequali-
ties	in	management	of	patients	with	different	types	of	ACS.
Methods:	We	analysed	1757	patients	with	a	non-	ST-	elevation	ACS	(NSTEACS)	and	
1184	with	 ST	 elevation	myocardial	 infarction	 (STEMI)	 or	 left	 bundle	 branch	 block	
(non-	classifiable	(NC)	ACS	(STEMI/NC	ACS	group),	consecutively	discharged	from	ten	
Portuguese	hospitals	with	different	specialisation	levels,	between	2008	and	2010.	We	
estimated	odds	ratios	(OR)	and	95%	confidence	intervals	(95%	CI)	for	the	association	
between	 sex	 and	 the	 performance	 of	 coronary	 angiography,	 reperfusion	 and	
revascularisation.
Results:	Among	STEMI/NC	ACS,	men	had	higher	probability	of	performing	coronary	
angiography	 than	 women	 (adjusted	 OR	=	1.64,	 95%	 CI:	 1.11-	2.44),	 while	 among	
NSTEACS	 patients	 there	was	 no	 significant	 difference	 by	 sex	 (adjusted	OR	=	1.26,	
95%	CI:	0.99-	1.62).	In	patients	who	underwent	coronary	angiography,	there	was	no	
difference	in	proportion	of	women	and	men	submitted	to	revascularisation,	regardless	
of	 the	ACS	 type.	Although	men	with	STEMI/NC	ACS	were	more	 likely	 to	undergo	
reperfusion	(crude	OR	=	2.17,	95%	CI:	1.68-	2.81),	the	effect	became	not	significant	
after	multivariable	adjustment	(adjusted	OR	=	1.33,	95%	CI:	0.96-	1.84).
Conclusion:	Women	diagnosed	with	STEMI/NC,	but	not	NSTEACS,	had	lower	proba-
bility when compared with men to be submitted to coronary angiography. There was 
no	difference	in	performance	of	reperfusion	and	revascularisation	by	sex.
1  | INTRODUCTION
In	 the	 last	decades,	one	of	 the	major	determinants	of	 the	decrease	
in coronary heart disease (CHD) mortality in Europe, in women and 
men,	was	a	more	effective	access	to	coronary	angiography.1 However, 
recent	data	show	that	men	with	an	acute	coronary	syndrome	(ACS)	
are	still	more	likely	to	undergo	an	invasive	approach.2 In Portugal, be-
tween	2010	and	2013,	16.5%	of	patients	with	non-	ST-	elevation	myo-
cardial	 infarction,	mostly	women,	were	 treated	with	 a	 conservative	
strategy.3	Although	from	2002	to	2013	a	three-	fold	 increase	 in	pri-
mary	angioplasty	was	observed,	the	proportion	of	women	remained	
approximately	the	same	(24.5%	and	26.2%,	respectively).4 These data 
were	obtained	from	registries	that	included	patients	admitted	to	car-
diology departments, but not to other departments, and to hospitals 
offering	 differentiated	 care,	 and	 therefore	might	 not	 represent	 the	
national	 trends	 in	 the	 invasive	 diagnostic-	therapeutic	 approach	 of	
women	and	men	with	ACS.
The	decrease	in	CHD	mortality	in	Portugal	was	found	to	be	greater	
among women compared to men,5	the	result	of	effective	primary	and/
or secondary prevention measures implemented in this group. Changes 
in	the	major	cardiovascular	risk	factors	in	Portugal	contributed	signifi-
cantly more to the CHD decrease among women than among men, 
mainly	due	to	 lifestyle	changes,	as	 the	effect	of	 risk	 factor	 lowering	
treatment was small and similar between sexes.1 Improvements in sex 
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differences	in	discharge	medications	after	an	ACS	as	well	as	in	drug-	
eluting stents use might also have contributed to these results.6,7
Sex	and	gender	differences	concerning	ACS	are	described	in	sev-
eral	 categories,	 namely	 risk	 assessment,	 disease	 awareness,	 comor-
bidities, presentation, treatment and outcomes,8 contributing to a 
potential	 different	 access	 to	health	 care	between	women	and	men.	
Real-	world	 data	 about	 sex	 differences	 in	 management	 of	 ACS	 pa-
tients, treated in hospitals with diverse characteristics, and consider-
ing possible relative contraindications to an invasive approach and to 
revascularisation,	represent	an	operational	measurement	of	effective	
access.	We	aimed	to	analyse	sex	differences	in	management	of	ACS,	
controlling	for	age,	hospital	characteristics,	cardiovascular	risk	factors,	
previous medical history, complications at admission and coronary 
anatomy,	within	a	sample	of	Portuguese	hospitals	serving	both	urban	
and	rural	populations	and	with	different	levels	of	specialisation.
2  | METHODS
2.1 | Study design and sample selection
Data	 for	 this	 study	 were	 collected	 within	 the	 framework	 of	 the	
EURopean	Hospital	Benchmarking	by	Outcomes	in	acute	coronary	syn-
drome Processes (EURHOBOP) project, a collaborative, multicentre and 
multinational	retrospective	study	of	patients	consecutively	hospitalised	
with	a	discharge	diagnosis	of	ACS	from	70	hospitals	in	7	European	coun-
tries (Finland, France, Germany, Greece, Italy, Portugal, and Spain),9,10 
For	the	current	analysis	we	used	data	from	patients	admitted	to	the	10	
Portuguese	 hospitals,	which	were	 selected	 to	 cover	 different	 regions	
from	the	mainland	country,	from	north	to	south	and	west	to	east	and	
including both coastal and interior regions, urban and rural populations. 
Furthermore,	 these	 hospitals	 had	 different	 characteristics,	 regarding	
population	served,	 facilities,	 technical	and	human	resources,	and	spe-
cialisation levels. These diverse settings were selected with the purpose 
of	 seeking	 representativeness	 of	 the	 general	ACS	population.	Overall	
five	hospitals	had	a	catheterisation	laboratory,	three	had	a	cardiac	sur-
gery	department,	in	one	patients	with	ACS	were	admitted	to	the	internal	
medicine department, as the hospital had no cardiology department or 
cardiologists,	four	were	university	hospitals,	the	number	of	beds	ranged	
from	280	 to	1124	and	 the	populations	 served	 ranged	 from	 less	 than	
300 000 to more than 700 000 people. Each hospital contributed with 
approximately 300 consecutive patients discharged between 2008 and 
2010	with	diagnosis	of	ACS	(International	Classification	of	Diseases	10th	
revision:	 I.21.0-	I	 21.9	 and	 I.20.0).	 From	 3009	ACS	 patients	 included,	
those	with	missing	data	on	the	type	of	ACS	were	excluded	(n	=	68).
2.2 | Procedures and data collection
With	 the	use	of	 standardised	 forms,	 trained	 investigators	extracted	
data	from	discharge	letters,	emergency	room	records	and	laboratory	
systems.	When	necessary,	 different	 sources	were	 cross-	checked	 to	
ensure	completeness	and	quality	of	the	 information.	 Information	on	
type	of	ACS,	 demographic	 characteristics,	 previous	medical	 history,	
admission data, procedures used during hospitalisation, severity 
indicators and complications during hospitalisation, including vital 
status	and	in-	hospital	medication	(the	main	classes	of	recommended	
drugs	for	patients	with	ACS)11,12 was extracted.
2.3 | Definition of variables and data analysis
Patients	with	left	bundle	branch	block	were	defined	as	non-	classifiable	
(NC)	 ACS	 (NC	ACS)	 and	 analysed	with	 STEMI	 patients	 (STEMI/NC	
ACS	group).
The	management	was	 considered	 invasive	 if	 coronary	 angiogra-
phy	was	performed.	Reperfusion	was	defined	as	either	thrombolysis	
or primary percutaneous coronary intervention; revascularisation, ei-
ther as percutaneous coronary intervention (PCI) or coronary artery 
bypass	 graft	 (CABG).	 Anaemia	 was	 defined	 as	 haemoglobin	 below	
12	g/dL	for	females	and	below	13	g/dL	for	males13 and renal impair-
ment	was	 subdivided	 in	 two	 groups:	 estimated	 glomerular	 filtration	
rate (eGFR) below 30 mL/min/1.73 m2 and between 30 and 60 mL/
min/1.73 m2.14	Angiographic	coronary	disease	was	defined	as	normal/
mild	if	coronary	arteries	were	normal	or	with	stenosis	<30%;	moderate	
for	stenosis	between	30%	and	70%;	and	severe	 for	any	obstruction	
>70%	or	>50%	if	the	obstruction	was	in	the	left	main	coronary	artery.	
Severe	coronary	disease	was	further	divided	into	1-	,	2-	and	3-	vessels	
disease	categories,	according	to	the	number	of	affected	arteries.	 In-	
hospital	complications	were	evaluated	by	sex	and	type	of	ACS	through	
a	composite	endpoint	of	pulmonary	oedema,	shock,	acute	renal	fail-
ure,	re-	infarction,	stroke	and	a	drop	of	haemoglobin	of	3	or	more	g/dL.	
In-	hospital	death	was	also	assessed	separately	by	sex	and	type	of	ACS.
What is known
• Several studies have suggested that women with acute 
coronary	syndrome	are	more	likely	to	be	treated	with	a	
conservative strategy than men.
•	 Studies	 in	 different	 settings	 support	 that	 disparities	 in	
care	 and	 outcomes	 of	 women	 and	men	 persisted	 over	
time.
•	 Whether	this	sex-gap	in	management	is	observed	for	di-
agnostic	or	also	for	invasive	therapeutic	coronary	proce-
dures;	 and	 for	 the	whole	 spectrum	 of	 presentations	 of	
acute	coronary	syndrome,	managed	in	hospitals	with	dif-
ferent	levels	of	specialisation	is	controversial.
What is new
•	 Women	with	 ST-elevation	 acute	myocardial	 infarction/
non-classifiable	(left	bundle	branch	block)	acute	coronary	
syndrome, but not with non-ST-elevation acute coronary 
syndrome,	 were	 less	 frequently	 submitted	 to	 coronary	
angiography than men.
•	 No	differences	in	reperfusion	or	revascularisation	among	
those managed invasively were observed between 
women	and	men	for	the	whole	spectrum	of	acute	coro-
nary syndrome presentations.
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The	 proportions	 of	 prescription	 of	main	 classes	 of	 drugs	 during	
hospitalisation	were	 assessed	 for	 eligible	 patients,	 according	 to	 sex,	
type	of	ACS	and	management	approach,	namely	 invasive	vs	conser-
vative	(according	to	the	performance	or	not	of	coronary	angiography).	
We	computed	composite	variables	for	drugs	combinations:	double	an-
tiplatelet therapy with aspirin and clopidogrel, 3- drug treatment [(as-
pirin	or	clopidogrel)	and	beta-	blocker	and	statin]	and	5-	drug	treatment	
[aspirin	and	clopidogrel	and	beta-	blocker	and	(angiotensin-	converting	
enzyme	inhibitors	 (ACEi)	or	angiotensin	receptor	blockers	 (ARB)	and	
statin].	 For	 simple	 antiplatelet	 therapy	 (aspirin	 or	 clopidogrel),	 hae-
moglobin	below	10	g/dL	for	females	and	below	11	g/dL	for	males	at	
admission was considered a contraindication. For double antiplatelet 
therapy,	 besides	 a	 low	value	of	haemoglobin	 at	 admission,	 previous	
atrial	 fibrillation	 or	 being	 on	 oral	 anticoagulation	 at	 admission	were	
considered	 also	 contraindications.	 A	 systolic	 blood	 pressure	 lower	
than	 100	mm	 Hg	 or	 severe	 renal	 failure	 (eGFR	 less	 than	 30	ml/
min/1.73 m2)	at	admission	were	considered	contraindications	for	ACEi	
or	ARB.	Contraindications	for	beta-	blockers	were	systolic	blood	pres-
sure	lower	than	100	mm	Hg	or	heart	rate	below	50	bpm	at	admission.
Potential	 confounders	of	 the	association	between	sex	and	man-
agement	were	grouped	as	follows:	hospital	characteristics,	cardiovas-
cular	 risk	 factors,	 cardiovascular	 history,	 complications	 at	 admission	
and	angiographic	coronary	disease	(the	latter	for	the	revascularisation	
models	only).	In	the	univariate	analysis,	we	identified	which	variables	
were associated with management (P-	value<.15),	using	logistic	regres-
sion.	Within	each	group	mentioned	above,	variables	with	a	significant	
effect	 on	 the	 dependent	 variable	were	 included	 in	 the	multivariate	
model	and	a	backward	strategy	was	used	to	exclude	the	least	signifi-
cant	variables,	based	on	Wald	test	(P-	value	<.05).	To	fit	the	final	model,	
we	departed	from	all	variables	with	significant	effect	on	outcome	de-
rived	from	the	intragroup	multivariate	modelling,	repeated	backward	
strategy	to	choose	the	significant	variables	and	performed	likelihood	
ratio	 test	 for	boundary	p	value.	 In	 sensitivity	 analysis,	we	examined	
the	sex	differences	in	management	for	STEMI	group	excluding	the	NC	
ACS	patients.	Data	were	analysed,	using	stAtA	version	11	for	Windows	
(Stata	Corp	LP,	College	Station,	TX,	USA).
2.4 | Ethics
The	study	was	approved	by	 the	ethics	committee	of	 the	University	
of	 Porto	 Medical	 School	 and	 the	 National	 Commission	 for	 Data	
Protection. These two entities agreed that it would not be necessary 
to	ask	for	patients’	 informed	consent,	since	the	study	was	based	on	
the	collection	of	retrospective	clinical	data	from	the	medical	records	
during	hospitalisation,	and	 the	confidentiality	of	patients’	 identifica-
tion was assured.
3  | RESULTS
3.1 | Baseline characteristics
A	total	of	2941	patients	were	included,	1757	(59.7%)	with	NSTEACS	
diagnosis	and	1184	(40.3%)	with	STEMI/NC	ACS	(Tables	1	and	2).
The	proportions	of	women	included	by	hospital	varied	between	
27.5%	and	39.2%	and	the	mean	age	of	the	patients	between	64.1	
and	70.2	years	old	(Table	1).	In	the	majority	of	the	hospitals,	the	pro-
portion	of	patients	with	STEMI/NC	ACS	was	above	40%,	however,	
in three hospitals lower proportions were observed; the lowest was 
24.7%	in	a	hospital	without	catheterisation	 laboratory	and	cardiol-
ogy	ward	(Table	1).	Only	in	one	hospital,	the	proportion	of	patients	
with	 previous	 history	 of	 myocardial	 infarction,	 PCI	 or	 CABG	was	
below	20%.	The	proportions	of	patients	with	 complications	 at	 ad-
mission	varied	 between	38.7%	 and	61.1%	between	hospitals.	The	
two	hospitals	with	the	lowest	and	the	highest	proportions	of	com-
plications at admission were similar in characteristics, namely were 
tertiary hospitals, with catheterisation laboratory, located in the 
coast and covering an urban predominantly population. In all hos-
pitals,	most	patients	had	severe	angiographic	coronary	disease	of	at	
least	of	one	vessel.	The	proportion	of	patients	who	had	at	least	one	
in-	hospital	 complication	 varied	 between	 7.3%	 in	Hospital	 de	 Faro	
and	23.7%	in	Centro	Hospitalar	do	Porto.	The	in-	hospital	mortality	
varied	 between	 0.8%	 in	 Centro	Hospitalar	Alto	Ave	 and	 14.6%	 in	
Centro Hospitalar Cova da Beira, the latter is located in the interior, 
had	no	catheterisation	laboratory	and	cardiology	ward,	therefore	pa-
tients	with	ACS	were	admitted	to	the	internal	medicine	department	
(Table 1).
Compared	to	men,	women	with	either	ACS	type	were	older,	had	
more	frequently	hypertension	and	diabetes	and	were	less	frequently	
current	 smokers.	Women	 had	 more	 comorbidities	 than	 men,	 inde-
pendently	of	 the	ACS	type:	 they	suffered	more	often	from	previous	
heart	failure,	atrial	fibrillation	and	renal	failure.	In	the	NSTEACS	pop-
ulation,	previous	myocardial	infarction,	PCI	or	CABG	were	more	prev-
alent	in	men.	Anaemia	and	renal	impairment	at	admission	were	more	
prevalent	 in	 women,	 who	 presented	 less	 often	 with	 severe	 angio-
graphic coronary disease (Table 2). Compared with men, the compos-
ite	endpoint	of	 in-	hospital	complications	(pulmonary	oedema,	shock,	
acute	renal	failure,	reinfarction,	stroke,	drop	in	haemoglobin	of	3	g/dL	
or	more)	was	more	frequently	observed	among	women	with	NSTEACS	
(15.3%	vs	11.2%,	P	=	.014)	and	with	STEMI/NC	ACS	(19.7%	vs	13.8%,	
P	=	.011).	Of	all	patients	included	in	this	analysis,	5.1%	of	women	and	
3.7%	 of	 men	 with	 NSTEACS	 died	 during	 hospitalisation	 (P	=	.159),	
while	among	STEMI/NC	ACS	patients,	 in-	hospital	death	was	signifi-
cantly	 higher	 among	women	 than	men	 (17.9%	vs	 8.3%,	P<.001,	 re-
spectively) (Table 2).
3.2 | Management
Compared with patients treated conservatively, women and men 
with	NSTEACS	or	STEMI/NC	ACS	who	were	treated	invasively	more	
frequently	had	prescription	of	 the	several	 recommended	classes	of	
drugs	 during	 hospitalisation.	 Patients	 with	 STEMI/NC	 ACS,	 both	
women and men, managed conservatively were the subgroup who 
had	 the	 lowest	 prescription	 of	 recommended	 drugs	 during	 hospi-
talisation	(Figure	1).	Women	with	NSTEACS	managed	conservatively	
were	 significantly	 less	 likely	 to	 receive	 statins	 (54.2%	 vs	 64.7%,	
P	=	.009)	 and	 5-	drug	 treatment	 (20.7%	 vs	 34.3%,	 P = .002) than 
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men	 with	 NSTEACS	 managed	 conservatively;	 while	 women	 with	
NSTEACS	managed	invasively	were	more	likely	to	receive	an	ACEi/
ARB	 during	 hospitalisation	 than	men	with	 the	 same	 diagnosis	 and	
management	approach	(69.3%	vs	61.9%,	P = .037, respectively). The 
remaining	sex	differences	in	prescription	of	drugs	during	hospitalisa-
tion	among	patients	without	 contraindications	were	not	 significant	
(Figure 1).
An	 invasive	 strategy	 was	 less	 frequent	 in	 women,	 regardless	
of	the	type	of	ACS	(56.6%	vs	71.8%,	P<.001,	and	62.5%	vs	80.8%,	
P<.001	 among	 patients	 with	 NSTEACS	 and	 STEMI/NC	 ACS,	 re-
spectively).	The	difference	in	the	odds	of	being	managed	invasively	
between	sexes	was	observed	in	the	STEMI/NC	ACS	group,	after	ad-
justment	for	patient	and	hospital	characteristics	(adjusted	odds	ratio	
[OR]	 1.64,	 95%	 confidence	 interval	 [95%	 CI]	 1.11-	2.44).	 Among	
patients	 performing	 coronary	 angiography,	 52.7%	 and	 76.5%	 of	
women	and	58.3%	and	81.6%	of	men	with	NSTEACS	and	STEMI/
NC	ACS,	 respectively,	were	 submitted	 to	 revascularisation.	 There	
was	 no	 difference	 by	 sex	 in	 the	 odds	 of	 revascularisation	 in	 both	
TABLE  2 Baseline	characteristics	of	patients	with	different	types	of	acute	coronary	syndrome,	by	sex
NSTEACS STEMI/NC ACS
Women Men P Women Men P
634 (36.1) 1123 (63.9) 341 (28.8) 843 (71.2)
Age	(y),	mean	(SD) 73.2 (11.8) 65.7	(12.7) <.001 73.2 (13.6) 63.1	(13.5) <.001
Cardiovascular	risk	factors
Hypertension 500	(78.9) 751	(66.9) <.001 246 (72.1) 461	(54.7) <.001
Diabetes 275	(43.4) 351	(31.3) <.001 104	(30.5) 206 (24.4) .032
Dyslipidaemia 327	(51.6) 634	(56.5) .049 146 (42.8) 384	(45.6) .391
Current	smoking 34	(5.4) 306 (27.3) <.001 29	(8.5) 323 (38.3) <.001
Cardiovascular history
Previous	MI,	PCI	or	CABG 156	(24.6) 382 (34.0) <.001 46	(13.5) 122	(14.5) .661
Previous HF 87 (13.7) 101 (9.0) .002 45	(13.2) 34 (4.0) <.001
Previous	AF 55	(8.7) 72 (6.4) .078 29	(8.5) 35	(4.2) .003
Chronic	renal	failure 214 (33.8) 236 (21.0) <.001 97	(28.5) 136 (16.1) <.001
Previous	stroke 67 (10.6) 98 (8.7) .204 31 (9.1) 52	(6.2) .074
Peripheral artery disease 21 (3.3) 59	(5.3) .061 4 (1.2) 20 (2.4) .185
Complications at admission
Pulmonary	oedema	or	shock 9 (1.4) 8 (0.7) .146 10 (2.9) 23 (2.7) .847
Anaemia 238 (39.0) 300 (28.0) <.001 115	(35.6) 156	(19.3) <.001
Renal impairment (GFR)
30	to	<60	ml/min/1.73	m2 264 (43.1) 257	(23.9) 136 (42.4) 182 (22.7)
<30	ml/min/1.73	m2 79 (12.9) 91	(8.5) <.001 44 (13.7) 38 (4.7) <0.001
Angiographic	coronary	disease
Normal/Mild 67 (18.8) 59	(7.5) 15	(7.1) 19 (2.8)
Moderate 15	(4.2) 34 (4.3) 5	(2.4) 11 (1.6)
Severe—1 vessel 117 (32.9) 254	(32.2) 105	(50.0) 347	(51.3)
Severe—2 vessels 78 (21.9) 227 (28.8) 48 (22.9) 180 (26.6)
Severe—3 vessels 79 (22.2) 215	(27.3) <.001 37 (17.6) 119 (17.6) .054
In- hospital complications
Pulmonary	oedema,	shock,	acute	
renal	failure,	re-	infarction,	stroke,	
drop	in	haemoglobin	≥3	g/dL
97	(15.3) 126 (11.2) .014 67 (19.7) 116 (13.8) .011
In- hospital death 32	(5.1) 41 (3.7) .159 61 (17.9) 70 (8.3) <.001
Total may not add to 2941 due to missing data.
Data are counts with percentages unless otherwise indicated.
AF,	atrial	fibrillation;	CABG,	coronary	artery	bypass	surgery;	GFR,	glomerular	filtration	rate;	HF,	heart	failure;	MI,	myocardial	infarction;	NSTEACS,	non-	ST-	
elevation	acute	coronary	syndrome;	PCI,	percutaneous	coronary	intervention;	SD,	standard	deviation;	STEMI/NC	ACS,	ST-	elevation	myocardial	infarction/
Non-	classifiable	acute	coronary	syndrome.
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NSTEACS	 (0.84,	 0.61-	1.14)	 and	 STEMI/NC	ACS	 (1.00,	 0.62-	1.62)	
after	 adjustment	 (Table	3).	 More	 men	 than	 women	 with	 STEMI/
NC	ACS	 had	 reperfusion	 therapy	 (67.9%	 vs	 49.3%,	 respectively).	
However,	 this	 significant	crude	association	between	male	sex	and	
reperfusion	(2.17,	1.68-	2.84)	was	explained	after	multivariable	ad-
justment	 (1.33,	0.96-	1.84).	 In	 the	sensitivity	analysis,	NC	ACS	pa-
tients (n = 163) were excluded and the results were comparable to 
primary results (Table 4).
4  | DISCUSSION
This	 study	 shows	 that	 women	 with	 STEMI/NC	 ACS,	 but	 not	 with	
NSTEACS,	were	 less	 frequently	 submitted	 to	 coronary	 angiography	
than	men,	 after	 controlling	 for	 age,	 characteristics	 of	 the	 hospitals,	
cardiovascular	risk	factors,	previous	medical	history	and	complications	
at	admission.	No	significant	differences	between	sexes	in	the	perfor-
mance	of	reperfusion	and	revascularisation	were	observed.
F IGURE  1 Proportion	of	patients	treated	with	pharmacological	treatment	during	hospitalisation	for	acute	coronary	syndrome	with	or	
without ST- elevation according to sex and management approach.
*P-value <.05
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We	 included	 10	 hospitals	with	 different	 levels	 of	 specialisation,	
located	in	heterogeneous	geographic	areas.	The	analysis	of	the	char-
acteristics	of	the	patients	included	by	hospital	identified	differences	in	
ACS	epidemiology	and	outcomes.	Between	and	within	country	differ-
ences	in	management	and	outcomes	of	patients	with	ACS	have	been	
described, but remain poorly understood.10,15,16 In Portugal, between 
1981	 and	 2012,	 relative	 declines	 of	 CHD	mortality	 indicators	were	
different	by	geographic	region;	consistent	decreases	in	mortality	rates	
were only observed in the most populated and urbanised regions.5 
Our	finding	of	significant	differences	by	hospital	in	in-	hospital	mortal-
ity	of	patients	with	ACS	deserves	further	analysis.
Of	patients	hospitalised	with	NSTEACS	and	with	STEMI/NC	ACS	
36.1%	and	28.8%,	respectively,	were	women,	similar	proportions	to	
the observed in the whole EURHOBOP sample.10	 Approximately	
40%	of	patients	of	our	sample	were	diagnosed	with	STEMI/NC	ACS;	
data	 from	 the	 Portuguese	 Registry	 of	 Acute	 Coronary	 Syndrome	
(ProACS)	 reported	 a	 similar	 proportion	 (41.2%).17 The prevalence 
of	cardiovascular	risk	factors	 in	women	and	men	with	ACS,	higher	
among	patients	with	NSTEACS	is	also	in	line	with	other	national	and	
international data.10,17	Particularly	relevant	is	the	high	prevalence	of	
diabetes	in	our	sample,	particularly	among	women	with	NSTEACS,	
higher than the observed in other countries.10	For	both	types	of	ACS	
data	from	the	overall	EURHOBOP	study	showed	that	Portugal	had	
one	of	the	highest	proportions	of	in-	hospital	events	and	mortality,	
even	 after	 exhaustive	 model	 adjustment.10	 Analysing	 data	 sepa-
rately	by	sex	and	type	of	ACS,	we	were	able	to	identify	a	subgroup	of	
patients	with	particularly	high	risk	of	in-	hospital	death,	women	with	
STEMI/NC	ACS	 (17.9%).	 Considering	 prescription	 of	 drugs	 during	
hospitalisation,	higher	differences	were	observed	between	patients	
with	different	management	approaches,	than	between	women	and	
men. The decision to proceed or not to an invasive approach may 
influence	the	prescription	of	recommended	drugs	for	patients	with	
ACS,	not	only	antiplatelet	therapy,	which	is	expected,	but	probably	
other	classes	of	drugs.	Our	results	are	in	line	with	previous	findings	
TABLE  3 Sex	differences	in	in-	hospital	management,	by	type	of	acute	coronary	syndrome	(women	are	the	reference	class)
Women  
n (%)
Men  
n (%) Crude OR (95% CI)
Adjusted OR 
(95% CI) Adjustment variables
NSTEACS
Diagnostic 
catheterisation
359	
(56.6)
806 
(71.8)
1.94	(1.59-	2.39) 1.26 (0.99- 1.62) Patient characteristics: age, dyslipidaemia, 
history	of	heart	failure,	stroke,	renal	impair-
ment at admission, anaemia at admission
Hospital	characteristics:	number	of	beds
Revascularisationa 189 
(52.7)
470 
(58.3)
1.26 (0.98- 1.62) 0.84 (0.61- 1.14) Patient characteristics: age, renal impairment at 
admission, angiographic coronary disease
Hospital	characteristics:	presence	of	catheterisa-
tion laboratory, university hospital
STEMI/NC	ACS
Diagnostic 
catheterisation
214 
(62.5)
681 
(80.8)
2.53	(1.91-	3.34) 1.64 (1.11- 2.44) Patient characteristics: age, dyslipidaemia, 
smoking,	history	of	myocardial	infarction,	
percutaneous intervention or coronary artery 
bypass	surgery,	of	heart	failure,	of	stroke,	of	
renal	failure,	renal	impairment	at	admission
Hospital	characteristics:	presence	of	catheterisa-
tion	laboratory,	number	of	beds
Reperfusionb 168 
(49.3)
572	
(67.9)
2.17 (1.68- 2.81) 1.33 (0.96- 1.84) Patient characteristics: age, dyslipidaemia, 
smoking,	history	of	myocardial	infarction,	
percutaneous intervention or coronary artery 
bypass	surgery,	of	heart	failure,	renal	
impairment and anaemia at admission
Hospital	characteristics:	presence	of	catheterisa-
tion laboratory, cardiothoracic surgery 
department
Revascularisationa 163 
(76.5)
555	
(81.6)
1.35	(0.93-	1.96) 1.00 (0.62- 1.62) Patient	characteristics:	age,	history	of	renal	
failure,	anaemia	at	admission,	angiographic	
coronary disease
Hospital	characteristics:	presence	of	catheterisa-
tion laboratory
CI,	confidence	interval;	NSTEACS,	non-	ST-	elevation	acute	coronary	syndrome;	OR,	odds	ratio;	STEMI/NC	ACS,	ST-elevation	myocardial	infarction/Non-	
classifiable	acute	coronary	syndrome.
aPercutaneous coronary intervention and/or coronary artery bypass surgery among those submitted to coronary angiography.
bThrombolysis or primary percutaneous coronary intervention.
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of	very	few	sex	differences	in	discharge	medications	of	patients	with	
ACS	in	Portugal,	after	adjusting	for	the	potential	confounding	effect	
of	age,	comorbidities	and	contraindications.6	Women	and	men	differ	
in	the	pathophysiology	and	mechanisms	of	coronary	heart	disease.	
Women	with	ACS	are	on	average	older	than	men,	suffer	from	more	
comorbidities, are more prone to atypical presentations, thrombus 
formation	and	plaque	erosion,	but	less	prone	to	suffer	from	severe	
obstructive coronary artery disease.18,19	Women	encounter	 longer	
delays	between	 the	onset	of	 symptoms	and	 first	medical	 contact,	
arrival at a hospital and evidence- based treatment.8	Additionally	al-
though	lower	cardiac	catheterisation	rates	seen	in	women	with	ACS	
were	considered	to	be	partially	due	to	women’s	own	preferences,20 
recent	data	suggest	that	differences	in	catheterisation	rates	by	sex	
may	be	driven	 largely	by	physicians,	 through	different	patterns	of	
counselling	and	 referral	 to	cardiovascular	 testing	between	women	
and	men,	and	not	by	differential	attitudes,	behaviours	and	decisions	
of	female	patients.21
Considering access to healthcare in a multilevel perspective, both 
factors	related	to	health	care	systems	and	to	patient22	explain	the	dif-
ference	in	management	of	women	and	men	with	ACS.	Several	deter-
minants,	at	both	levels,	that	are	not	independent	and	influence	each	
other	and	operate	at	different	times	during	the	process	of	illness	and	
care,	 probably	 enable	 or	 hinder	 differently	 in	women	 and	men,	 the	
ability	to	perceive,	seek,	reach,	pay	and	engage	in	health	care	and	the	
ability	of	the	system	to	fulfil	the	needs	of	the	patient.22
Compared	with	data	reported	by	the	ProACS	from	2010	to	2013,	
a	 lower	proportion	of	NSTEACS	patients	 in	 the	EURHOBOP	cohort	
were	treated	invasively	(66.3%	vs	84.8%).3	Although	part	of	this	dif-
ference	may	be	dependent	on	a	true	increase	in	the	invasive	treatment	
of	patients	with	ACS,	the	results	observed	in	the	ProACS	may	be	an	
overestimation	of	the	true	proportion,	due	to	the	fact	that	only	hos-
pitals with higher specialisation levels were included in this registry. 
In	NSTEACS	patients,	only	 those	with	unstable	 angina,	without	 risk	
criteria and no recurrent symptoms are recommended a non- invasive 
testing	for	ischaemia	(preferably	with	imaging)	before	deciding	on	an	
invasive evaluation.11	All	the	others	should	be	treated	invasively,	un-
less	some	contraindication	exists	or	the	risks	appear	to	outweigh	the	
benefits.	The	factors	that	should	be	taken	into	account	to	weigh	risks	
and	benefits	are	related	with	clinical	presentation,	comorbidities,	risk	
stratification,	frailty,	cognitive	status	and	estimated	life	expectancy.11 
After	 adjusting	 for	 several	 of	 these	 factors,	 no	difference	 in	perfor-
mance	of	coronary	angiography	between	sexes	was	observed	 in	the	
NSTEACS	group,	representing	an	improvement	in	the	sex	equality	of	
access to evidence- based treatment.2
In	 STEMI	 patients,	 the	main	 limitation	 to	 reperfusion	 therapy	 is	
the	 time	of	presentation	after	 symptoms	onset.	Early	mechanical	or	
pharmacological	reperfusion	should	be	performed	within	the	first	12	
hours	from	symptoms	onset;	whether	PCI	is	also	beneficial	in	patients	
presenting	more	 than	12	hours	 after	 symptoms	onset	 is	more	 con-
troversial.12	The	use	of	reperfusion	therapy	in	our	sample	is	similar	to	
the	observed	in	ProACS	covering	years	2002-	2008	(62.5%	vs	61.9%,	
respectively),23	but	 lower	than	the	observed	 in	 the	second	phase	of	
the	 ProACS	 (84.8%).17	 Implementation	 of	 a	 pre-	hospital	 fast-	track	
network	 in	 Portugal	 improved	 reperfusion	 rates	 in	 STEMI	 patients,	
through an increase in primary angioplasty.4	Studies	performed	with	
data	from	the	ProACS	were	not	reported	by	sex,	which	limits	further	
comparisons.	Among	STEMI/NC	ACS	patients,	different	probabilities	
of	performing	coronary	angiography	by	sex	might	result	from	distinct	
patient and hospital delays.8 In 2008, Portugal was among the coun-
tries	performing	less	primary	PCI	in	Europe.24	One	major	factor	con-
tributing	for	this	finding	might	be	the	high	proportion	(55%)	of	patients	
who	were	admitted	more	than	12	hours	after	symptom	onset;4 with 
higher delays being expected among women. The subjective experi-
ence	of	symptoms	 influences	patients’	attitudes	 in	help	seeking	and	
professionals’	 interpretation	 of	 clinical	 presentations,	 thus	 affecting	
access	to	effective	health	care.25
TABLE  4 Sex	differences	in	in-	hospital	management	of	patients	with	ST-	elevation	myocardial	infarction	(women	are	the	reference	class)
Women  
n (%)
Men  
n (%) Crude OR (95% CI)
Adjusted OR (95% 
CI) Adjustment variables
STEMI
Diagnostic 
catheterisation
189 
(72.1)
636 
(83.8)
2.00 (1.43- 2.78) 1.99 (1.31- 3.00) Patient characteristics: age, dyslipidaemia, 
history	of	stroke,	of	renal	failure
Hospital	characteristics:	presence	of	catheteri-
sation	laboratory,	number	of	beds
Reperfusiona 162 
(61.8)
559	
(73.7)
1.72 (1.28- 2.32) 1.37 (0.97- 1.94) Patient characteristics: age, dyslipidaemia, renal 
impairment at admission
Hospital	characteristics:	presence	of	catheteri-
sation laboratory
Revascularisationb 152	
(80.4)
529	
(83.2)
1.20 (0.79- 1.82 1.01 (0.60- 1.70) Patient characteristics: age, angiographic 
coronary disease
Hospital	characteristics:	presence	of	catheteri-
sation laboratory
CI,	confidence	interval;	OR,	odds	ratio;	STEMI,	ST-	elevation	myocardial	infarction.
aThrombolysis or primary percutaneous coronary intervention.
bPercutaneous coronary intervention and/or coronary artery bypass surgery among those submitted to coronary angiography.
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In	both	 types	of	ACS,	no	differences	 in	 revascularisation	among	
those managed invasively were observed between women and men. 
This	also	represents	a	sex-	gap	improvement	in	access	to	care.	When	
the	 decision	 to	 proceed	 to	 an	 invasive	 approach	 is	made,	 risks	 and	
benefits	 of	 revascularisation	 have	 already	 been	 evaluated.26 In our 
cohort,	 a	 significant	proportion	of	patients	of	both	 sexes,	especially	
in	 the	NSTEACS	 group	was	 not	 revascularised.	 Clinical	 and/or	 ana-
tomic reasons such as non- obstructive coronary heart disease, or 
coronary lesions not amenable to intervention, as well as patient and 
system	delays	for	STEMI/NC	ACS,	may	explain	these	revascularisation	
proportions.
4.1 | Limitations
Given	 the	 retrospective	 nature	 of	 this	 study	 and	 the	 data	 sources,	
the	validity	of	the	conclusions	relies	on	the	accuracy	and	complete-
ness	of	the	original	documentation.	Although	we	considered	the	main	
confounding	variables	at	the	individual	and	hospital	level,	no	detailed	
information	on	 socioeconomic	 status,	 clinical	presentation	and	 time	
delays was available.
5  | CONCLUSIONS
In	 a	 real-	life	 setting,	women	with	STEMI/NC	ACS	are	 less	 likely	
than	men	 to	 be	managed	 invasively.	 No	 sex	 differences	 in	 rep-
erfusion	 and	 revascularisation	 were	 observed	 in	 both	 types	 of	
ACS,	which	represents	an	important	achievement,	and	help	to	un-
derstand the greater declines in CHD mortality observed among 
women compared to men in Portugal. Further improvements are 
still	 necessary,	 especially	 in	 the	 management	 of	 women	 with	
STEMI/NC	ACS.	To	reduce	inequalities	in	management	of	patients	
with	ACS	in	Portugal,	the	sex-	gap	in	analysis	and	report	of	results	
from	national	registries	and	other	data	sources	must	be	improved,	
and patients admitted to hospitals with lower specialisation levels 
should be included.
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Introduction and objectives: Despite greater awareness of disparities in care and outcomes of women 
and men with acute myocardial infarction (AMI), no consistent attenuation of these differences over last 
decade has been observed. We aimed to identify differences by sex in management and 30-day mortality 
using the European Society of Cardiology Acute Cardiovascular Care Association quality indicators (QI) 
for AMI. 
Methods: The 20 QIs proportions and standard errors were calculated for 771 patients with AMI who 
were admitted to the cardiology department of two tertiary hospitals in Portugal between August 2013 
and December 2014. The association between the composite QI and 30-day mortality was derived from 
logistic regression. 
Results: Significantly fewer eligible women received timely reperfusion, were discharged on dual 
antiplatelet therapy, on high intensity statins and were referred to cardiac rehabilitation than men. Women 
less often received recommended interventions (59.6% vs 65.2%, p<0.001) and also had a higher mean 
GRACE 2.0 risk score adjusted 30-day mortality (3.0% vs 1.7%, p<0.001). An inverse association 
between the composite QI and crude 30-day mortality was observed for both sexes (odds ratio [OR] 0.08, 
95% confidence interval [95% CI] 0.01-0.64 for the highest performance tertile compared to the lowest). 
Conclusions: Performance in AMI management is lower in women compared to men and is associated 
with higher 30-day mortality, still worse for women. Objective and guideline supported QIs in constant 
assessment of practice´s quality have the potential to improve healthcare delivery and prognosis in overall 
AMI population and also to bridge the gap between women and men. 
Introducción y objetivos: A pesar de una mayor conciencia de las disparidades en el tratamiento y 
resultados en mujeres y hombres con infarto agudo de miocardio (IAM), no se observó una atenuación 
consistente de estas diferencias en la última década. El objetivo del estudio fue identificar diferencias por 
sexo en el tratamiento y la mortalidad a 30 días utilizando los indicadores de calidad (IC)  de la Asociación 
de Cuidados Cardiovasculares Agudos de la Sociedad Europea de Cardiología para el IAM. 
Métodos: Las proporciones y los errores estándar de los 20 IC se calcularon para 771 pacientes con IAM 
que ingresaron en el departamento de cardiología de dos hospitales terciarios en Portugal, entre agosto de 
2013 y diciembre de 2014. La asociación entre el IC compuesto y la mortalidad a 30 días se analizó por
regresión logística.
Resultados: Significativamente menos mujeres elegibles recibieron una reperfusión oportuna, tuvieran 
alta con doble terapia antiplaquetaria, con estatinas de alta intensidad y fueron remitidas a rehabilitación 
cardíaca en comparación con los hombres. Las mujeres recibieron con menos frecuencia las intervenciones 
recomendadas (59,6% vs 65,2%, p <0,001) y también tuvieron un score de riesgo GRACE 2.0 más alto 
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INTRODUCTION
ajustado a la mortalidad a 30 días (3,0% vs 1,7%, p <0,001). Se observó una asociación inversa entre el IC 
compuesto y la mortalidad bruta a 30 días para ambos sexos (odds ratio [OR] 0,08, intervalo de confianza 
95% [IC 95%] 0,01-0,64 para el tercil de mayor rendimiento en comparación con el menor).
Conclusiones: el rendimiento en el tratamiento del IAM es inferior en las mujeres que en los hombres y 
se asocia con una mayor mortalidad a los 30 días, aún peor para las mujeres. Los IC objetivos y basados 
en directrices, para la evaluación constante de la calidad de la práctica, tienen el potencial de mejorar la 
prestación y el pronóstico de la atención médica en los pacientes con IAM en general y también de reducir 
el gap entre mujeres y hombres.
Abbreviations
ACS: acute coronary syndrome
AMI: acute myocardial infarction
NSTEMI: Non-ST elevation myocardial infarction
QI: quality indicator
PCI: percutaneous coronary intervention
STEMI: ST elevation myocardial infarction
Abreviaturas:
IAM: infarto agudo de miocardio 
IAMCEST: infarto agudo de miocardio con elevación del 
segmento ST
IAMSEST: infarto agudo de miocardio sin elevación del 
segmento ST
IC: indicador de calidad 
ICP: intervención coronaria percutánea
SCA: síndrome coronario agudo
In recent decades, basic and clinical investigation helped 
to better understand the multifactorial and multidimensional 
differences between women and men suffering from an acute 
coronary syndrome (ACS).1 An emerging interest in coronary 
heart disease (CHD) in women revealed sex differences in 
the pathophysiology and clinical presentation, in preventive 
interventions and diagnostic strategies, in management of ACS, and 
in the response to therapies.2 Despite these differences, evidence 
supports equal benefit of evidence-based treatment of ACS for 
women and men and the need to promote stringent guideline 
implementation in management of women with ACS.3 
Comparing quality of care of ACS by sex is challenging 
because of the multiple dimensions of the process of care.4 Based 
on the European Society of Cardiology (ESC) guidelines for 
the management of ACS,3, 5 the ESC Acute Cardiovascular Care 
Association (ACCA) proposed a set of quality indicators (QI) for 
the management of AMI.4 They comprise 7 domains across 20 
QIs including the evaluation of the key aspects of the AMI care 
pathway. Recently these indicators were validated using data from 
the National Health Service of England and Wales (Myocardial 
Ischaemia National Audit Project [MINAP]) and showed 
potential to improve care and reduce unwarranted variation in 
death from AMI.6 These indicators may also be a useful tool to 
study sex inequalities in the ACS process of care and outcomes in 
contemporary settings. Using a prospective cohort study, we aimed 
to assess differences by sex in quality of care and 30-day mortality, 
by the application of the ESC ACCA QIs for AMI.
METHODS
Study Design and Sample Selection
The EPIHeart cohort study was designed with the a priori 
working hypotheses of the presence of inequalities in management 
and outcomes of patients with CHD in Portugal. This study 
included all consecutive patients admitted between August 2013 
and December 2014 to the cardiology departments of two tertiary 
hospitals in two regions in northern Portugal (Hospital de São 
João, Porto, covering part of the metropolitan area of Porto in the 
coast; and Hospital de São Pedro, Vila Real, covering the interior, 
northeastern region). These two centres are high volume units 
(more than 250 ACS hospitalisations annually). Eligible patients 
were 18 years old or older, living in the catchment area of these 
hospitals, not institutionalised before the event, expected to be 
hospitalised for at least 48 hours and who were diagnosed with 
type 1 (spontaneous) ACS. Of 1297 patients initially considered, in 
164 the diagnosis of ACS was not confirmed, 60 were discharged 
or transferred and 18 died before being invited. Further 44 were 
unable to answer the questionnaire due to clinical instability, no 
understanding of Portuguese, hearing problems, or cognitive 
impairment. Seventy-two patients refused to participate. Enrolled 
patients who were discharge alive, had valid contact details and 
agreed to continue in the study were interviewed 6 months after 
discharge (n=890). For this analysis only patients with a discharge 
diagnosis of ST elevation myocardial infarction (STEMI) or non-
ST elevation myocardial infarction (NSTEMI) were included, as 
ESC ACCA QIs were proposed for these types of ACS.4 A total of 
771 patients were analysed. The study protocol was in compliance 
with the principles of the Declaration of Helsinki and was approved 
by the Ethics Committee of both hospitals. All patients gave written 
informed consent. 
Procedures, data collection and definition of variables
Data were collected by trained researchers through structured 
interviews with patients and extended review of medical records, 
including discharge notes and exams reports. Patients were also 
asked to complete the Mini-Mental Status Examination (MMSE)7 
and their self-care and mobility activities of daily living was 
assessed using the Modified Barthel Index (BI).8 For patients who 
were discharged alive before 30th day after admission, vital status 
was obtained from the 6 months follow-up interview.
Marital status was considered partnered for married patients 
or living in civil union. Completed years of schooling were 
classified into four categories: less than 4 (little formal education), 
4 (elementary school), less than 12 (high school), and 12 or more 
years (secondary education or more).
Cognitive impairment was defined based on the MMSE score, 
taking into account established cut-offs for individual education 
level.9 Physical disability was assigned to patients scoring less than 
90 in the BI.8, 10 
ESC quality indicators
Each of 20 QIs4 was calculated for patients eligible for 
the procedure/treatment (and without contra-indications) with 
complete data. For QIs of the “reperfusion/invasive strategy” 
domain we considered eligible: 1) STEMI patients with onset of 
symptoms to diagnosis (first medical contact) time less than 12 
hours; 2) NSTEMI patients at intermediate or high risk (those 
presenting at least one of the following criteria: diabetes mellitus, 
renal dysfunction defined as Cockcroft-Gault estimated glomerular 
filtration rate (eGFR) less than 30 ml/min/1.73 m2, left ventricular 
ejection fraction (LVEF) equal to or less than 0.40, heart failure, 
prior percutaneous coronary intervention (PCI), prior coronary 
artery bypass surgery (CABG), GRACE risk score higher than 
140).4 Major relative contra-indications to coronary angiography 
were severe anaemia (admission haemoglobin less than 8 mg/dl) 
and/or severe renal failure (eGFR less than 30 ml/min/1,73m2 at 
admission).11, 12  
Variables to calculate the QIs of the “reperfusion/invasive 
strategy” domain were derived directly from collected data, except 
door-in door-out time for STEMI transferred patients, ascertained 
indirectly. Using exact times of admission to the non-PCI and 
PCI capable hospitals, we estimated the time of transportation 
between these two hospitals by ambulance applying the ArcGIS 
version 10.4.1 Network Analysist and an updated street network 
dataset provided by Environmental Systems Research Institute 
(ESRI). For each street segment, the street network dataset includes 
information on the traffic, average speed, type of street (main, 
secondary, highway), allowing to accurately estimate the shortest 
time-distance (minutes) between the hospitals’ point locations. 
Hospital locations were geocoded using Google Maps. We added 
10 minutes to estimated time of transportation to take into account 
time delays related with preparation of the patient and staff in the 
ambulance. 
To calculate individual GRACE 2.0 risk score13 we used 
“diuretic usage” as a surrogate for Killip class II for 39 patients, and 
19 patients had no information regarding ST segment deviation. 
For CRUSADE bleeding score,14 haematocrit  was obtained by 
formula: admission haemoglobin*2.94.15
For the anti-thrombotics QIs, patients at high bleeding risk 
(CRUSADE score higher than 50),14 with previous haemorrhagic 
stroke or discharged on oral anticoagulation were considered non-
eligible. Although clinical trials of secondary prevention treatment 
in MINOCA (Myocardial Infarction With Non-obstructive 
Coronary Artery Disease) patients are lacking, observational data 
showed a neutral effect of dual antiplatelet therapy on long-term 
outcomes and a trend toward an increased bleeding rate, therefore 
supporting that it is reasonable to treat this subgroup of patients with 
simple antiplatelet therapy.16 We performed a sensitivity analysis, 
considering patients with MINOCA (absence of obstructive 
coronary artery disease ≥50% stenosis) non-eligible for the quality 
indicators that include dual antiplatelet therapy.
A systolic blood pressure lower than 100 mmHg or severe 
renal failure (eGFR less than 30 ml/min/1,73m2) at discharge were 
contra-indications for angiotensin converting enzyme inhibitors 
(ACEI) or angiotensin receptor blockers (ARB). Contra-indications 
for beta-blockers were systolic blood pressure lower than 100 
mmHg at discharge, asthma and 2nd or 3rd degree atrioventricular 
block (Supplementary Table 1).
In the calculation of the opportunity-based main composite QI, 
the numerator was the sum of points of individual main indicators 
and the denominator the sum of points of applicable indicators, 
with all 12 indicators weighted equally (if fulfilled=1).
Data Analysis
To examine differences between women and men, the chi-
square or Fisher’s test was used for categorical variables and the 
t-test or Mann-Whitney test for continuous variables. For the QIs, 
proportions and standard errors (SE) were calculated for eligible 
patients and without missing data for the procedure or treatment.
The GRACE risk score adjusted 30-day mortality was 
estimated based on predicted probabilities derived from logistic 
regression. The association between the composite QI and crude 
30-day mortality was assessed using a logistic regression model; 
independent variable of the performance was categorised into low, 
intermediate and high attainment according to tertiles distribution 
of the whole study sample. 
All analyses were performed using STATA version 11.1 for 
Windows (Stata Corp LP, College Station, TX) and R version 
2.12.1 (R Foundation for Statistical Computing, Vienna, Austria), 
with statistical significance determined at 5%.
RESULTS
Baseline characteristics
Women (n=202, 26.2%) were older (68.6 vs 61.4 years, 
p<0.001), were more likely to be unpartnered, less educated, were 
more often disabled, and had a lower income compared with men. 
Women more frequently had hypertension and diabetes, and were 
more often obese and never smokers, compared with men. Women 
were also more likely to have prior atrial fibrillation and cancer than 
men. There were no significant differences regarding a previous 
history of ischemic heart disease, heart failure, renal failure and 
stroke by sex. Women more frequently had cognitive impairment 
than men and disability for activities of daily living (Table 1).
Admission characteristics, risk stratification and management
NSTEMI was the final diagnosis in 412 patients (53.4%), 64% 
patients were firstly admitted to a PCI capable hospital and 24% 
were admitted through a fast track system, without differences by 
sex (Table 2). 
Patient and system delays5 were longer for women than men, 
for both types of AMI (Table 2). Among STEMI patients, women 
had significantly higher median times for symptoms onset to first 
medical contact (FMC) and for PCI capable hospital admission to 
arterial access. The median time between hospital admission and 
coronary angiography was significantly longer in women with 
NSTEMI than in men (Table 2). 
Women were more often admitted with hemodynamic 
instability when compared with men, had lower mean eGFR, 
scored higher in GRACE and CRUSADE and were less likely 
to be submitted to invasive procedures regardless of myocardial 
infarction type (Table 2).
Quality indicators (Table 3)
Domain 1: Centre Organisation. These two centres do not 
routinely assess relevant times for the reperfusion process in 
STEMI patients and one centre participates in a regular registry for 
quality assessment.
Domain 2: Reperfusion/invasive strategy. Only 21.1% of 
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Table 1 Baseline demographic, socioeconomic and previous medical history characteristics of women and men with acute myocardial 
infarction*.
*Values are number and percentage unless otherwise indicated.
Total may not add to 100% due to missing data.
BI, Barthel index;  BMI, body mass index; CABG, coronary artery bypass surgery; CVD, cardiovascular diseases; MMSE, Mini-Mental 
State Examination; PCI, percutaneous coronary intervention;  SD, standard deviation.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Women 
(n=202) 
Men 
(n=569) 
p 
Age (years), mean (SD) 68.6 (12.6) 61.4 (12.7) <0.001 
Socioeconomic    
   Marital status    
       Partnered 119 (59.2) 467 (82.7) <0.001 
   Education    
Little formal education 87 (43.5) 58 (10.3)  
Elementary school 64 (32.0) 230 (40.9)  
High school 26 (13.0) 171 (30.4)  
Secondary education or more 23 (11.5) 104 (18.5) <0.001 
   Employment status    
Employed/housewives 60 (29.9) 203 (35.9)  
Unemployed 16 (8.0) 85 (15.0)  
Retired 82 (40.8) 205 (36.3)  
Disabled 43 (21.4) 72 (12.7) 0.001 
   Household income (euros)    
<500  67 (33.2) 106 (18.6)  
501-1000 55 (27.2) 187 (32.9)  
1001 – 2000 19 (9.4) 122 (21.4)  
>2000 13 (6.4) 67 (11.8)  
No response 48 (23.8) 87 (15.3) 0.001 
   Region    
Porto 98 (21.7) 353 (78.3)  
Northeastern region of Portugal  104 (32.5) 216 (67.5) 0.001 
Cardiovascular risk factors    
   Smoking    
Never 162 (80.2) 155 (27.2)  
Current 31 (15.4) 236 (41.5)  
Former 9 (4.5) 178 (31.3) <0.001 
   Hypertension 163 (80.7) 344 (60.5) <0.001 
   Diabetes mellitus 78 (38.6) 159 (27.9) 0.005 
   Dyslipidaemia 124 (61.4) 342 (60.2) 0.769 
   BMI  (kg/m2)    
Mean (SD) 27.5 (5.0) 26.9 (4.2) 0.157 
Under or normal weight 72 (37.3) 179 (33.7)  
Overweight 71 (36.8) 247 (46.5)  
Obese 50 (25.9) 105 (19.8) 0.048 
   Family history of CVD 87 (46.3) 205 (40.4) 0.160 
Previous medical history    
   Myocardial infarction, PCI and/or CABG 31 (15.4) 104 (18.4) 0.332 
   Heart failure 16 (7.9) 33 (5.8) 0.297 
   Renal failure 11 (5.5) 42 (7.4) 0.350 
   Atrial fibrillation 18 (8.9) 24 (4.2) 0.012 
   Stroke 25 (12.4) 48 (8.4) 0.100 
   Cancer 22 (10.9) 38 (6.7) 0.055 
   Cognitive impairment (MMSE score) 71 (37.2) 91 (17.6) <0.001 
   Disability (BI score) 41 (21.4) 38 (7.2) <0.001 
Table 2 Clinical presentation, patient and system delays, risk stratification and management of women and men with acute myocardial 
infarction*.
*Values are number and percentage unless otherwise indicated.
Total may not add to 100% due to missing data.
a Killip class III or IV; or shock at admission.
ACEI/ARB, angiotensin converting enzyme inhibitors/angiotensin receptor blockers; CABG, coronary artery bypass surgery; 
eGFR (CG), estimated glomerular filtration rate (Cockcroft-Gault); FMC, first medical contact; IQR, interquartile range;
NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation; STEMI, ST elevation 
myocardial infarction.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Women 
(n=202) 
Men 
(n=569) 
p 
NSTEMI (vs STEMI) 113 (55.9) 299 (52.6) 0.406 
Admission to a PCI-capable hospital 126 (62.4) 367 (64.5) 0.589 
Admission through fast track system 34 (20.6) 120 (25.0) 0.253 
Patient and system delays, median (IQR)    
 STEMI (min)    
   Symptom onset – FMC 119 (60-300) 81 (45-190) 0.040 
   First medical contact – arterial access 197 (113-630) 183 (95-415) 0.411 
   Symptom onset – arterial  access 460 (220-1096) 308 (190-779) 0.078 
   PCI-capable hospital admission- arterial access 96 (55-189) 66 (34-203) 0.028 
   First  hospital admission- arterial access 124 (79-477) 107 (52-336) 0.133 
   Door-in door-out time for transferred patients 156 (96-378) 134 (73-248) 0.230 
   Onset of symptoms to diagnosis    
      <12 hours 77 (89.5) 242 (92.0)  
      12-24 hours 6 (7.0) 11 (4.2)  
      >24h hours 3 (3.5) 10 (3.8) 0.582 
 NSTEMI    
     Symptom onset – FMC (min) 185 (60-395) 120 (60-333) 0.119 
     Hospital admission- coronary angiography time (hours) 32 (20-70) 27 (17-55) 0.049 
Admission variables/risk stratification    
Heart rate, mean (SD), bpm 81 (23) 77 (18) 0.003 
Systolic blood pressure, mean (SD), mmHg 146 (63) 141 (42) 0.286 
Cardiac arrest at admission 10 (5.0) 22 (3.9) 0.507 
ST-segment deviation on admission 143 (72.6) 410 (73.9) 0.725 
Hemodynamic instability at admissiona 26 (12.9) 24 (4.2) <0.001 
Baseline haematocrit at admission, mean (SD), % 38.3 (4.7) 42.8 (5.4) <0.001 
GFR (CG) mean (SD) 79.0 (37.4) 95.8 (41.4) <0.001 
Calculated GRACE risk score     
   NSTEMI mean (SD) 142 (3.8) 132 (2.0) 0.014 
   STEMI mean (SD) 168 (4.6) 141 (2.0) <0.001 
Calculated CRUSADE risk score    
   NSTEMI mean (SD) 41 (17) 21 (16) <0.001 
   STEMI mean (SD) 36 (15) 19 (13) <0.001 
Management approach     
   STEMI    
      Coronary angiography 86 (96.6) 269 (99.6) 0.019 
      Primary PCI 52 (74.3) 196 (86.3) 0.017 
      Thrombolysis 10 (11.2) 18 (6.7) 0.163 
  NSTEMI    
     Coronary angiography 101 (89.4) 286 (95.7) 0.017 
     Revascularization  64 (56.6) 220 (73.6) <0.001 
PCI 54 (47.8) 158 (52.8) 0.036 
CABG 11 (9.7) 65 (21.7) 0.005 
Moderate or severe left ventricular systolic dysfunction 42 (20.9) 94 (16.8) 0.188 
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Figure 1. Association between the composite opportunity-based 
quality indicator tertiles of attainment and crude 30-day mortality 
for women and men with acute myocardial infarction.
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women and 33.5% of men received timely reperfusion (p=0.041). 
The median time from FMC to arterial access for primary PCI 
patients was similar between women and men. Among NSTEMI 
patients, eligible women less often received coronary angiography 
within 72 hours after admission than men (73.0% vs 83.8% 
p=0.063). 
Domain 3: In hospital risk assessment. GRACE risk score 
was only assessed in 8% of NSTEMI patients, and CRUSADE 
bleeding score in 4.2% of all AMI patients; with no differences by 
sex. LVEF was similarly recorded in women and men (78.7% vs 
82.1%, p=0.294). 
Domain 4: Anti-thrombotics during hospitalisation. Above 
90% of patients received P2Y12 inhibitors, and a similar proportion 
was treated with fondaparinux or low molecular weight heparin 
(94.4% vs 91.6%, p=0.359, for women and men respectively). 
Fondaparinux alone was prescribed to only about 10% of patients. 
There was a significant difference in proportion of eligible women 
discharged on dual antiplatelet therapy compared with men (90.9% 
vs 95.9%, p=0.025). After excluding patients with MINOCA 
[20 (9.9%) women and 26 (4.6%) men], this difference was still 
observed (89.7% vs 96.1%, for women and men respectively, 
p=0.006). 
Domain 5: Secondary prevention discharge treatment. 
Significantly fewer women than men were discharged on high 
intensity statins (atorvastatin≥40 mg or rosuvastatin≥20 mg) 
(46.9% vs 61.8%, p<0.001), but no differences between sexes were 
observed in prescriptions of ACEI/ARB and of beta blockers at 
discharge.
Domain 6: Patient satisfaction. In contrast to cardiac 
rehabilitation referral, eligible women received smoking cessation 
advice more often than men (14.9% vs 26.3%, p=0.001 and 51.7% 
vs 28.6%, p=0.011, respectively).
Domain 7: Composite quality indicators. About 60% of women 
and 65% of men received the interventions they were eligible for 
(p<0.001). For the secondary composite QI, 54.0% of women and 
60.9% of men with AMI received all the secondary prevention 
drugs for which they were eligible for (p=0.174). The results 
were similar after excluding patients with MINOCA (54.1% vs. 
60.8%, p=0.212). Outcome quality indicator. There were 15 deaths 
within 30 days after admission, 8 in women and 7 in men. The 
mean GRACE 2.0 risk score adjusted 30-day mortality was 3.0% 
in women and 1.7% in men (p<0.001).
Quality indicators and mortality 
An inverse association between the composite opportunity 
based QI (by tertiles of attainment) and crude 30-day mortality 
was observed, both for women and men (Figure 1). Patients with 
higher attainment of recommended care were less likely to die 
in comparison with patients in category of low (odds ratio [OR] 
0.15, 95% confidence interval [95% CI] 0.03-0.66 and OR 0.08, 
95% CI 0.01-0.64 for patients in intermediate and high attainment, 
respectively). 
DISCUSSION
Using the EPIHeart prospective cohort study and the ESC 
ACCA QIs for AMI, performance for women was lower than 
for men in 6 domains. Fewer women than men received timely 
reperfusion, were discharged on dual antiplatelet therapy and on 
high intensity statins, were referred for cardiac rehabilitation and 
scored lower in the main composite QI for advisable interventions. 
An inverse association between the attainment of composite QI and 
mortality was observed for both sexes. Without differences by sex, 
we found low levels of ischemic and bleeding risk stratification 
assessment using GRACE and CRUSADE prognostic tools and of 
use of fondaparinux in NSTEMI eligible patients.  
The ACS care pathway is complex to evaluate, patient and 
system factors have competing effects on patient flow through the 
health care system, often influence each other and act at different 
times during an episode of illness and care.17 Disparities in health 
care provided to women and men and in outcomes are multifactorial 
and occur at different levels of the ACS pathway process of 
care.18, 19 The differences in demographic, socioeconomic and 
cardiovascular risk factors, comorbidities and severity presentation 
found between women and men of our cohort are in accordance 
with updated data focused on the multifactorial determinants of sex 
disparities in CHD management and outcomes.2
The results on QIs in the reperfusion/invasive strategy 
strengthens the importance of timeliness of care delivery in the 
evaluation of care.20 Time-based QIs are significantly influenced 
by hospital system factors adjusted for patient factors, namely 
patient delay times.21 In fact, the high level of reperfusion distracts 
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attention from a low level of timely reperfusion for both sexes, 
significantly lower for women; and for patients admitted to both 
PCI and non-PCI capable hospitals. The very low proportion of 
patients transferred from non-PCI capable hospitals for primary 
PCI, particularly women, within the target 30 minutes door-in 
door-out time is particularly relevant in terms of health policy and 
planning. According to the Codi Infart registry of Catalonia, first 
medical contact to artery opening time above 120 minutes was 
strongly associated with first medical contact in a centre without 
a catheterization laboratory.22  Implementation of the national 
coronary fast track system in Portugal largely contributed to a 
twofold increase in primary angioplasty from 2010 to 2015,23 but 
no data exist about the parallel achievement and improvement of 
timely reperfusion. The implementation of these networks, which 
favour primary angioplasty rather than thrombolysis, might result in 
time delays that outweigh the benefits of mechanical reperfusion.22  
The non-significantly different proportion of women submitted 
to coronary angiography within 72 hours from admission, when 
compared to men, may indicate an improvement in timely invasive 
strategy for NSTEMI patients. Among patients with NSTEMI, 
indication for an invasive approach depends on numerous factors, 
including clinical presentation, comorbidities, risk stratification, 
frailty, cognitive status, estimated life expectancy, among others.3 
Frailty, worse cognitive status, other comorbidities, a lower 
estimated life expectancy increases with age, and women of our 
cohort were significantly older than men. Not all these factors were 
considered in the QI assessment, however the main NSTEMI QI of 
the invasive strategy is a time-based QI, measures delay times and 
not the decision to proceed to an invasive approach.
The very low level of performance of GRACE and CRUSADE 
assessment among both women and men should be addressed, as 
objective risk assessment using risk scores provides superior risk 
discrimination when compared with physician estimated risk.24 
Use of incomplete drugs combinations after an ACS is 
associated with a higher risk of cardiovascular morbidity and 
all-cause mortality.25 Results from a retrospective cohort study 
revealed that in Portugal women with STEMI were less likely 
to be discharged on aspirin and clopidogrel.26 These results are 
in line with our finding of a lower proportion of eligible women 
discharged on dual antiplatelet therapy. High-intensity statins are 
recommended in all patients with AMI, irrespective of cholesterol 
concentration at presentation.27 Previous studies reporting equally 
very high prescription of statins for secondary prevention after an 
ACS among women and men do not inform about the specific type 
of statins.6, 26 However, poorer compliance with recommendation 
for high-intensity dose statins has been already reported28 and 
results from EPIHeart study enlarge the knowledge about existing 
sex differences in prescription of this evidence based treatment. The 
use of lower-intensity statin therapy may be considered in patients 
at increased risk of side effects from statins (e.g. elderly, hepatic or 
renal impairment, previous side effects, or a potential for interaction 
with essential concomitant therapy).27 In real-world practice, 
patients who besides this frail condition have very low baseline 
low-density lipoprotein cholesterol (LDL-C), are more probably 
candidates to be discharged on lower-intensity statin therapy, which 
is not necessary a wrong practice. We do not have the LDL-C levels 
at presentation, nor were able to identify this subgroup of patients 
with increased risk of side effects from statins. In anti-thrombotics 
and secondary prevention discharge treatment no differences by sex 
were observed, with high levels of performance for all treatments, 
except for fondaparinux. Treatment with fondaparinux was also the 
QI with the widest hospital variation in the MINAP register.6 Not 
all possible relative contra-indications to prescription of different 
classes of drugs were taken into account, however the most relevant 
variables were considered to achieve our objectives.
Increasing referral to cardiac rehabilitation, especially among 
women can further reduce differences in mortality after an 
ACS between women and men, considering that referral to and 
attendance at cardiac rehabilitation is associated with a significant 
mortality reduction in women, comparatively better than that in 
men.29 The higher smoking cessation advice observed for eligible 
women compared to men may be explained by evidence of higher 
appropriateness of this particular care for women, since women 
who smoke have a greater risk of developing cardiovascular disease 
than male smokers.1
Women had twice the 30-day mortality rate of men, adjusted for 
GRACE score. However, other factors not captured by the GRACE 
risk score that may have impact on outcomes, namely patient’s 
adherence to secondary prevention, frailty, among others, were not 
addressed, which limits definitive conclusions on the association 
between sex and 30-day mortality rate.30, 31  
Considering the low number of deaths in our cohort and the 
difficulty to demonstrate the relation between a single QI and 
clinical outcome,32 we used the composite QI to measure the relation 
between process and outcome indicators. We found an inverse 
relation between attainment of this QI covering the spectrum of 
AMI care pathway and crude mortality; however this finding has to 
be considered with caution, since the small number of deaths within 
the tertiles of attainment of the composite QI precluded adjustment 
for possible confounders. Guideline recommended management 
and treatment performance indicators have already been associated 
with outcomes for patients with AMI.20, 33 Our results are in line with 
findings that despite more than a decade since gender disparities 
in management and outcomes were described for the first time in 
a large-scale observation study34 sex-related differences have not 
been eliminated.35, 36 Further studies are needed to explore the 
reasons behind our findings, particularly to explore potential causal 
pathways to the associations between sex and management and 
outcomes, among patients with ACS.
Quality indicators in addition to stating an explicit diagnostic or 
therapeutic action to be performed, define how to identify patients 
for whom a specific action should be taken. It is not surprising that 
there is not a unique and universal standardised set of QIs for ACS; 
in 2015, the Spanish Society of Cardiology and the Spanish Society 
of Thoracic and Cardiovascular Surgery organized a task force 
to define outcome and process indicators of hospital cardiology 
practice.37 Measuring and reporting variations by sex using 
validated QIs has the potential to further reduce sex inequalities in 
quality of care, with the ultimate goal of decreasing the still higher 
short term mortality of women with AMI. 
Study limitations
These results report to two centres and do not represent the 
national scenario for ACS quality of care and outcomes. Because 
of eligibility criteria, for some QI small samples were used, but 
sampling was consecutive and the two hospitals contributed with 
320 and 451 patients each. Although door-in door-out time for 
STEMI transferred patients was ascertained indirectly, we do not 
expect systematic errors in calculation with the methodology used. 
Patients who died before the interview were older (81.5±11.8 
vs 64.0±13.0 years, p<0.001), were more often women (66.7% vs 
26.0%, p<0.001), and more frequently had a diagnosis of STEMI 
(81.3% vs 43.4%, p=0.003) than did participants. Patients who 
were not enrolled because of clinical instability or inability to 
understand the questionnaire because of cognitive impairment were 
older (75.2±10.1 vs 64.0±13.0 years, p<0.001), but there were no 
differences in sex proportion (male 68.2% vs. 74.1%, p=0.389) 
and ACS type (STEMI 37.2% vs. 46.6%, p=0.257). Patients who 
refused to participate were older (72.7±11.0 vs 64.0±13.0 years, 
p<0.001), were less often partnered (65.7% vs 76.8%, p=0.036), 
and had little formal education (43.1% vs 19.7%, p<0.001) 
compared with participants. Refusals were equally often male 
(65.3% vs. 73.8%, p=0.119) and diagnosed with STEMI (37.1% vs. 
46.6%, p=0.130) as participants. The higher risk of non-inclusion 
of women due to death in the early hours of admission means that a 
greater difference by sex in mortality would be expected. We have 
no further information on other characteristics and outcomes of 
these high risk patients.
CONCLUSIONS 
Applying the ESC ACCA QIs, we observed differences in 
quality of care at different levels of the care pathway between 
women and men with AMI. These findings and the association of the 
composite QI with 30-day mortality, which is still higher in women, 
(and despite the fact that we cannot conclude that this difference in 
outcome is explained by the sex per se) provide evidence to support 
the measuring of these validated QIs separately by sex, to improve 
guideline recommended management and reduce mortality from 
AMI in women.
What is known about the topic?
Differences in management and outcomes in acute myocardial 
infarction patients were observed between women and men. 
Suboptimal care of women with acute myocardial infarction 
persisted through time. Use of the European Society of Cardiology 
Acute Cardiovascular Care Association quality indicators, which 
capture the key aspects of the acute myocardial infarction care 
pathway, has potential to improve care and reduce unwarranted 
variation in death.
What does this study add?
Adherence to validated performance measures for acute 
myocardial infarction is still lower in women compared to men and 
is associated with higher 30-day mortality. Timely reperfusion, 
discharge on dual antiplatelet therapy and on high intensity 
statins, and referral to cardiac rehabilitation were identified as 
targets to reduce sex inequalities in management of these patients. 
Use of the European Society of Cardiology Acute Cardiovascular 
Care Association quality indicators for management of acute 
myocardial infarction has also potential to bridge the gap between 
women and men.  
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Domain of care Type of QI Description Components/eligibility 
1.Centre 
organization 
1.1 Main  
 Centre is part of a network organisation. 
Single emergency phone number; pre-hospital ECG; pre-hospital activation 
of the catheterisation laboratory. 
 1.2 Secondary 1 Centre routinely assess relevant times for the reperfusion process in STEMI patients. 
Times from ‘call to first medical contact’, ‘first medical contact to door’, 
‘door to arterial access’; and ‘door-in-door-out’ for centres without a 
catheterisation laboratory on site. 
 1.3 Secondary 2 Centre participates in a regular programme for quality assessment.  
2.Reperfusion-
invasive strategy 2.1 Main (STEMI 1) 
Proportion of STEMI patients eligible 
reperfused. Onset of symptoms to diagnosis <12 h. 
 2.2 Main (STEMI 2) Proportion of STEMI patients eligible with timely reperfusion. 
For fibrinolysis: <30 mins from diagnosis (FMC) to needle; for primary PCI 
and admission to PCI capable centres: <60 mins from door to arterial 
access; for transferred patients: door-in door-out time of <30 mins. 
 2.3 Main NSTEMI 
Proportion of high-intermediate risk NSTEMI 
patients who receive coronary angiography 
within 72 h after admission. 
High-intermediate risk: at least one: diabetes mellitus, renal dysfunction 
(eGFR<30 ml/min/1.73 m²), LVEF⩽0.40, heart failure, recent PCI, prior 
CABG, GRACE risk score >140 or recurrent symptoms or ischaemia on 
non-invasive testing. 
 2.3 Secondary (STEMI) 
Time between the FMC and arterial access for 
primary PCI.  
3.In hospital risk 
assessment 3.1 Main (1) 
Proportion of NSTEMI patients with GRACE 
risk score assessment. 
GRACE risk score numerical value assessed and recorded in the discharge 
letter. 
 3.2 Main (2) Proportion of AMI patients with CRUSADE bleeding score assessment. 
CRUSADE bleeding score numerical value assessed and recorded in the 
discharge letter. 
 3.3  Main (3)  Proportion of AMI patients with LVEF assessment. 
LVEF numerical value assessed and recorded in the report of the last 
echocardiography during hospital stay. 
4.  Anti-
thrombotics 
during 
hospitalisation 
4.1 Main  (1) 
Proportion of patients with ‘adequate P2Y12 
inhibition’ on discharge. 
 
For ticagrelor: AMI patients without previous haemorrhagic stroke, high 
bleeding risk, fibrinolysis or oral anticoagulation; prasugrel was not 
prescribed, for clopidogrel: no indication for prasugrel or ticagrelor and no 
high bleeding risk. 
 4.2 Main (2) Proportion of patients with NSTEMI treated with fondaparinux. 
Exclusion of candidates for immediate (⩽2 h) invasive strategy or with 
eGFR<20 ml/min. 
 4.3 Secondary Proportion of eligible patients discharged on dual antiplatelet therapy. 
Eligible: patients with CRUSADE risk score <50 and without oral 
anticoagulation on discharge. 
5. Secondary 
prevention-
discharge 
treatment 
5.1 Main Proportion of patients with AMI discharged on  statins at high intensity. Atorvastatin ⩾40 mg or rosuvastatin ⩾20 mg. 
 5.2 Secondary (1) 
Proportion of patients with AMI and clinical 
evidence of HF/LVEF ⩽0.40 discharged on 
ACEI/ARB. 
Contra-indications:  systolic blood pressure of less than 100 mmHg or 
severe renal failure (eGFR <30 ml/min). 
 5.3 Secondary (2) 
Proportion of patients with AMI and clinical 
evidence of HF/LVEF ⩽0.40 discharged on 
beta-blockers. 
Contra-indications:   systolic blood pressure of less than 100 mmHg at 
discharge, asthma and 2nd or 3rd degree atrioventricular block. 
6. Patient 
satisfaction 6.1 Main  
Feedback regarding the patient’s experience 
systematically collected. 
Recommendation to attend a cardiac rehabilitation programme used as 
surrogate. 
7. Composite 
and outcome QI 
7.1 Main composite 
(CQI) Opportunity-based CQI. 
Centre is part of a network organisation; STEMI patients reperfused; 
coronary angiography in high ischaemic risk AMI patients; GRACE in 
NSTEMI; CRUSADE in AMI patients; LVEF before discharge; low dose 
aspirin; adequate P2Y12 inhibition; ACEI/ARB in patients with 
HF/LVEF⩽0.40; beta-blockers in HF/LVEF⩽0.40; high intensity statins;  
cardiac rehabilitation referral. 
 7.2 Secondary CQI All-or-none CQI based on 3 or 5 components, according to the LVEF. 
For patients without HF/with LVEF>0.40: low-dose aspirin, P2Y12 
inhibitor, high-intensity statins. For patients with HF/with LVEF⩽0.40: 
low-dose aspirin, P2Y12 inhibitor, high-intensity statins, ACEI/ARB, beta-
blockers. 
 7.3 Secondary outcome 
30-day mortality rate adjusted for the GRACE 
2.0 risk score. 
No information about follow-up was available for 29 patients and GRACE 
2.0 risk score was not possible to calculate for 19 patients. 
Supplementary Table 1  Description of the ESC ACCA QIs for AMI domains.
ACEI/ARB, angiotensin converting enzyme inhibitors/angiotensin receptor blockers; AMI, acute myocardial infarction; CABG, 
coronary artery bypass surgery; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; FMC, first medical contact; HF, 
heart failure; LVEF, left ventricular ejection fraction; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary 
intervention; QI, quality indicator; STEMI, ST elevation myocardial infarction.
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Research
AbstrACt
Objectives Prompt diagnosis of acute coronary syndrome 
(ACS) remains a challenge, with presenting symptoms 
affecting the diagnosis algorithm and, consequently, 
management and outcomes. This study aimed to identify 
sex differences in presenting symptoms of ACS. 
Design  Data were collected within a prospective cohort 
study (EPIHeart). 
setting Patients with confirmed diagnosis of type 1 
(primary spontaneous) ACS who were consecutively 
admitted to the Cardiology Department of two tertiary 
hospitals in Portugal between August 2013 and December 
2014. 
Participants  Presenting symptoms of 873 patients (227 
women) were obtained through a face-to-face interview. 
Outcome measures: Typical pain was defined according to 
the definition of cardiology societies. Clusters of symptoms 
other than pain were identified by latent class analysis. 
Logistic regression was used to quantify differences in 
presentation of ACS symptoms by sex. 
results Chest pain was reported by 82% of patients, 
with no differences in frequency or location between 
sexes. Women were more likely to feel pain with an 
intensity higher than 8/10 and this association was 
stronger for patients aged under 65 years (interaction 
P=0.028). Referred pain was also more likely in women, 
particularly pain referred to typical and atypical locations 
simultaneously. The multiple symptoms cluster, which 
was characterised by a high probability of presenting 
with all symptoms, was almost fourfold more prevalent in 
women (3.92, 95% CI 2.21 to 6.98). Presentation with this 
cluster was associated with a higher 30-day mortality rate 
adjusted for the GRACE V.2.0 risk score (4.9% vs 0.9% for 
the two other clusters, P<0.001).
Conclusions While there are no significant differences in 
the frequency or location of pain between sexes, women 
are more likely to feel pain of higher intensity and to 
present with referred pain and symptoms other than pain. 
Knowledge of these ACS presentation profiles is important 
for health policy decisions and clinical practice.
IntrODuCtIOn
Acute coronary syndrome (ACS) is still 
one of the main causes of death worldwide 
and in Europe.1 2 Coronary heart disease 
mortality has decreased in the last decades 
in high-income countries because of primary 
prevention and improvement in treat-
ment of patients with ACS.2 Attainment of 
the maximal benefit of treatment of these 
patients is threatened by delayed diagnosis, 
partly dependent on clinical suspicion of 
ACS. The subjective experience of symptoms 
influences patients’ attitudes in seeking help 
and professionals’ interpretation of clinical 
presentations.3 Early recognition of ACS may 
be challenging because while patients with 
presumed ACS have contact with healthcare 
providers,4 many patients do not have an elec-
trocardiogram (ECG) before hospitalisation.5 
Therefore, physicians frequently have to 
make decisions that are only clinically based.
The population of patients with atypical 
ACS presentation is still not well charac-
terised.6 Women and men generally have 
the same type of symptoms during an ACS 
episode, although the proportion presenting 
with different combinations of symptoms 
varies.7 This conflicting evidence can be partly 
explained by the diverse methodology used, 
strengths and limitations of this study
 ► Within a prospective cohort study, presenting 
symptoms of acute coronary syndrome were 
obtained through a structured questionnaire applied 
within the first 48 hours after admission.
 ► Consecutive sampling, the detailed clinical 
information obtained through the questionnaire 
and adjustment for several confounding variables 
strengthens our results.
 ► The results of this study are valid for stable patients 
admitted to the hospital and who were able to 
answer the questionnaire in the acute phase of the 
acute coronary syndrome.
 ► Some of the sex differences in presenting symptoms 
may be influenced by selection bias because 
of a higher risk of non-inclusion of women due 
to misdiagnosis or death in the early hours of 
admission.
Papers  |  93
94
2 Araújo C, et al. BMJ Open 2018;8:e018798. doi:10.1136/bmjopen-2017-018798
Open Access 
with few prospective studies, usually without a specific 
questionnaire. In prospective studies, small convenience 
samples were used and confounding was not always 
adequately addressed.8 9 Therefore, sex-specific research 
on ACS presentation is a challenge and priority.10
This study aimed to analyse sex differences in presenting 
symptoms of ACS within a prospective cohort study, taking 
into account the contribution of age, socioeconomic data, 
previous history of coronary heart disease, risk factors, 
comorbidities, type of ACS and coronary anatomy to the 
presenting symptoms.
MethODs
study design and sample selection
The EPIHeart cohort study was designed to identify 
inequalities in management and outcomes of patients 
with ACS. This study included all consecutive patients 
who were admitted between August 2013 and December 
2014 to the Cardiology Department of two tertiary hospi-
tals in two regions in northern Portugal (Hospital de São 
João, Porto, covering the metropolitan area of Porto in 
the coast; and Hospital de São Pedro, Vila Real, covering 
the interior, northeastern region). Eligible patients were 
aged 18 years or older who lived in the catchment area 
of these hospitals (districts: Porto, Vila Real, Bragança, 
and Viseu), with confirmed diagnosis of type 1 (primary 
spontaneous) ACS. The diagnosis of type 1 ACS and the 
classification in different subtypes was determined by the 
treating cardiologist, based on symptoms and signs at 
presentation, ECG findings and the increase in cardiac 
enzyme levels (high-sensitivity troponin I or T were used), 
according to the third universal definition of myocar-
dial infarction.11 The patients were also expected to be 
hospitalised for at least 48 hours and not institutionalised 
before the event. Of 1297 patients initially considered, 
in 164 the diagnosis of type 1 ACS was not confirmed, 
60 were excluded due to discharge or transfer before 
the interview, 18 died before being invited and 44 were 
unable to answer the questionnaire because of clinical 
instability, no understanding of Portuguese, hearing 
problems or cognitive impairment. Seventy-two patients 
refused to participate. For this analysis, we excluded 61 
patients who were not admitted because of a symptom 
(patients referred by a doctor, after a scheduled appoint-
ment or diagnostic exam), 4 with vasospastic angina and 
1 illicit drug user. A total of 873 patients were included 
(figure 1). The study protocol was in compliance with the 
principles of the Declaration of Helsinki. All patients gave 
written informed consent.
Procedures and data collection
Presenting symptoms were obtained face-to-face using a 
structured questionnaire applied by trained interviewers, 
within the first 48 hours after admission, whenever 
possible. Over the following days, a second interview was 
conducted to collect data on sociodemographic charac-
teristics and risk factors. Medical records were reviewed 
to extract data regarding previous medical history, admis-
sion information and clinical data during hospitalisation.
Pain, referred pain and symptoms other than pain 
were measured dichotomously (yes/no). For the loca-
tion of pain (direct and referred), patients were asked 
to point out where pain was occurring. To measure the 
intensity of pain, a 10-point scale (0, no pain; 10, pain 
of maximal intensity) was used. Symptoms other than 
pain included dyspnoea at rest, exertional dyspnoea, 
sweating, nausea, vomiting, dizziness, blurry vision, 
presyncope, syncope, palpitation, weakness and an 
open-ended question of 'other' (12 items). Answers to 
the last item enabled identification of two other rela-
tively frequent symptoms, other digestive symptoms 
and discomfort. Activity at the onset of the episode was 
measured dichotomously, including sleeping, rest, and 
any exertion. A stress trigger was assigned if the patient 
answered 'yes' for at least one of following events within 
24 hours preceding the episode: accident, recent diag-
nosis of disease, financial problems and news of death/
disease of a relative/friend.
Marital status was considered partnered for married 
patients or living in civil union. Education was recorded 
as completed years of schooling and classified into four 
categories: <4 (little formal education), 4 (elemen-
tary school), <12 (high school) and 12 or more years 
(secondary education or more). Occupations were clas-
sified into major professional groups, according to the 
Portuguese Classification of Occupations 2010,12 inte-
grated in the International Standard Classification of 
Occupations (ISCO/2008).
Definition of variables
Although symptoms of ACS have been widely described, 
their value for diagnosis of ACS is not unanimously 
recognised.13–15 After discussion with clinical cardiologists 
of our team, we opted to use Cardiology Societies’ posi-
tion papers to define direct and referred pain locations 
and to select symptoms to evaluate.16 17 Direct pain loca-
tion was classified as follows: 1) typical for retrosternal, 
precordial, right thoracic or bilateral thoracic pain (chest 
pain); 2) atypical for epigastric pain or located in the 
back, left arm or shoulder, right arm or shoulder, neck or 
jaw and 3) a mixture when both typical and atypical loca-
tions were present. Referred pain location was considered 
as follows: 1) typical if pain referred to the left arm or 
shoulder, right arm or shoulder, neck or jaw; 2) atypical 
if pain referred to retrosternal, precordial, right thoracic, 
bilateral thoracic, epigastric or back regions and 3) a 
mixture for referred pain in typical and atypical locations.
Patients rarely present with a single symptom during 
an episode of ACS, and present with multiple symptoms 
instead that do not occur in isolation and may cluster.18 
There has been increasing interest in symptom cluster 
analysis in cardiovascular disease because it aids in assess-
ment by enhancing recognition of patients with similar 
symptom profiles.19 Groups of symptoms other than pain 
were obtained by latent class analysis.
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The small group of non-classified (NC) patients 
with ACS (patients with left bundle branch block) was 
grouped with patients with ST-elevation myocardial 
infarction (STEMI) (STEMI/NC ACS group). Non-ST-el-
evation ACS (NSTEACS) included unstable angina and 
non-ST-elevation acute myocardial infarction or subacute 
myocardial infarction.
Considering the possible association between coronary 
anatomy and clinical presentation, we grouped patients 
according to coronary angiography into five groups: 
managed conservatively; non-obstructive coronary artery 
disease; lesions exclusively in the anterior descending 
artery; lesions in the right and/or circumflex artery 
and lesions in the left main coronary artery, three-vessel 
disease or disease both in the anterior descending artery 
and the right or circumflex artery.
Data analysis
Continuous variables are expressed as mean and stan-
dard deviation (SD) or as median and interquartile range 
(IQR). Categorical variables are shown as number and 
percentage. To compare differences between women and 
men, and by age groups, the χ2 test or Fisher’s exact test 
was used for categorical variables and the t-test, Mann-
Whitney U test or Kruskal-Wallis test for continuous vari-
ables. Latent class analysis was used to identify distinct 
groups of individuals from a sample (clusters) who were 
homogeneous within the group. This was based on the 
Figure 1 Flow chart of the study population. ACS, acute coronary syndrome.
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fact that performance of an individual in a set of items is 
explained by a categorical latent variable with K classes 
(clusters), commonly called latent classes. The number of 
latent clusters was defined according to the Akaike infor-
mation criterion (AIC). Starting from one single cluster 
and increasing one cluster at each step, the best solution 
was identified when an increase in the number of clusters 
did not lead to a decrease in the AIC.
Patient and system delays, severity indicators, risk strat-
ification using calculated GRACE and CRUSADE risk 
scores, left ventricular systolic dysfunction and 30-day 
mortality rate adjusted for the Global Registry of Acute 
Coronary Events  (GRACE)  V.2.0 risk score,20 were 
assessed according to the presence of typical (chest) pain 
and cluster of symptoms other than pain. The 30-day 
mortality adjusted for the GRACE V.2.0 risk score was 
estimated based on predicted probabilities derived from 
logistic regression. Logistic regression was used to identify 
variables associated with clinical presentation. Variables 
with P<0.15 for a crude association with the end point 
were entered in the initial model and a backward strategy 
was used to exclude the least significant variables, based 
on Wald tests. We were then able to obtain the most parsi-
monious model with all the important determinants. 
Previous data support significant interaction between 
age and sex with clinical presentation, attenuated with 
advancing age, mainly in those aged 65 years or older.3 
We assessed for effect measure modification by strati-
fying adjusted analyses based on two age groups (under 
65 and 65 years or older). Considering the relevance of 
analysing sex differences in ACS clinical presentation in 
younger patients, we also performed the age-stratified 
multivariate models using 55 years as cut-off age. Sex, age 
(continuous) and type of ACS were forced to remain in 
the models.
All analyses were performed using STATA V.11.1 for 
Windows (StataCorp, College Station, Texas, USA) and R 
V.2.12.1 (R Foundation for Statistical Computing, Vienna, 
Austria).
results
baseline characteristics
Women (n=227, 26.0%) were older (69.1 vs 62.2 years, 
P<0.001) and more frequently lived in the interior region 
(52.4% vs 38.7%, P<0.001) than men. Women were more 
often treated conservatively and had non-obstructive 
coronary artery disease more frequently than men. In this 
sample, no difference by sex was observed in the type of 
ACS, where 56.6% of the patients had a discharge diag-
nosis of NSTEACS (table 1).
Women more frequently had hypertension (81.5% 
vs 62.7%, P<0.001) and diabetes (38.8% vs 29.9%, 
P=0.014), and were more frequently obese (25.5% vs 
18.5%, P=0.020) and never smokers compared with men 
(P<0.001, table 1). Men were submitted to percutaneous 
coronary intervention more often than women. There 
were no significant differences in a previous history of 
renal failure, prior myocardial infarction, prior coronary 
artery bypass surgery, prior heart failure and dementia by 
sex (table 1).
Women were more likely to be unpartnered, disabled, 
less educated and had a lower income compared with 
men. The median time that elapsed between admission 
and application of the symptom questionnaire was slightly 
longer in women than in men (table 1).
symptom characteristics by sex and age
Because differences in symptoms by sex and age were 
similar in direction and magnitude in STEMI/NC ACS 
and NSTEACS (see online supplementary table 1 and 2), 
both types of ACS were analysed together.
Although pain was present in most patients, men 
presented with pain more frequently than did women 
(97.4% vs 94.3%, P=0.028), with a higher sex difference 
among patients aged 80 or more years (88.0% vs 93.5%). 
Older patients presented less often pain, but the difference 
by age group in both sexes was not significant (table 2). 
No difference was found in the location of pain by sex. 
Approximately 80% of patients felt chest pain (typical 
pain). Older women presented less frequently with chest 
pain and had chest pain and pain in other locations 
(mixture group) more often than did younger women 
(P=0.014). Referred pain was observed more frequently 
in women and in younger patients (only significant for 
men, P=0.024); again in the older age group, the differ-
ence between women and men was notorious (56.8% vs 
39.7%, respectively). Atypical and mixture referred pain 
were more frequent in women than in men (P<0.001), 
mainly in women aged ≥65 years (P=0.009). Women felt 
pain with higher intensity than did men (median (IQR): 
9 (8–10) vs 8 (6–9), P<0.001), without a difference by age 
(table 2). Women presented with symptoms other than 
pain more frequently than did men (82.8% vs 68.9%, 
P<0.001), with no difference by age group in both sexes 
(table 2).
Considering symptoms other than pain, the AIC 
optimum value supported a preference for a three-cluster 
solution (AIC 7207.508, 6869.390, 6862.476 and 6870.372 
for one, two, three and four clusters, respectively). 
Cluster 1 had low endorsement probabilities for all items 
(no symptoms cluster). Cluster 2 had a high probability 
for dyspnoea at rest and sweating, and a low probability 
for the remaining items (dyspnoea and sweating cluster). 
Cluster 3 had high probabilities for all items (multiple 
symptoms cluster). This three-cluster model made sense 
conceptually to cardiologists of our team. Clusters counts 
and probabilities of occurrence of symptoms in estab-
lished clusters are shown in online supplementary table 
3. Differences in proportions of women and men in the 
three clusters were observed (P<0.001, table 2). Cluster 
1 was the most prevalent, in which men presented with 
the no symptoms cluster more frequently (76.9% vs 
62.6%) and the multiple symptoms cluster less frequently 
(4.8% vs 15.9%) than did women. Higher differences of 
multiple symptoms cluster proportions between women 
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Table 1 Baseline demographic, socioeconomic and clinical characteristics in the whole sample and by sex*
Total
(n = 873)
Women
(n = 227)
Men
(n = 646) P value
Age (years), mean (SD) 64.0 (13.0) 69.1 (12.7) 62.2 (12.7) <0.001
Socioeconomic status
  Marital status
  Partnered 667 (76.8) 133 (58.9) 534 (83.2) <0.001
  Education
  Little formal education 172 (19.9) 95 (42.4) 77 (12.0)
  Elementary school 337 (39.1) 73 (32.6) 264 (41.3)
  High school 213 (24.7) 32 (14.3) 181 (28.3)
  Secondary education or more 141 (16.3) 24 (10.7) 117 (18.3) <0.001
  Employment status
  Employed/looking after home 282 (32.6) 64 (28.3) 218 (34.1)
  Unemployed 107 (12.4) 16 (7.1) 91 (14.2)
  Retired 334 (38.6) 93 (41.2) 241 (37.7)
  Disabled 143 (16.5) 53 (23.5) 90 (14.1) <0.001
  Subjective social class
  Low 281 (32.2) 81 (35.7) 200 (31.0)
  Lower-middle 281 (32.2) 58 (25.6) 223 (34.5)
  Higher-middle/high 60 (6.9) 16 (7.1) 44 (6.8)
  No response 251 (28.8) 72 (31.7) 179 (27.7) 0.097
  Household income (€)
  <500 204 (23.4) 77 (33.9) 127 (19.7)
  501–1000 276 (31.6) 60 (26.4) 216 (33.4)
  1001–2000 146 (16.7) 22 (9.7) 124 (19.2)
  >2000 88 (10.1) 14 (6.2) 74 (11.5)
  No response 159 (18.2) 54 (23.8) 105 (16.3) <0.001
  Region
  Metropolitan area of Porto 504 (57.7) 108 (47.6) 396 (61.3)
  Northeastern region of  
Portugal
369 (42.3) 119 (52.4) 250 (38.7) <0.001
Cardiovascular risk factors
  Smoking habit
  Never 369 (42.3) 184 (81.0) 185 (28.6)
  Current 283 (32.4) 34 (15.0) 249 (38.5)
  Former 221 (25.3) 9 (4.0) 212 (32.8) <0.001
  Hypertension 590 (67.6) 185 (81.5) 405 (62.7) <0.001
  Diabetes mellitus 281 (32.2) 88 (38.8) 193 (29.9) 0.014
  Dyslipidaemia 535 (61.4) 144 (63.4) 391 (60.6) 0.454
  BMI (kg/m2)
  Median (IQR) 26.5 (18.0–44.6) 26.7 (19.5–37.9) 26.4 (18.2–39.2) 0.531
  Underweight 11 (1.4) 2 (0.9) 9 (1.5)
  Normal weight 272 (33.4) 80 (37.0) 192 (32.1)
  Overweight 366 (44.9) 79 (36.6) 287 (47.9)
  Obese 166 (20.4) 55 (25.5) 111 (18.5) 0.020
  Family history of CVD 303 (34.7) 73 (32.2) 230 (35.6) 0.105
Continued
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and men were observed among patients in the older age 
group. The proportion of dyspnoea and sweating cluster 
was similar in men and women (table 2).
Approximately 45% of patients were at rest and 35% 
were under physical effort at the beginning of the 
episode. Older women were more frequently at rest at 
the beginning of the episode and younger women were 
more frequently under effort (p=0.011). Less than 10% 
of patients identified a stressful event in the previous 
24 hours, with no difference by sex, but among men, 
a younger age was slightly associated with this trigger 
(P=0.045, table 2).
Multivariate models
Despite the higher probability of women below or above 
65 years to present without pain than men, no differences 
were observed in the adjusted pain frequency and loca-
tion between men and women. Referred pain was more 
likely to be experienced by women (<65 years: adjusted 
OR 2.90, 95% CI 1.47 to 5.72; ≥65 years: 1.60 (95% CI 
0.99 to 2.60), interaction P=0.528). Moreover, women 
below or above 65 years had a higher probability of having 
pain radiating to typical and atypical locations and of 
feeling pain with an intensity higher than 8 (table 3). The 
association between intensity of pain and female sex was 
stronger for patients below 65 years (interaction P=0.028) 
(table 3).
The presence of at least one symptom other than pain 
occurred almost two times more often in women than in 
men. With cluster 1 as the reference, clusters 2 and 3 were 
positively associated with female sex, with the latter being 
statistically significant. The multiple symptoms cluster 
was almost fourfold more likely in women than in men 
(3.92, 95% CI 2.21 to 6.98 in the whole sample, interac-
tion P=0.501) (table 3).
No difference in the type of patients’ activities at the 
beginning of the episode by sex was observed (table 3).
Performance of age-stratified multivariate models 
using the 55 years cut-off revealed similar results to the 
observed using the 65 years cut-off, with some differences 
mainly in the strength of association of some clinical 
presentation variables with sex among the younger age 
group (see online supplementary table 4). Although still 
not significant, among patients below 55 years, women 
were less likely to present with typical chest pain (0.65, 
95% CI 0.23 to 1.86). A stronger association between 
female sex and referred pain, and intensity of pain higher 
than 8/10, among patients in the younger age groups was 
observed using the 55 instead of the 65 years cut-off. The 
remaining results were similar in direction and strength 
of association (table 3 and online supplementary table 
4). The precision of the estimates is lower using the 55 
cut-off, due to the small sample of patients below 55 years.
Total
(n = 873)
Women
(n = 227)
Men
(n = 646) P value
Previous medical history
  Renal failure 64 (7.3) 14 (6.1) 50 (7.7) 0.434
  Myocardial infarction 156 (17.9) 34 (15.0) 122 (18.9) 0.186
  PCI 100 (12.4) 18 (8.4) 82 (13.8) 0.041
  CABG 34 (4.2) 5 (2.3) 29 (4.9) 0.111
  Heart failure 63 (7.5) 21 (9.6) 42 (6.8) 0.172
  Dementia 7 (0.8) 4 (1.8) 3 (0.5) 0.060
ACS type
  STEMI/NC ACS 379 (43.4) 101 (44.5) 278 (43.0)
  NSTEACS 494 (56.6) 126 (55.5) 368 (57.0) 0.703
Coronary anatomy
  Non-obstructive disease 57 (6.9) 22 (10.6) 35 (5.61)
  Left anterior descending artery only 162 (19.5) 38 (18.3) 124 (19.9)
  Right and/or circumflex artery only 196 (23.6) 46 (22.1) 150 (24.0)
  Mixture 417 (50.1) 102 (49.0) 315 (50.5)
  Not submitted to coronary angiography 41 (4.7) 19 (8.4) 22 (3.4) 0.004
Symptom questionnaire application
  Time from admission (hours), median (IQR) 42.1 (25.0-68.0) 45.4 (28.5-72.3) 40.0 (24.0-67.4) 0.052
*Values are number and percentage unless otherwise indicated.
ACS, acute coronary syndrome; BMI, body mass index; CABG, coronary artery bypass surgery; CVD, cardiovascular diseases; IQR, 
interquartile range; NSTEACS, non-ST elevation acute coronary syndrome; PCI, percutaneous coronary intervention; STEMI/NC ACS, ST-
elevation myocardial infarction/non-classifiable acute coronary syndrome.
Table 1 Continued 
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Clinical presentation and outcomes
Patients with a diagnosis of STEMI/NC ACS who 
presented with atypical or mixture pain took longer to 
seek medical care (135 vs 85 min, P=0.012) and had 
longer total ischaemic times (414 vs 328 min, P=0.080) 
than patients with chest pain (table 4). Among patients 
with NSTEACS, differences in time delays according to 
pain location were not significant. Patients with atypical 
or mixture pain presented more frequently with haemo-
dynamic instability at admission (9.7% vs 4.6%, P=0.014) 
and had also more often moderate-to-severe left ventric-
ular systolic dysfunction (32.9% vs 24.9%, P=0.052) than 
patients with chest pain. The 30-day mortality adjusted 
for GRACE V.2.0 was not significantly different between 
patients with chest pain and those with atypical or mixture 
pain (table 4).
Among patients with STEMI/NC ACS, the total isch-
aemic time was longer for patients with the multiple 
symptoms cluster compared with patients who presented 
with the two other symptoms clusters (533 vs 321 and 
384 min, P=0.111). Patients with the multiple symptom 
cluster presented more often with haemodynamic insta-
bility at admission than patients with the other symptoms 
clusters (13.4% vs 6.4% and 4.2%, P=0.034). The mean 
30-day mortality rate adjusted for the GRACE V.2.0 risk 
score was significantly higher for patients presenting with 
the multiple symptom cluster (4.9% vs 0.9% for the two 
other clusters, P<0.001) (table 4).
Table 3 Differences between women and men in clinical presentation of acute coronary syndrome, by age group (men are the 
reference class)
Symptoms
<65 years ≥65 years Interaction 
P value Adjusted forOR 95% CI OR 95% CI
Pain 0.76 0.14 to 4.0 0.52 0.19 to 1.47 0.777 Age, type of ACS, marital status, 
dyslipidaemia, CABG
Typical (chest) pain (vs 
atypical or mixture)*
0.97 0.44 to 2.14 1.71 0.90 to 3.23 0.973 Age, type of ACS, coronary 
anatomy, region, smoking, 
dyslipidaemia, previous heart 
failure
Referred pain 2.90 1.47 to 5.72 1.60 0.99 to 2.60 0.528 Age, type of ACS, coronary 
anatomy, region, income, social 
class, previous renal failure
Radiation type†
Typical 1 Reference 1 Reference Age, type of ACS, employment 
status, regionAtypical 1.49 0.70 to 3.20 1.38 0.72 to 2.66 0.415
Mixture 1.77 0.73 to 4.29 2.75 1.36 to 5.57 0.606
Pain intensity
(higher than 8/10)
3.81 2.04 to 7.13 2.03 1.22 to 3.37 0.028 Age, type of ACS, coronary 
anatomy, education, professional 
group, previous AMI
Symptoms 1.98 1.00 to 3.91 1.85 1.10 to 3.12 0.799 Age, type of ACS, region, previous 
AMI, previous heart failure
Symptom clusters‡
Cluster 1 1 Reference 1 Reference Age, type of ACS, professional 
group, region, previous AMICluster 2 1.07 0.53 to 2.15 1.67 0.97 to 2.87 0.246
Cluster 3 3.14 1.15 to 8.62 4.23 2.03 to 8.81 0.501
Activity group
Sleeping 1 Reference 1 (Reference) Age, type of ACS, previous heart 
failureRest 0.68 0.33 to 1.38 1.38 0.74 to 2.57 0.284
Exertion 0.77 0.37 to 1.59 1.70 0.89 to 3.25 0.408
*Pain location: typical—retrosternal, precordial, right thoracic or bilateral thoracic; atypical—epigastric, back, left arm or shoulder, right arm or 
shoulder, neck or jaw;  mixture—typical and atypical location.
†Radiation type: typical—left arm or shoulder, right arm or shoulder, neck or jaw; atypical: retrosternal, precordial, right thoracic, bilateral 
thoracic, epigastric or back regions; mixture— typical and atypical irradiation.
‡Symptom clusters: cluster 1 (no symptom cluster)—low endorsement probabilities for all items; cluster 2 (dyspnoea and sweating cluster)—
high probability for dyspnoea at rest and sweating; cluster 3 (multiple symptoms cluster)—high probabilities for all items (dyspnoea at rest, 
exertional dyspnoea, sweating, nausea, vomiting, dizziness, blurry vision, presyncope, syncope, palpitation, weakness, other symptoms, 
other digestive symptoms and discomfort).
ACS,  acute coronary syndrome; AMI, acute myocardial infarction; CABG, coronary artery bypass surgery. 
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Patients with atypical or mixture chest pain and 
patients with the multiple symptom cluster had higher 
mean GRACE and median Can Rapid risk stratifica-
tion of Unstable angina patients Suppress ADverse 
outcomes (CRUSADE) risk scores (table 4).
DIsCussIOn
In our study, after adjustment, no differences in the 
frequency and location of pain by sex were observed. 
Referred pain, pain radiating to typical and atypical loca-
tions and pain of higher intensity were more likely to 
occur among women. Women were also more likely than 
men to present with symptoms other than pain. Three 
clusters of symptoms other than pain were identified. 
Women were more likely to present with the multiple 
symptoms cluster. Presenting with the multiple symptoms 
cluster was associated with a higher mean 30-day mortality 
rate adjusted for the GRACE V.2.0 risk score.
Differences between women and men in perception 
of symptoms of ACS might be explained by anatomical, 
physiological, biological and psychosocial differences 
that influence each other.9 21 We measured several vari-
ables of these different domains. Differences in symptom 
presentation by sex might be the result of differences in 
response to history-taking,10 differences in neural recep-
tors and pathways involved in pain and subtle differences 
in the location and type of atherosclerotic lesions.22 23 
Our findings of similar ACS symptoms between women 
and men are consistent with previous studies,7 24 as well 
as our finding that women are more likely to have atyp-
ical presentations.9 We observed that women have a 
higher likelihood of atypical referred pain and of several 
concomitant symptoms other than pain, common to 
other cardiac and non-cardiac diagnoses.
In our study, chest pain was the most frequent symptom 
in both sexes, consistent with previous studies.25–27 Among 
those with pain, typical chest pain was observed in 82% of 
patients, regardless of sex. The remaining patients had 
pain in less typical locations and were thus prone to misdi-
agnosis and undertreatment and, consequently, to worse 
outcomes.28 Considering differences in characteristics of 
pain by sex, studies suggested that women, in particular 
older women, were less likely to have the chief complaint 
of chest pain associated with acute myocardial infarction, 
while after adjustment, among patients aged 65 years or 
under, female sex was no longer a significant predictor.29 
Studies reported that chest pain did not differ between 
women and men,9 others that women have pain in the 
neck and back more often than men,30 31 without distin-
guishing between direct and referred pain. In our study, 
referred pain was observed in 61% of patients, was more 
frequent in women and typical referred pain was only 
observed in 33%. Notably, a study on diagnostic acuity 
of ACS symptoms showed that shoulder and arm pain 
was predictive of the diagnosis of ACS for women only.24 
Another study Gender and Sex Determinants of Cardio-
vascular Disease: From Bench to Beyond Premature 
Acute Coronary Syndrome (GENESIS PRAXY) on sex 
differences in ACS symptom presentation in patients 
aged 55 years or younger showed that being a woman 
was independently associated with ACS presentation 
without chest pain.27 Although the association was not 
significant, and relied on a small sample of patients, our 
finding that women aged 55 years or younger were less 
likely to present with typical chest pain is in line with the 
GENESIS PRAXY study result.27 We were also able to find 
a stronger association between female sex and presence 
of referred pain, and of pain with intensity higher than 
8 among the younger subgroups of patients (aged below 
55 and 65 years). These findings stress the relevance 
of taking into account age for studying the association 
between sex and clinical presentation. However, further 
conclusions on the role of age to this relation are limited 
by the small number of women below 55 years included 
in our study. Differences in age distribution, in clinical 
presentation measuring, in selection and definition of 
confounder variables limit conclusive comparisons of 
studies evaluating differences in frequency and location 
of pain between women and men.
According to previous studies, with regard to other 
symptoms, a higher proportion of women have less typical 
symptoms than men.8 31 Women have also reported other 
symptoms, such as indigestion, palpitations, nausea, 
numbness in the hands and unusual fatigue, more 
frequently than men.9 In our cohort, three symptom clus-
ters were identified. Women had the multiple symptoms 
cluster more frequently than did men, characterised by 
high probabilities for all symptoms. Age did not change 
the association between female sex and presentation with 
symptoms other than pain and with the multiple symp-
toms cluster. According to Rosenfeld et al, women are 
more likely to cluster in a similar class, called the heavy 
symptom burden class.32 With regard to ACS symptom 
clustering, there are contradictory findings on identified 
clusters, the proportion of patients per cluster and differ-
ences between clusters regarding demographic factors. 
In our study, clusters 1 and 3 (low and high probabilities 
for all symptoms, respectively) are in line with observa-
tions of other settings.18 33 A recent systematic review of 
symptom clusters in cardiovascular disease34 identified 
clusters with the most symptoms and clusters with the 
lowest number of symptoms. Our dyspnoea and sweating 
cluster has two common symptoms similar to the Riegel 
et al26 stress symptoms cluster, which includes shortness of 
breath, sweating, nausea, indigestion, dread and anxiety.
Methodological differences related to sampling and 
measuring might explain these different results. Strengths 
of our study include consecutive sampling, a question-
naire with detailed clinical information was systemati-
cally applied and we adjusted for several confounding 
variables.
The value of symptoms for diagnosis of ACS varies 
across studies.13 14 35 Overall, the diagnostic performance 
of chest pain characteristics for diagnosis is limited, with 
likelihood ratios close to 1.36 Sensitivity for individual 
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symptoms of ACS, using the 13-Item ACS Checklist, 
ranges from 27% to 67% for women and 14% to 72% for 
men. Additionally, specificity ranges from 33% to 78% for 
women and 34% to 78% for men, with different associa-
tions between some symptoms and diagnosis of ACS by 
sex.24 However, physicians still base the likelihood of ACS 
mainly on symptoms and use the ECG to rule in the diag-
nosis.37 Evaluation of these patients is mostly unchanged, 
without implementation of evidence-based assessment 
tools in clinical practice to improve diagnostic accu-
racy. Public health messages should take into account 
the complexity of presenting symptoms of ACS, particu-
larly the significant proportion of women and men with 
ACS without typical chest pain. Additionally, there is a 
higher likelihood of atypical referred pain and multiple 
concomitant symptoms in women. These factors should 
be accounted for to encourage timely and appropriate 
care of patients with ACS.
Presenting without chest pain and with the multiple 
symptoms cluster was associated with several markers of 
higher ACS severity and longer time delays, particularly 
significant among patients with STEMI/NC ACS. In our 
study, presenting with the multiple symptoms cluster, 
but not with atypical or mixture location of pain, was 
associated with a higher mean 30-day mortality adjusted 
for GRACE risk score. These results are consistent 
with data from the GRACE registry, which showed that 
patients with symptoms other than pain experienced 
greater morbidity and higher in-hospital mortality 
across the spectrum of ACS.28 Other registry showed 
that the higher in-hospital mortality observed among 
women and men without chest pain, decreased or even 
reversed with advanced age.38 Mortality is adjusted 
for GRACE risk score; however, we cannot conclude 
that the difference in outcome observed is explained 
by symptoms other than pain per se. Previous studies 
showed that the higher in-hospital mortality of patients 
with ACS who presented without chest pain was mostly 
due to late hospital arrival, comorbidities and underuse 
of medications and invasive procedures. 3 6 38 These 
studies focused mainly on presence of chest pain to 
define atypical presentation and used medical record 
reviews to characterise clinical presentation. More 
studies are needed to further explore the association 
between symptoms other than pain and outcomes.
limitations
Participants were interviewed as soon as possible after 
admission, but this does not obviate the retrospective 
nature of data collection and the possibility of recall bias. 
Furthermore, preceding interviews by physicians may 
have influenced answers to the questionnaire; however, 
different consequences in women and men are not 
expected. The results of this study are valid for stable 
patients, who were admitted to the hospital and were 
able to answer the questionnaire in the acute phase of 
ACS. This type of study misses patients who die before 
reaching the hospital, patients who do not seek medical 
care, patients who are mistakenly discharged or misdi-
agnosed and admitted to non-cardiology departments. 
This sample selection process may contribute to under-
estimate the true prevalence of ACS atypical presentation 
in women and men.27 For patients who were eligible but 
not enrolled, only information on sex, age and type of 
ACS was available. Patients who died before the inter-
view were older (81.5±11.8 vs 64.6±13.1 years, P<0.001), 
were more often women (66.7% vs 26.0%, P<0.001) and 
more frequently had a diagnosis of STEMI (81.3% vs 
43.4%, P=0.003) than did participants. Patients who were 
discharged or transferred to another hospital before 
the interview had STEMI less often (25.0% vs 43.4%, 
P=0.005) and patients who were not enrolled because of 
clinical instability or inability to understand the question-
naire were older. Patients who refused to participate were 
older (72.7±11.0 vs 64.0±13.0 years, P<0.001), were less 
often partnered (65.7% vs 76.8%, P=0.036) and had little 
formal education (43.1% vs 19.7%, P<0.001) compared 
with participants. Except for deceased patients, no differ-
ence in sex proportion was observed between participants 
and non-participants. We cannot exclude that some of 
the sex differences were caused by selection bias because 
of a higher risk of non-inclusion of women due to death 
in the early hours of admission, or due to a possible 
higher probability of misdiagnosis in women, particularly 
those with unstable angina.39 Considering that atypical 
presentation is associated with a worse prognosis and with 
a higher probability of misdiagnosis, the proportion of 
patients with ACS presenting without typical chest pain 
or that of women with an atypical presentation could be 
even higher.28
COnClusIOn
This study shows no significant differences in the 
frequency and location of pain by sex, but approxi-
mately 20% of patients do not present with chest pain, 
regardless of sex. Women are more likely to report 
referred pain and multiple symptoms simultaneously. 
Presentation with the multiple symptoms cluster pain 
is associated with higher 30-day mortality adjusted for 
GRACE score. Health education messages should take 
into account the complexity of presentation of ACS and 
emphasise the possible non-chest location of pain in 
both sexes and the higher probability of concomitant 
symptoms other than pain in women. Further sex-strat-
ified analysis of ACS presentation, also addressing the 
role of age for the relation between sex and clinical 
presentation, is required to determine the diagnostic 
accuracy of symptoms by sex.
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Supplementary Table 3. Marginal percentage of subjects with each symptom in each assigned cluster* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Values are percentages. 
*Cluster 1: no symptom cluster; † Cluster 2: dyspnoea and sweating cluster; ‡Cluster 3: multiple symptoms cluster. 
 
 Symptom clusters 
 Cluster 1* 
n=639 
Cluster 2† 
n=167 
Cluster 3‡ 
n=67 
Dyspnoea at rest 17.4 34.2 37.3 
Exertional dyspnoea 6.0 2.1 14.5 
Sweating 22.2 89.6 71.7 
Nausea and vomiting 6.5 9.7 41.4 
Dizziness 2.6 18.0 74.1 
Blurry vision 0.6 4.4 27.5 
Presyncope 1.3 11.4 42.7 
Syncope 1.6 3.6 10.5 
Palpitations 0.3 5.4 19.5 
Weakness 7.5 17.8 64.4 
“Other symptoms” 4.5 5.5 12.8 
Other digestive 
symptoms 
1.0 1.0 1.4 
Discomfort 1.3 1.1 4.2 
Supplementary Table 4. Differences between women and men in clinical presentation of acute coronary 
syndrome, by age group (< 55 vs ≥55 years old) 
(men are the reference class). 
 
ACS, acute coronary syndrome; AMI, acute myocardial infarction; CABG: coronary artery bypass surgery; CI, confidence interval; 
OR, odds ratio. 
*All women below 55 years old presented with pain. 
†Pain location: Typical - retrosternal, precordial, right thoracic, or bilateral thoracic; Atypical - epigastric, back, left arm or 
shoulder, right arm or shoulder, neck, or jaw; Mixture - typical and atypical location. 
‡Radiation type: Typical - left arm or shoulder, right arm or shoulder, neck, or jaw; Atypical: retrosternal, precordial, right 
thoracic, bilateral thoracic, epigastric, or back regions; Mixture: typical and atypical irradiation. 
§Symptom clusters: cluster 1 (no symptom cluster) - low endorsement probabilities for all items; cluster 2 (dyspnoea and sweating 
cluster) - high probability for dyspnoea at rest and sweating; cluster 3 (multiple symptoms cluster) - high probabilities for all items 
(dyspnoea at rest, exertional dyspnoea, sweating, nausea, vomiting, dizziness, blurry vision, presyncope, syncope, palpitation, 
weakness, other symptoms, other digestive symptoms and discomfort). 
 
 <55 
years 
 >=55 
years 
   
Symptoms OR 95% CI OR 95% CI Interaction 
p-value 
Adjusted for 
Pain --* --* 0.46 0.18-1.18 0.777 Age, type of ACS, marital status, 
dyslipidaemia, CABG 
       
Typical (chest) pain 
(vs atypical or 
mixture)† 
0.65 0.23-1.86 1.55 0.88-2.71 0.973 Age, type of ACS, coronary anatomy, 
region, smoking, dyslipidaemia, 
previous heart failure 
       
Referred pain 3.81 1.41-10.3 1.73 1.14-2.61 0.528 Age, type of ACS, coronary anatomy, 
region, income, social class, previous 
renal failure. 
       
Radiation type‡       
   Typical 1  Reference 1  Reference  Age, type of ACS, employment status, 
region 
 
   Atypical 1.19 0.41-3.45 1.34 0.77-2.35 0.415 
   Mixture 1.43 0.40-5.16 2.56 1.39-4.71 0.606 
       
Pain intensity 
(higher than 8/10) 
5.23 2.17-12.60 2.09 1.35-3.24 0.028 Age, type of ACS, coronary anatomy, 
education, professional group, previous 
AMI 
       
Symptoms 1.88 0.76-.4.66 1.91 1.21-3.04 0.799 Age, type of ACS, region, previous 
AMI, previous heart failure 
       
Symptom clusters§       
   Cluster 1 1 Reference 1 Reference  Age, type of ACS, professional group, 
region, previous AMI    Cluster 2 0.88 0.31-2.50 1.49 0.93-2.38 0.246 
   Cluster 3 3.30 0.99-10.97 4.08 2.07-8.05 0.501 
       
Activity group       
   Sleeping 1  Reference 1  (Reference)  Age, type of ACS, previous heart 
failure    Rest 0.74 0.25-2.19 1.08  0.64-1.81 0.284 
   Exertion 0.89 0.29-2.67 1.27 0.74-2.16 0.408 
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smokers (OR 0.52, 95% CI 0.28–0.99) and patients of a higher 
social class (OR 0.16, 95% CI 0.05–0.48) were less likely to 
seek medical care. The performance of ECG was associated 
with male sex (OR 2.56, 95% CI 1.11–5.87), health subsystem 
coverage (OR 3.88, 95% CI 1.11–13.53), and living in the 
northeastern region (OR 9.07, 95% CI 4.07–20.24), whereas 
cognitive impairment (OR 0.37, 95% CI 0.15–0.92) and being 
employed (OR 0.36, 95% CI 0.14–0.97) were inversely associ-
ated.  Conclusions: These results suggest there are opportu-
nities to improve the diagnosis of myocardial ischemia be-
fore acute coronary events.  © 2017 S. Karger AG, Basel 
 Introduction 
 The triage of patients with possible myocardial isch-
emia is often difficult, and failure to recognize ischemia 
as a cause of acute chest pain has serious implications  [1] . 
Prodromal symptoms and signs occurring before unsta-
ble angina and myocardial infarction and precipitating 
physician visits have been reported for over 4 decades  [2] . 
 Keywords 
 Chest pain · Diagnosis · Delivery of health care · Acute 
coronary syndrome  
 Abstract 
 Objectives: The aim of this study was to assess the propor-
tion of patients with a first episode of acute coronary syn-
drome (ACS) reporting preceding chest pain, having previ-
ously sought medical care and undergone the performance 
of exams, and to identify the determinants of seeking medi-
cal advice and undergoing electrocardiogram (ECG).  Meth-
ods: Within a cohort study, 690 patients with a first episode 
of ACS were evaluated. A questionnaire was applied to as-
sess chest pain within the preceding 6 months of the event 
and health system resources utilization. Determinants were 
identified by logistic regression.  Results: Preceding chest 
pain was reported by 61% of patients, 43% of these sought 
medical help, of whom less than half underwent ECG, and in 
39% pain was attributed to a problem of the heart. Patients 
with hypertension were more likely to seek medical care (ad-
justed odds ratio, OR, 2.13, 95% CI 1.29–3.51), and former 
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Of several prodromal symptoms, chest pain was consid-
ered the best single predictor of a subsequent cardiac 
event  [2] . 
 Most patients with first-onset chest pain still do not 
have a diagnosis at presentation or in the subsequent 6 
months, including those who undergo cardiac investiga-
tions  [3] . Potential missed opportunities of diagnosis and 
the management of coronary heart disease (CHD) have 
been described in primary care and in emergency depart-
ment settings, based on medical record review, and have 
proved to be dependent on patient and health care system 
determinants  [4, 5] . Furthermore, only about 25% of 
those with chest pain, either cardiac or noncardiac, actu-
ally seek medical advice from a family physician or by 
presenting to a hospital emergency department  [6] . 
 The “symptom iceberg”  [7] , defined as the prevalence 
of significant symptoms in the community that are not 
referred for professional advice, was assessed for several 
symptoms commonly evaluated in primary care. From a 
public health perspective, exploring the “symptom ice-
berg” in patients with a first episode of acute coronary 
syndrome (ACS), by evaluating reported chest pain be-
fore the ACS, may unveil a window of opportunity to im-
prove the diagnosis and treatment of patients with CHD 
and eventually to prevent the cardiac event. Furthermore, 
the management of patients with chest pain who seek 
medical help is challenging, and myocardial ischemia can 
be misdiagnosed for different reasons  [8] . Several testing 
modalities were developed to assist the diagnosis and risk 
stratification of patients with chest pain; however, clinical 
judgment continues to be paramount to the management 
of these patients. Clinical history, physical examination, 
and a resting electrocardiogram (ECG) remain the cor-
nerstone for the initial evaluation of suspected CHD, in 
both inpatient and outpatient settings  [9–11] . In this 
study, we aimed to assess the proportion of ACS patients 
who reported preceding chest pain, having sought medi-
cal care and the performance of exams because of the 
pain, and to identify determinants of seeking medical ad-
vice and referral to ECG.
 Methods 
 Study Design and Sample Selection 
 EPIHeart is a prospective cohort study designed to assess in-
equalities in the management and outcomes of patients with CHD 
in Portugal. The cohort consists of all consecutive patients dis-
charged between August 2013 and December 2014 from the cardi-
ology departments of 2 tertiary hospitals in 2 regions in northern 
Portugal (Hospital de São João, Porto, covering part of the metro-
politan area of Porto on the coast, and Hospital de São Pedro, Vila 
Real, covering the interior, northeastern region). The inclusion 
criteria were as follows: being discharged with a diagnosis of ACS 
type 1, aged 18 years or older, living in the catchment area of these 
hospitals, not having been institutionalized before the event, and 
expected to be hospitalized for at least 48 h. Initially, 1,297 patients 
were considered; the diagnosis was not confirmed in 164, 60 were 
discharged or transferred, and 18 died before the invitation to par-
ticipate. A further 44 patients were excluded due to inability to 
complete the questionnaire (clinical instability, poor understand-
ing of the Portuguese language, hearing problems, or cognitive im-
pairment). Seventy-two patients refused to participate. For this 
analysis, patients with previous ACS, percutaneous coronary in-
tervention, or coronary artery bypass graft ( n = 198) documented 
in medical records, and patients with incomplete data on chest 
pain episodes preceding the index ACS ( n = 51) were excluded. 
Only the first hospital admission was considered if a patient had 
more than 1 hospitalization for ACS during the study period. A 
total of 690 patients were analyzed. The study protocol was in com-
pliance with the principles of the Declaration of Helsinki and was 
approved by the Ethics Committee of both hospitals. All patients 
gave their written informed consent for inclusion. 
 Procedures and Data Collection 
 Detailed information about sociodemographic characteristics, 
risk factors, comorbidities, previous medical history, and present-
ing symptoms was obtained by trained researchers through struc-
tured interviews with the patients during their hospitalization. Pa-
tients were asked if they had experienced acute and recurrent chest 
pain within the past 6 months, beside the episode of the index 
event. Patients who reported 1 or more episodes of preceding chest 
pain were interviewed about the date of the occurrence, their 
health-seeking attitudes and health system resources utilization, 
i.e., health system unit/units sought, complementary exams per-
formed, and cause attributed to the pain (“problem of the heart” 
[including “myocardial infarction” and “angina pectoris”], “prob-
lem not of the heart,” “nothing important,” “not informed about 
the suspected cause” [from the open-ended question of “Other, 
what?”], and “do not know”). This questionnaire is presented in 
the Appendix. Regardless of reporting pain in the previous 6 
months or not, additional data on previous (within the preceding 
year) medical appointments in the public or private sectors, of 
which specialty (primary care physician, cardiologist, internal 
medicine specialist, psychiatrist, other), and medication used at 
the time of the index event were collected. Additional information 
regarding patients’ cardiovascular risk factors and comorbidities, 
as well as data on the type of ACS for index hospitalization, was 
extracted from clinical records. The Mini-Mental Status Examina-
tion (MMSE)  [12] was used do assess the cognitive status and dis-
ability was measured using the modified Barthel Index  [13] . 
 Definition of Variables 
 Education was categorized as nonelementary and elementary 
according to the mandatory years of schooling in Portugal, which 
varies by age of birth. Elementary education corresponds to 4 or 
more years of schooling if born before 1967, 6 or more years if born 
between 1967 and 1980, and 9 or more years if born thereafter. The 
subjective social class was considered according to self-report as: 
lower class, lower middle class, upper middle class, and upper 
class. Occupations were classified into major professional groups, 
according to the Portuguese Classification of Occupations 2010, 
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 Table 1.  Baseline characteristics of patients with and without chest pain prior to the ACS
No chest pain
(n = 272)
Chest pain in the
previous 6 months
(n = 418)
p
Mean age ± SD, years 62.9 ± 13.7 63.2 ± 13.2 0.755
Male 201 (73.9) 302 (72.3) 0.634
Cognitive impairment (MMSE) 70 (26.2) 83 (20.2) 0.069
Disability (BI score) 27 (9.9) 28 (6.7) 0.128
Socioeconomic position
Region
Metropolitan area of Porto 139 (51.1) 235 (56.2)
Northeastern region 133 (48.9) 183 (43.8) 0.187
Living alone 31 (11.5) 59 (14.4) 0.287
Elementary education 203 (74.6) 314 (75.5) 0.801
Employed 92 (34.0) 126 (30.2) 0.304
Occupation
Upper white collar 50 (20.3) 60 (15.8)
Lower white collar 48 (19.5) 97 (25.5)
Blue collar 148 (60.2) 223 (58.7) 0.126
Subjective social class
Lower/lower middle class 159 (59.3) 274 (65.9)
Upper middle/upper class 23 (8.6) 31 (7.5)
Refused to answer 48 (17.9) 49 (11.8) 0.059
Private health insurance coverage 39 (14.4) 47 (11.4) 0.255
Health subsystem coverage 50 (18.5) 63 (15.2) 0.259
Cardiovascular risk factors
Hypertension 174 (64.0) 269 (64.4) 0.918
Smoking
Never 116 (42.7) 179 (42.8)
Current 94 (34.6) 141 (33.7)
Former 62 (22.8) 98 (23.4) 0.968
Diabetes mellitus 73 (26.8) 139 (33.3) 0.074
Dyslipidemia 149 (55.0) 246 (58.9) 0.316
Overweight/obese 175 (64.6) 276 (66.8) 0.543
Family history of CVD 106 (40.8) 172 (42.7) 0.626
Previous medical history
Heart failure 12 (4.4) 19 (4.6) 0.934
Renal failure 15 (5.5) 23 (5.5) 0.994
Atrial fibrillation 11 (4.0) 21 (5.0) 0.550
Stroke 29 (10.7) 31 (7.4) 0.139
Cancer 18 (6.6) 29 (6.9) 0.870
Medical visits in the previous year
Primary care 204 (75.6) 330 (79.0) 0.297
Public hospital 76 (28.0) 136 (32.6) 0.205
Cardiologist in the hospital 12 (15.8) 20 (14.7) 0.833
Private sector 94 (34.7) 124 (29.9) 0.186
Cardiologist in the private sector 18 (19.4) 41 (33.1) 0.025
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integrated in the International Standard Classification of Occupa-
tions  [14] , and grouped into 3 categories: upper white collar (ex-
ecutive civil servants, industrial directors and executives, profes-
sionals and scientists, and middle management and technicians), 
lower white collar (administrative and related workers, and service 
and sales workers), and blue collar (farmers and skilled agricul-
tural workers, fisheries workers, skilled workers, craftsmen and 
similar, machine operators and assembly workers, and unskilled 
workers). Retired and disabled subjects and housewives were clas-
sified considering their previous main occupation. 
 Cognitive impairment was defined based on the MMSE score, 
taking into account established cut-offs for individual education 
level  [15] . Physical disability was assigned to patients scoring less 
than 90 in the Barthel Index  [13, 16] . 
 Direct pain was considered typical if located in the chest; referred 
pain was considered typical if referred to the left arm or shoulder, 
right arm or shoulder, neck, or jaw  [10] . Clusters of symptoms oth-
er than pain were obtained by latent class analysis  [17] .
 We defined 3 groups of patients according to report of preced-
ing chest pain: no chest pain, at least 1 episode of chest pain in the 
previous 6 months, at least 1 episode of chest pain in the previous 
week. Patients with preceding chest pain were further categorized 
according to their health system-seeking attitude (yes/no) and to 
the performance of ECG (yes/no) for those who sought health care 
system assistance.
 Data Analysis 
 Groups of patients were compared using the χ 2 or Fisher test 
for categorical variables, and the  t test for continuous variables. 
Logistic regression was used to identify variables associated with 
health service-seeking behavior and with the performance of ECG. 
Variables with univariate association ( p < 0.15) with the endpoint 
were used to build multivariable models with a backward strategy 
based on the Wald test to select relevant variables ( p < 0.05). All 
analyses were performed using STATA version 11.1 for Windows 
(Stata Corp LP, College Station, TX, USA) and R version 2.12.1 (R 
Foundation for Statistical Computing, Vienna, Austria). 
 Results 
 Baseline Characteristics 
 Baseline characteristics of patients who reported chest 
pain within the 6 months preceding the index episode of 
ACS ( n = 418, 61%), compared to those who did not, are 
shown in  Table  1 . In this predominantly male cohort 
(73.1%) with a mean age of 63.0 ± 13.5 years, more simi-
larities than differences were observed in the baseline 
characteristics of patients who did not and did report pre-
Table 1 (continued)
No chest pain
(n = 272)
Chest pain in the
previous 6 months
(n = 418)
p
Drug treatment prior to index episode
Antiplatelet drug 50 (18.4) 94 (22.5) 0.189
ACEI/ARB 106 (39.0) 178 (42.7) 0.333
Beta-blockers 33 (12.1) 60 (14.4) 0.397
Calcium channel blockers 55 (20.2) 80 (19.2) 0.738
Nitrates 8 (2.9) 27 (6.5) 0.039
Statins 77 (28.3) 137 (32.9) 0.208
Oral anticoagulation 8 (2.9) 10 (2.4) 0.662
Clinical presentation during index episode
NSTEACS 113 (41.7) 245 (58.9) <0.001
Chest pain 214 (82.6) 330 (81.5) 0.709
Typical referred pain 84 (55.6) 133 (53.6) 0.697
Cluster of symptoms other than pain1
Cluster 1 185 (69.6) 260 (68.8)
Cluster 2 57 (21.4) 83 (22.0)
Cluster 3 24 (9.0) 35 (9.3) 0.979
 Values are n (%) unless otherwise indicated. Totals may not add to 100% due to missing data. ACEI, angio-
tensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BI, Barthel Index; CVD, cardiovascu-
lar disease; SD, standard deviation; MMSE, Mini-Mental Status Examination; NSTEACS, non-ST elevation acute 
coronary syndrome. Bold represents significant p values (p < 0.05).  
1 Cluster 1 (no symptom cluster): low endorsement probabilities for all items; cluster 2 (dyspnea and sweating 
cluster): high probability for dyspnea at rest and sweating; cluster 3 (multiple symptoms cluster): high probabil-
ities for all items. 
Do
wn
loa
de
d 
by
: 
Ve
rla
g 
S.
 K
AR
GE
R 
AG
, B
AS
EL
17
2.
16
.7
.1
12
 - 
12
/2
9/
20
17
 9
:2
1:
51
 A
M
 Missed Opportunities in Symptomatic 
Patients before a First ACS 
 Cardiology 2018;139:71–82 
DOI: 10.1159/000484713
75
ceding chest pain. At least 1 primary care physician visit 
within the previous year was reported by 78% of patients, 
and a physician visit at the public hospital was reported by 
31%, of whom 15% were seen by a cardiologist. Use of the 
private sector was reported by 32% of the patients, of 
whom about a quarter had a cardiology appointment, 
which was more often reported by patients with chest pain 
in the preceding 6 months of the acute event compared 
with patients without preceding pain (33.1 vs. 19.4%,  p = 
0.025). At admission for the index ACS, 20.9% of patients 
were on antiplatelet drugs and 31.1% on statins. Nitrates 
were the only drugs more often used prior to the index 
event by patients who reported preceding chest pain (6.5 
vs. 2.9%,  p = 0.039). We were not able to define the clinical 
indications and the exact time of these prescriptions, par-
ticularly whether these drugs were started before or after 
the episode(s) of preceding chest pain. The first ACS epi-
sode of patients who had reported chest pain prior to the 
index event was more frequently a non-ST elevation ACS.
 Flow of Patients with Previous Chest Pain through the 
Health Care System 
 Of the 418 patients who reported chest pain within the 
6 months preceding the first ACS, 43% reported having 
sought assistance from the health care system, the major-
ity in the public sector, namely a primary care center 
(61%) or a public hospital (37%). An ECG was performed 
in less than half of the subgroup of patients who sought 
the health care system, 41% had a blood test and less than 
a quarter underwent other exams, including echocardio-
gram and an exercise stress test. Neither performance of 
myocardial perfusion scintigraphy nor coronary angiog-
raphy was reported. Pain was attributed to a problem of 
the heart in 39% of these patients and to a problem not of 
the heart in 26%. A total of 21% of patients were not in-
formed or did not know the suspected cause of the chest 
pain ( Fig. 1 ). Among the subgroup of patients who re-
ported that chest pain was cardiac in origin, 51% under-
went an ECG, 41% a blood test, and 30% other exams 
23 (44%) underwent an ECG
22 (39%) underwent a blood test
10 (18%) underwent other exams
 3 (5%) - echocardiogram
 9 (16%) - X-ray
 0 - exercise stress test
 0 - Holter
Pain was attributed to:
14 (25%) - problem of the heart
22 (39%) - problem not of the heart
10 (18%) - nothing important
5 (9%) - were not informed
2 (4%) - do not know
56 (31%) sought the
health care system
Chest pain in
the previous week
181 (26%)
18 (32%) - primary care center
31 (55%) - public hospital
5 (9%) - private hospital
4 (7%) - private clinic
83 (46%) underwent an ECG
75 (41%) underwent a blood test
43 (24%) underwent other exams
 14 (8%) - echocardiogram
 14 (8%) - X-ray
 11 (6%) - exercise stress test
   5 (3%) - Holter
Pain was attributed to:
71 (39%) - problem of the heart
47 (26%) - problem not of the heart
33 (18%) - nothing important
20 (11%) - were not informed
18 (10%) - do not know
181 (43%) sought the
health care system
Chest pain in
previous 6 months
418 (61%)
111 (61%) - primary care center
66 (37%) - public hospital
15 (8%) - private hospital
28 (16%) - private clinic
690 patients
with ACS
(first episode)
 Fig. 1. Diagram of the flow of patients with previous chest pain through the health care system. 
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 Table 2.  Characteristics of patients with chest pain within the 6 months preceding the ACS according to their health system-seeking 
behavior and the performance of an ECG
Health system seeking  Performance of electrocardiogram
no (n = 237) yes (n = 181) p no (n = 98) yes (n = 83) p
Mean age ± SD, years 62.0 ± 13.1 64.9 ± 13.2 0.030 66.1 ± 12.8 63.5 ± 13.8 0.197
Male 173 (73.0) 129 (71.3) 0.696 63 (64.3) 66 (79.5) 0.024
Cognitive impairment (MMSE) 45 (19.3) 38 (21.5) 0.591 27 (27.8) 11 (13.8) 0.023
Disability (BI score) 18 (7.6) 10 (5.5) 0.395 7 (7.1) 3 (3.6) 0.301
Socioeconomic position
Region
Metropolitan area of Porto 135 (57.0 100 (55.3) 70 (71.4) 30 (36.1)
Northeastern region 102 (43.0) 81 (44.8) 0.726 28 (28.6) 53 (63.9) 0.001
Living alone 30 (13.0) 25 (13.9) 0.790 13 (13.3) 12 (14.6) 0.791
Elementary education 179 (76.8) 130 (73.5) 0.432 67 (69.1) 63 (78.8) 0.147
Employed 83 (35.2) 43 (23.8) 0.012 18 (18.4) 25 (30.1) 0.064
Occupation
Upper white collar 40 (18.2) 20 (12.5) 9 (10.3) 11 (15.1)
Lower white collar 56 (25.5) 41 (25.6) 24 (27.6) 17 (23.3)
Blue collar 124 (56.4) 99 (61.9) 0.305 54 (62.1) 45 (61.6) 0.608
Subjective social class
Lower/lower middle class 141 (70.9) 133 (85.8) 66 (84.6) 67 (87.0)
Upper middle/upper class 27 (13.6) 4 (2.6) 2 (2.6) 2 (2.6)
Refused to answer 31 (15.6) 18 (11.6) <0.001 10 (12.8) 8 (10.4) 0.894
Private insurance coverage 31 (13.4) 16 (8.9) 0.152 5 (5.1) 11 (13.4)
Health subsystem coverage 43 (18.4) 20 (11.1) 0.039 7 (7.1) 13 (15.7) 0.068
Cardiovascular risk factors
Hypertension 137 (57.8) 132 (72.9) 0.001 73 (74.5) 59 (71.1) 0.607
Smoking
Never 89 (37.6) 90 (49.7) 51 (52.0) 39 (47.0)
Current 88 (37.1) 53 (29.3) 26 (26.5) 27 (32.5)
Former 60 (25.3) 38 (21.0) 0.044 21 (21.4) 17 (20.5) 0.670
Diabetes mellitus 68 (28.7) 71 (39.2) 0.024 35 (35.7) 36 (43.4) 0.293
Dyslipidemia 130 (54.9) 116 (64.1) 0.057 62 (63.3) 54 (65.1) 0.802
Overweight/Obese 155 (66.5) 121 (67.2) 0.881 64 (66.0) 57 (68.7) 0.701
Family history of CVD 98 (43.6) 74 (41.6) 0.689 41 (42.7) 33 (40.2) 0.739
Previous medical history
Heart failure 8 (3.4) 11 (6.1) 0.189 1 (1.0) 10 (12.1) 0.002
Renal failure 11 (4.6) 12 (6.6) 0.377 4 (4.1) 8 (9.6) 0.134
Atrial fibrillation 7 (3.0) 14 (7.7) 0.027 8 (8.2) 6 (7.2) 0.815
Stroke 21 (8.9) 10 (5.5) 0.197 6 (6.1) 4 (4.8) 0.702
Cancer 20 (8.4) 9 (5.0) 0.167 4 (4.1) 5 (6.0) 0.549
Clinical presentation during index episode
NSTEACS 128 (54.0) 117 (65.4) 0.020 40 (52.0) 33 (56.9) 0.567
Chest pain 190 (81.6) 140 (81.4) 0.969 76 (80.0) 64 (83.1)
Typical referred pain 81 (58.3) 52 (47.7) 0.098 30 (49.2) 22 (45.8) 0.728
Cluster of symptoms other than pain1
Cluster 1 156 (68.1) 104 (69.8) 59 (70.2) 45 (69.2)
Cluster 2 51 (22.3) 32 (21.5) 17 (20.2) 15 (23.1)
Cluster 3 22 (9.6) 13 (8.7) 0.933 8 (9.5) 5 (7.7) 0.868
 Values are n (%) unless otherwise indicated. Totals may not add to 100% due to missing data. BI, Barthel Index; CVD, cardiovascu-
lar disease; SD, standard deviation; MMSE, Mini-Mental Status Examination; NSTEACS, non-ST elevation acute coronary syndrome. 
Bold represents significant p values (p < 0.05). 
1 Cluster 1 (no symptom cluster): low endorsement probabilities for all items; cluster 2 (dyspnea and sweating cluster): high probabil-
ity for dyspnea at rest and sweating; cluster 3 (multiple symptoms cluster): high probabilities for all items.
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(13% echocardiogram, 10% X-ray, 7% exercise stress test, 
and 6% Holter monitoring).
 Chest pain in the week before hospitalization was re-
ported by 181 patients. Of the 31% of patients who sought 
the health care system, 55% used the public hospital and 
32% the primary care center. ECG was performed in 41%, 
a blood test in 39%, and other exams in 18% of these pa-
tients. Pain was attributed less often to a heart problem 
(25%) compared with the group of patients with pain in 
the preceding 6 months ( Fig. 1 ).
 Predictors of Health Care System-Seeking Behavior 
and of Performance of an ECG  
 Health care-seeking behavior and the performance of 
an ECG because of preceding chest pain were associated 
with different sociodemographic characteristics, risk fac-
tors, comorbidities, previous medical history, and clinical 
presentation during the index episode ( Table 2 ). 
 Predictors independently associated with entering the 
health care system because of chest pain within 6 months 
of the ACS are presented in  Table 3 . Patients with hyper-
tension (adjusted odds ratio, OR, 2.13, 95% CI 1.29–3.51) 
were more likely to seek health care assistance, while for-
mer smokers (OR 0.52, 95% CI 0.28–0.99) and patients 
who considered themselves to belong to an upper middle 
or upper class (OR 0.16, 95% CI 0.05–0.48) were less like-
ly to seek the health care system.
 Men were twice as likely to be referred to ECG as wom-
en (OR 2.56, 95% CI 1.11–5.87). ECG performance was 
also strongly associated with living in the northeastern 
region (9-fold more likely than among Porto residents) 
and being covered by a health subsystem (almost 4-fold 
more likely when compared with patients without such 
coverage). Cognitive impairment and being employed 
were inversely associated with the performance of an 
ECG ( Table 3 ).
 Discussion  
 Of patients admitted with a first ACS, 61% reported 
chest pain within the previous 6 months, of whom less 
than half reported seeking care and undergoing an ECG. 
In the week preceding the acute event, approximately a 
quarter reported chest pain, and less than a third of symp-
tomatic patients sought the health care system, mainly a 
public emergency department. Different demographic, 
socioeconomic – including geographic residence and 
health subsystem coverage – and cardiovascular risk fac-
tors were found to be associated with health care system-
seeking behavior and with referral to ECG. 
 In Portugal, the national health system (NHS) is “uni-
versal, comprehensive and almost free”  [18] . Besides the 
NHS, the Portuguese health system has 2 other coexisting 
and overlapping systems: special health insurance 
schemes for particular professions or sectors called the 
health subsystems, and private voluntary health insur-
ance  [18] . In contrast with other settings, there are no 
 Table 3.  Determinants of health system-seeking behavior among 
patients with preceding chest pain and performance of ECG 
among patients with pain who sought medical care
Adjusted OR (95% CI)
Health system-seeking behavior1
Sex
Female 1
Male 1.20 (0.66 – 2.17)
Age (per year) 1.00 (0.98 – 1.02)
Subjective social class
Lower/lower middle class 1
Upper middle/upper class 0.16 (0.05 – 0.48)
Refused to answer 0.56 (0.29 – 1.06)
Hypertension
No 1
Yes 2.13 (1.29 – 3.51)
Smoking
Never 1
Current 0.60 (0.31 – 1.14)
Former 0.52 (0.28 – 0.99)
Performance of ECG2
Sex
Female 1
Male 2.56 (1.11 – 5.87)
Age (per year) 0.99 (0.95 – 1.02)
Cognitive impairment
No 1
Yes 0.37 (0.15 – 0.92)
Region
Metropolitan area of Porto 1
Northeastern region 9.07 (4.07 – 20.24)
Employed
No 1
Yes 0.36 (0.14 – 0.97)
Health subsystem coverage
No 1
Yes 3.88 (1.11 – 13.53)
 1 Models adjusted for sex, age, subjective social class, hyperten-
sion, and smoking.
2 Models adjusted for sex, age, cognitive impairment, region, 
employment status, and health subsystem coverage. All indepen-
dent variables were included in the model as categorical, except age 
(continuous).
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specific units for chest pain evaluation in Portugal. Pa-
tients with new-onset chest pain who seek emergency 
care, either public or private, are evaluated by physicians 
of interdisciplinary emergency departments who may ask 
for an evaluation by a cardiologist. Among noninvasive 
imaging modalities for ischemia, the Portuguese NHS 
currently reimburses only exercise stress tests and myo-
cardial perfusion scintigraphy if referral is from the pri-
mary care. Furthermore, other noninvasive imaging mo-
dalities for ischemia are only available in some private 
and public hospitals. The private sector has protocols 
with health subsystems or private health insurance for 
medical consultations and for the performance of these 
noninvasive imaging modalities  [18] .
 Depending on the time span before the ACS to define 
preceding chest pain, on the setting (outpatient vs. inpa-
tient), and on the methodology used in other studies, the 
prevalence of chest pain before ACS varied  [4, 5, 19] and 
was higher for patients with non-ST elevation acute myo-
cardial infarction, in accordance with our results  [20] . A 
proportion of 61% for chest pain in the previous 6 months 
is similar to previous findings from the 1970s  [2] . As far 
as we know, no recent similar evidence is available to 
compare with our results. 
 Information on the reasons why people seek medical 
advice when symptoms of chest pain emerge is scarce 
 [21] , except in the context of myocardial infarction. So-
ciodemographic, symptom onset context, cognitive, af-
fective/psychological, behavioral, and clinical factors in-
fluenced prehospital delay among patients with myocar-
dial infarction  [22] . Furthermore, decisions regarding 
actions in response to the ischemic symptoms depend on 
patients’ preexisting ideas about coronary disease and the 
extent to which their symptom experience matches their 
expectations  [23] . 
 Almost 60% of patients reporting chest pain did not 
seek medical help. The perception of having a high social 
status, probably because of associated feelings of security, 
hope, and health  [24] , was associated with a lower prob-
ability of seeking help in our cohort. A possible explana-
tion for patients with hypertension being more likely to 
seek help for chest pain is the patient’s recognition of the 
role of hypertension as a cardiovascular risk factor due to 
health promotion activities, for example the “Portuguese 
Action against Salt and Hypertension.” Additionally, pri-
mary care centers have an organized management ap-
proach to patients with hypertension and the correct sur-
veillance of patients with high blood pressure can lead to 
1 of the family doctors’ financial incentives  [18] . The fact 
that current/former smokers of our cohort were less like-
ly to seek help due to chest pain may be at least in part 
related to a lower awareness of cardiovascular risk among 
smokers compared with hypertensive patients. Although 
Portugal introduced partial smoking-free legislation in 
bars and restaurants in 2008, the lack of funding for to-
bacco control limits media campaigns  [25] . Additionally, 
compared with hypertension, smoking cessation consul-
tations are not so well organized and are not a perfor-
mance indicator with financial incentive in the primary 
care sector  [18] .
 Most patients who reported preceding chest pain and 
sought medical help used the public sector, namely the 
general practitioner or the emergency department of a 
public hospital, the latter more often by patients with 
chest pain within the preceding week of the acute event. 
The fact that more than 75% of patients with an ACS, 
independently of reporting chest pain previously to the 
ACS or not, visited a primary care doctor in the preced-
ing year further strengthens the potential role of the pri-
mary care sector to improve recognition of myocardial 
ischemia and the management of risk factors. The type 
of health care professional seen appears to be moderated 
by the frequency and severity of acute chest pain  [26] . 
The low agreement in the risk stratification of patients 
presenting to the emergency department with chest pain 
between emergency department physicians and cardi-
ologists, even with the application of objective risk 
scores  [27] , contributes to illustrate the difficulties in di-
agnosis. 
 Pain was attributed to a problem of the heart in 39% of 
patients who reported chest pain over the previous 6 
months and sought medical help, and in a quarter of the 
subgroup who reported symptoms in the preceding week. 
Considering the high prevalence of noncardiac chest pain 
in the population  [28] , chest pain prior to an ACS might 
be nonischemic in some patients. However, for the sub-
group of patients with symptoms occurring closer to the 
index event, the probability that chest pain was cardiac in 
origin was higher and, strikingly, these patients less fre-
quently reported that chest pain was attributed to a prob-
lem of the heart. 
 The diagnosis of angina is challenging, mainly because 
it relies on clinical judgement  [9] . Depending on clinical 
and epidemiological characteristics, the probability of a 
patient with chest pain having CHD can vary from less 
than 10% to more than 90%. We evaluated reported chest 
pain in a cohort of patients with a high cardiovascular risk 
profile, therefore even if physicians considered chest pain 
to be atypical angina or noncardiac pain, a large propor-
tion, if not most, would not score low for pretest probabil-
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ity of CHD. Only for patients with a low pretest probabil-
ity (<15%) of stable CHD, no further investigation is 
needed to exclude the diagnosis  [9] . Referral to ECG was 
used as a surrogate for the intention of further investiga-
tion of possible cardiac chest pain, as this exam is the cor-
nerstone of the initial evaluation of patients whatever the 
type of health institution sought and is easily identified by 
patients. The low rates of performance of an ECG or oth-
er testing modalities, including exercise stress test (which 
was also low for the subgroup of patients who reported 
that pain was cardiac in origin), and the absence of per-
formance of myocardial perfusion scintigraphy and coro-
nary angiography, favor that inaccurate noninvasive cor-
onary ischemia testing may be one of the factors contrib-
uting to the misdiagnosis of symptoms of myocardial 
ischemia  [4] . Furthermore, the type of noninvasive test 
performed for diagnosing CHD suggests that the choice 
of the exam largely depended on physician preference 
and/or local availability  [29] . The fact that ECG is an 
exam with a wide availability and acceptability, with low 
costs and lack of contraindications, strengthens the hy-
pothesis that inaccurate clinical judgment and the pretest 
probability evaluation are other important determinants 
of misdiagnosis. 
 In our cohort, fewer women than men reported the 
performance of an ECG because of chest pain. The sub-
jective experience of symptoms influences professionals’ 
interpretation of clinical presentations  [30] . Atypical pre-
sentations among women  [31] , the perception of a lower 
risk of CHD compared with men  [32] , and gender bias in 
the use of investigations for patients with stable angina 
have been observed  [33] . Cognitive impairment was in-
dependently associated with a lower referral for ECG; 
poor communication is a factor contributing to the mis-
diagnosis of symptoms of myocardial ischemia  [4] . 
 Lower levels of psychological distress and health dis-
order observed in employed compared with not em-
ployed people have been attributed to employment status 
itself, rather than to demographic attributes and other so-
cioeconomic variables  [34] . This favorable profile of em-
ployed subjects may determine differences in perception 
and/or the communication of symptoms by patients and 
in the perception of CHD risk by physicians, and result in 
a lower probability for the performance of an ECG. 
 In Portugal, relative declines of CHD mortality indica-
tors between 1981 and 2012 varied by geographic region, 
with consistent decreases in mortality rates observed only 
in the most populated and urbanized regions  [35] . De-
spite the universal coverage of the NHS, resources and 
health professionals are concentrated in the major urban 
centers and along the coast, leaving the inland, specifi-
cally the northeastern region, underserved  [18] . Patients 
from the metropolitan area of Porto less often reported 
the investigation of chest pain by ECG. In contrast with 
referral for other diagnostic exams, for example coronary 
angiography which is highly related to accessibility to car-
diac catheterization laboratories  [36] , referral for ECG, 
an exam that is widely available, may depend more on 
physician attitudes. Meeting the expectations of patients 
or peers, as well as malpractice concerns, were some of the 
reasons found to explain the variation in physicians’ pro-
pensity to test and treat  [37] . 
 Finally, the health subsystem coverage increased the 
probability of the performance of an ECG. Cardiac test-
ing is more accessible and less expensive for patients with 
health subsystems, probably resulting in inequalities in 
diagnostic test performance between covered and not 
covered patients  [38] .
 Limitations  
 Information on preceding chest pain and having 
sought health care was self-reported by patients during 
the first days of hospitalization and therefore may be 
prone to recall bias. However, the decision to use a ques-
tionnaire instead of a medical record review was ground-
ed on 2 main limitations of the latter method: no informa-
tion about previous chest pain for patients with symp-
toms who did not seek health care system assistance, and 
for those who seek help but for whom no information is 
recorded (the physician might not register the case). The 
second limitation would be a lack of detailed information 
about health service utilization related with the pain.
 Correct identification of patients without previous 
ACS, percutaneous coronary intervention, or coronary 
artery bypass graft depends on high-quality data records. 
However, we assumed a high accuracy and completeness 
of reports, as these are variables systematically registered 
in discharge letters and electronic records of patients with 
ACS. 
 Selection bias due to patient refusal to participate and 
losses during recruitment are other potential limitations. 
For these patients, there is no information about the his-
tory of chest pain or of characteristics influencing the de-
cision-making process regarding seeking health care as-
sistance. Among the patients enrolled, the proportion of 
participation was high – only 6.9% did not answer the 
questionnaire about reported chest pain and heath care 
utilization. 
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Questionnaire
1. Besides this chest pain episode, have you had any other episodes?
□ (0) No □ (1) Yes □ (88) Do not know
1.1 Have you felt recurrent chest pain in the last six months?
□ (0) No □ (1) Yes □ (88) Do not know
1.1.1. Date of pain onset (dd/mm/yyyy)   __/__/____ 
1.1.2. Have you sought any health institution?
□ (0) No □ (1) Yes □ (88) Do not know 
1.1.2.1. If yes, which health institution did you seek? [point out several options]
□ (1) Primary care center □ (2) Public hospital
□ (3) Private hospital □ (4) Private clinic
□ (5) Other. Which one? _____________________ □ (88) Do not know
1.1.2.1.1. Have any ECG been performed? □ (0) No □ (1) Yes □ (88) Do not know
If yes, how many?   __ __
1.1.2.1.2. Have any blood tests been performed? □ (0) No □ (1) Yes □ (88) Do not know
If yes, how many?   __ __
1.1.2.1.3. Have other complementary diagnostic exams been performed? □ (88) Do not know  
□ (0) No □ (1) Yes If yes, which one/s? ______________
1.1.2.1.4. What did they say it was attributable to? [point out several options]
□ (1) Myocardial infarction
□ (2) Angina pectoris 
□ (3) One problem of the heart
□ (4) One problem not of the heart
□ (5) Nothing important
□ (6) Other. What? _______________
□ (88) Do not know
1.2. Have you had any acute episodes of chest pain in the last six months?
□ (0) No □ (1) Yes □ (88) Do not know 
1.2.1. If yes, how many episodes?   __ __ □ (88) Do not know
 Conclusions 
 Preceding chest pain was reported by most patients 
with a first ACS; however, less than half of them sought 
medical care or underwent an ECG due to those symp-
toms. There are potential broad opportunities to improve 
the diagnosis of myocardial ischemia before a first acute 
coronary event. Our results reinforce the need to explore 
patient and system barriers to access to appropriate care 
for patients with chest pain, and support the need of ef-
fective health education strategies for improving myocar-
dial ischemia symptom awareness and appropriate health 
care system-seeking behaviors.
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Episode 1 
1.3. Date (dd/mm/yyyy)   __/__/____
1.3.1 Have you sought any health institution?
□ (0) No □ (1) Yes □ (88) Do not know 
1.3.1.1. If yes, which health institution did you seek? [point out several options]
□ (1) Primary care center □ (2) Public hospital
□ (3) Private hospital □ (4) Private clinic
□ (5) Other. Which one? ___________________ □ (88) Do not know
1.3.1.1.1. Have any ECG been performed? □ (0) No □ (1) Yes □ (88) Do not know
If yes, how many?   __ __
1.3.1.1.2. Have any blood tests been performed? □ (0) No □ (1) Yes □ (88) Do not know
If yes, how many?   __ __
1.3.1.1.3. Have other complementary diagnostic exams been performed? □ (88) Do not know  
□ (0) No □ (1) Yes If yes, which one/s? ______________
1.3.1.1.4. What did they say it was attributable to? [point out several options]
□ (1) Myocardial infarction
□ (2) Angina pectoris 
□ (3) One problem of the heart
□ (4) One problem not of the heart
□ (5) Nothing important
□ (6) Other. What?  _______________
□ (88) Do not know
Episode 2
1.4. Date (dd/mm/yyyy)   __/__/____
1.4.1. Have you sought any health institution?
□ (0) No □ (1) Yes □ (88) Do not know 
1.4.1.1. If yes, which health institution did you seek? [point out several options]
□ (1) Primary care center □ (2) Public hospital
□ (3) Private hospital □ (4) Private clinic
□ (5) Other. Which one? _____________ □ (88) Do not know
1.4.1.1.1. Have any ECG been performed? □ (0) No □ (1) Yes □ (88) Do not know
If yes, how many?   __ __
1.4.1.1.2. Have any blood tests been performed? □ (0) No □ (1) Yes □ (88) Do not know
If yes, how many?   __ __
1.4.1.1.3. Have other complementary diagnostic exams been performed? □ (88) Do not know
□ (0) No □ (1) Yes If yes, which one/s? ______________
1.4.1.1.4. What did they say it was attributable to? [point out several options]
□ (1) Myocardial infarction
□ (2) Angina pectoris 
□ (3) One problem of the heart
□ (4) One problem not of the heart
□ (5) Nothing important
□ (6) Other. What?  _______________
□ (88) Do not know
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In this thesis, we evaluated inequalities in CHD in Portugal using process and outcome indicators, 
and focusing on sex/gender and region. We were able to identify specific targets for future research and 
improvement in the CHD equity and quality of care. We dismantled several of the steps of the complex 
CHD process of care; starting from outcomes, we moved backward until the symptomatic stage before an 
ACS, considering each step as an opportunity to promote CHD prevention. Selection of patient samples 
and sources of data, definition of variables, and analysis and interpretation of data implied judgment 
and choices, driven by the conceptual models of socioeconomic determinants of health and of access to 
health care and by the clinical knowledge of CHD care perceived by our team, a perspective that clinicians 
uniquely possess [112].
Data sources and methodology
Our objectives were pursued through different sources of data, each with different strengths and 
limitations, functioning as complementary between them.
Mortality data from CHD provided from Statistics Portugal was easy to obtain and in Portugal has 
universal coverage. Data availability by Nomenclature of Territorial Units for Statistics (NUTS) was set 
up by Eurostat at the beginning of the 1970s when dividing the European Union´s territories to produce 
regional statistics [265]. The last change in the classification of the Portuguese NUTS II territorial units 
was made in 2002 [266]. Stability of this classification is particularly relevant to the analysis of time-
series [267]. Quality of death certification, namely accuracy of causes of death and correct coding are 
also crucial to correctly interpret our results. One index of the quality of reporting causes of death is 
the proportion of deaths coded as ill-defined causes, which has decreased in Portugal [268]. Universal 
coverage and standardisation of procedures for the whole country reduces the probability of geographic 
differences in the quality of cause-of-death information, therefore ensuring a high level of comparability 
in mortality statistics by Portuguese region. Furthermore, changing or revising coding rules would have a 
greater impact if we were considering specific codes of diseases, but we studied the whole group of CHD.
Patient level data were obtained from two other sources, both cohort studies performed on a subgroup 
of CHD patients, those with an ACS. The EURHOBOP project’s main goal was the development of a tool to 
benchmark European hospitals in AMI and PCI, based on predicted in-hospital mortality. In 10 Portuguese 
hospitals, a comparison of ACS management between women and men was assessed by evaluating the 
performance of coronary angiography, and of reperfusion and revascularisation among patients treated 
invasively. Strengths of this database were consecutiveness, standardisation in the definition of variables 
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and process of collecting, and also the criteria used to select the Portuguese hospitals. The population 
studied was managed in hospitals that cover different regions, from North to South, including both coastal 
and interior regions, different human and material resources, and levels of specialisation. Limitations derive 
mainly from potential missing variables that could impact pre-treatment status and influence decisions on 
management, and a lack of information about timeliness of the procedures which would also be relevant. This 
is related with the fact that the variables were collected to the main goal of the European project, which was 
to provide a simple and precise benchmarking model, balancing parsimony and performance [138].
The EPIHeart study was the third data source, driven by the a priori hypothesis of inequalities in CHD in 
Portugal. Sample size, selection bias and losses to follow-up are potential limitations of the cohort, which 
were considered when analysing our results. The inclusion of two hospitals, that are both tertiary, cover 
two distinct populations in the northern region of Portugal, was relevant to the main objectives. The major 
strength is availability of detailed and standardised information on exposure, confounding and outcome 
variables that were very useful to further disentangle the complex ACS process of care. We ensured 
relevant aspects related with quality of data, namely correct identification of the type of ACS, appropriate 
evaluation of severity of the patient condition to determine whether they were appropriate candidates 
for performance measures, correct characterisation of the process of care to be able to compare it with 
the performance standard, data to perform risk adjustment of outcomes, to ensure that differences are 
attributable to care and not to underlying patient characteristics.
Inequalities in CHD management and outcomes in Portugal
The goal of reducing within country variations in CHD burden is considered a worldwide target [269]. 
By revealing that the CHD mortality decrease observed at the national level in the last three decades 
conceal different mortality trends by region (Paper 1), we have strengthened the relevance of this goal for 
Portugal, and we have further objectively identified what regions need special attention, namely Alentejo 
and Azores. Similar geographic CHD mortality disparities persisting over time were observed in other 
settings [270].
Available information by Portuguese region on sociodemographic characteristics of the population, 
allocation of health system resources, prevalence of risk factors, and on process indicators for CHD was 
used to provide insights into possible differences in outcomes by region. However, we were not able to 
objectively explain why those differences were observed to guide changes within each region and improve 
equity. This is one of the limitations of outcome process indicators pointed out by Donabedian [102].
Greater relative declines in CHD mortality observed for women compared to men were found in most 
Portuguese regions, the result of effective primary and secondary prevention strategies directed to 
women. Considering evidence of stagnation in the decrease in CHD mortality in young adults, especially 
women observed in other settings [271], our results are encouraging but do not obviate the relevance of 
continuously monitoring.
Moving toward to the patient level and to management of ACS, we found differences in the conservative/
invasive approach between women and men with STEMI and ACS with LBBB, but not with NSTEACS. Women 
with STEMI/NC ACS were the subgroup of patients who had the highest in-hospital mortality (Paper 2). 
The first and noteworthy factor limiting the comparison of our results with available data gathered 
from national registries, namely with data from the Portuguese Registry of Acute Coronary Syndromes 
and with the Portuguese National Registry of Interventional Cardiology, is related with the lack of report of 
results of the registries by sex [157,260]. Furthermore, these registries only cover cardiology departments, 
participation is voluntary and consecutiveness of patients within participating centers is not assured. 
Nevertheless, some remarks can be made.
According to results of the national registry from the 2002-2008 period, coronary angiography was 
performed in 62% of the whole sample [157], slightly lower than the observed in our sample. Compared with 
the same results, the proportion of patients undergoing revascularisation was higher in our cohort (66.9% vs 
38%) [157]. Data from the registry reported to the 2010-2013 period showed a higher proportion of patients 
managed invasively (84.8%), probably an overestimation of the true proportion, due to the overrepresentation 
of patients admitted to hospitals with high level of specialisation. The differences in ACS epidemiology and 
outcomes observed between the ten Portuguese hospitals included in EURHOBOP, although deserving 
further research, strengthen the importance of including patients admitted to hospitals with different levels 
of specialisation, to better represent the whole ACS population of patients.
According to data from 2008, Portugal was among the countries performing less primary PCI in Europe 
[272]. Authors who participated and analysed these results considered that the main factor explaining this 
finding was the high proportion (55%) of patients admitted more than 12 hours after symptom onset [157,260]. 
Although our results are in line with the increasing proportion of reperfusion, and by primary angioplasty 
relative to fibrinolysis observed in Portugal (from 2002 to 2013, there was a three-fold increase in primary 
angioplasty rates per million population) [260], the significant difference of management between women 
and men with STEMI/ non-classifiable (LBBB) ACS of our cohort deserves attention. Our large consecutive 
sample, the inclusion of hospitals with different characteristics and the possibility of taking several potentially 
important confounders into account strengthens this finding.
For our third objective, which was drawn with the intention of further analysing differences in 
management and outcomes between women and men with CHD, we opted to use QIs for the management 
of AMI developed by ESC/ACCA [133] (Paper 3). The decision to use this tool to investigate potential sex 
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inequalities was supported by several reasons. They link evidence and quality assessment; were proposed 
by the ESC, taking into account recent European guidelines; include different domains across several 
indicators for evaluating the key aspects of the complex AMI care pathway; they include an outcome 
indicator, 30 day mortality adjusted for the GRACE 2.0 risk score and the possibility of evaluating its 
association with management.
STEMI patients were considered eligible for reperfusion if admitted within 12 hours from symptom 
onset. The very high proportion of reperfusion observed for this subgroup of STEMI patients supports the 
previous hypothesis of delayed presentation in Portugal to be one main factor explaining low proportions 
of reperfusion, compared with other European countries. But this encouraging result became disappointing 
when we looked to the indicator related with timeliness of reperfusion. A low level of timely reperfusion 
was observed, significantly lower for women than for men (21.1% vs 33.5%, p=0.041). Although primary PCI 
remains the optimal reperfusion strategy for patients with STEMI, recommended timelines seem to be 
not met in Portugal. Not all the closest hospitals have the capability to perform primary PCI, therefore a 
significant number of patients will need to have an ambulance bypass the closest hospital or be transferred 
from non-PCI hospitals (in our cohort 36.1% of AMI patients). According to our results, looking to timely 
reperfusion of patients admitted to non-PCI capable hospitals is particularly relevant. In other developed 
countries, also with an organized transfer system for STEMI such as Denmark, 65% of transferred STEMI 
patients experienced a system-related delay (time from first contact with the health care system to the 
initiation of reperfusion therapy) of greater than 120 minutes, which was independently associated with 
increased mortality [273]. If the step forward in Portugal should target patient and health system barriers 
to achieve the target time windows for primary PCI for all patients or should identify settings where timely 
primary PCI is accepted as not being achievable, and where a formal proposal of the pharmacoinvasive 
strategy (fibrinolysis followed by coronary angiography) as standard of care would be more effective and 
safer should be evaluated [96].
We observed similar proportions of pharmacological therapy for secondary prevention prescription, 
when comparing with previous results from our team [274]. The lower proportion of eligible women 
discharged on dual antiplatelet therapy was previously observed for women with STEMI in the Portuguese 
sample of EURHOBOP [274]. With the analysis of statins type and doses, we uncovered a poorer compliance 
for high intensity dose statins following AMI, and also another sex gap in management. Referral to cardiac 
rehabilitation was significantly lower for women, compared to men. Recently published results from the 
2013-14 national survey on cardiac rehabilitation in Portugal were not reported by sex. According to these 
data, 8% of patients with AMI were admitted to phase II cardiac rehabilitation program in 2013, while in 
2007 the correspondent number was 3% [275].
The very low level of performance of the GRACE and the CRUSADE risk assessment among women and 
men is particularly relevant. Besides its better risk discrimination when compared with physician estimated 
risk [84], decisions on place, type and time of acute management should be made according to its calculation 
[45]. Considering the low level of the GRACE risk assessment for NSTEACS patients of our cohort, time 
of coronary angiography most often was not based on its calculation. These QIs propose the timeline of 
72 hours from admission as a standard performance measure for NSTEMI coronary angiography, although 
guidelines advise procedures within two hours and 24 hours from admission for very-high and high risk 
patients, respectively [45]. This is a very objective example of the difference between guidelines and QIs 
statements. This decision about considering the 72 hours timeframe for all NSTEMI patients is in accordance 
with the Dutch position [276]. The Dutch ACS working group appointed several reasons to not consider 
referral within 24 hours to be a necessity for their situation: the lack of strong support to an early invasive 
approach from available meta-analysis; the argument that the TIMACs trial results were only a hypothesis-
generating result in a trial which did not show a significant reduction of the primary endpoint of death or 
myocardial infarction; results of the Invasive versus Conservative Treatment in Unstable coronary Syndromes 
(ICTUS) trial showing good results with a more conservative (selective invasive) treatment of NSTEACS 
patients [277]; and reasons related with the Dutch specific organisation of the health care system [276].
Despite the low number of deaths, women had almost twice the GRACE 2.0 risk score 30-day mortality 
rate compared with men. Mortality was inversely associated with the composite QI, which captures several 
steps from the AMI care pathway. This association is conceptually relevant, favouring the future use of 
this composite QI to improve quality of care of AMI patients. Obviously, not all determinants influencing 
outcomes are included in this composite QI. For example, besides timely invasive strategy, the intensity 
(dosage, combination, and duration) of periprocedural antithrombotic treatment largely varies and can 
also influence outcomes [278].
Presenting symptoms of ACS, by impacting health care seeking/reaching, and also diagnosis, are 
critical for ACS management, and particularly may impact eligibility for reperfusion of STEMI patients. 
The decision to analyse differences by sex in clinical presentation of ACS was strengthened by results of 
previous papers and supported by the conceptual frameworks of our research hypothesis (Paper 4).
With the application of a structured questionnaire within the first 48 hours after admission, we 
distinguished direct and referred pain, we evaluated symptoms other than pain and their clustering, 
activity at the onset of the episode and stress triggers. This detailed information, and the adjustment 
for several confounding variables strengthens our results. Previously, it has been reported that 63% of 
patients admitted to a tertiary Portuguese hospital with an ACS were not able to correctly interpret their 
symptoms, namely to attribute them to a problem of the heart, and that women were less likely to correctly 
interpret the clinical presentation of ACS compared with men [279]. Several factors can contribute to this 
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lower illness perception of women, clinical presentation itself is probably one, namely the more frequent 
occurrence of multiple symptoms other than pain, common to other cardiac and non-cardiac diagnoses, 
among women. The possible impact on outcomes of presenting with the multiple symptoms cluster, 
considering that these patients had a higher mean 30-day mortality adjusted for GRACE, deserves further 
research. Patients` interpretation of ACS symptoms is a known cause of delay in reaching the hospital 
[280], directly influencing the seeking health care decision and behaviour, but also, correct interpretation 
of symptoms by professionals. We did not find significant differences between clinical presentation by 
type of ACS, namely STEMI/non-classifiable ACS and NSTEACS, therefore the decision to analyse them 
together. However, and considering women with STEMI have a lower probability of performing coronary 
angiography and timely reperfusion, the association between clinical presentation and patient and system 
delays may have a stronger impact for women with STEMI.
A first ACS already signals the failure of primary prevention, thus the relevance to CHD prevention to study 
chest pain, health resource seeking and utilisation before the acute event (Paper 5). Patients with a first 
episode of ACS very frequently reported preceding chest pain, which triggered health seeking behaviours 
and medical investigation in less than half. Demographic, socioeconomic characteristics, region, health 
subsystem coverage and risk factors accounted for differences in seeking medical care and performance of 
investigation through ECG. In a context of universal coverage health system, we were able to identify barriers 
in access both in the demand and supply determinants, and therefore opportunities for CHD prevention.
Chest pain is a common presentation to primary care and emergency departments worldwide. The care 
of these patients is challenging and has a high impact, both because timely diagnosis of several of its 
causes, namely of CHD, is of paramount importance for patient well-being and survival; but also because 
ruling out serious causes of chest pain, and diagnosing non-cardiac causes is determinant to avoid 
unnecessary occupation of health services, exams and to reduce costs. This task is difficult, diagnostic 
tools have not shown appropriate acuity to rule out ACS in patients with chest pain [281]. The model of 
Chest Pain Centres was initiated in 1981 in one hospital in Baltimore, while in 1998, the Society of Chest 
Pain Centres was created to improve evaluation of patients with symptoms suggestive of ischemia [282]. 
Some European countries, including the United Kingdom and Germany adopted this model, and created 
chest pain units (CPUs) to manage patients with acute chest pain. The German Cardiac Society runs a 
nation-wide certification campaign for specialised CPUs. According to data which reports to October 2015, 
228 CPUs have been successfully certified in Germany and 300 CPUs were needed for full coverage and to 
close gaps in rural regions [283]. Between December 2008 and June 2014, about two-thirds of the patients 
admitted to CPUs in Germany received transthoracic evaluation [284], while for the period between 
January 2010 and April 2011, only 5.4% underwent cardiac computed tomography during the index CPU 
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stay [285]. The authors concluded that the use of cardiac computed tomography should be reconsidered 
during the next update of the CPU certification criteria [285]. Evidence supports the association between 
implementation of CPUs and prognosis of patients with ischemic origin of the symptoms, with additional 
cost-saving [286,287].
Public health implications
Our results support that tackling CHD inequalities in Portugal requires policies and investment at 
the population, patient and health system levels. The Commission on Social Determinants of Health 
recommended three aims of intervention to reduce health inequalities, namely to improve daily living 
conditions; to address inequitable distribution of power, money, and resources; and to measure and 
understand the problem and assess the impact of action.
We gave important insights to select targets and operational tools for the latter aim of intervention. First, 
we identified the need to improve the availability of high quality, timely and reliable disaggregated data by 
age, sex/gender, socioeconomic position and geographic location, including determinants of incidence and 
outcomes of CHD. Mortality data from Statistics Portugal should be analysed and reported by region and 
sex; the sex-gap in analysis and report of results from the National Registries of ACS and of Interventional 
Cardiology should also be improved. There is a need to further study differential barriers to access to effective 
and timeliness reperfusion and secondary long term management between women and men with an ACS in 
Portugal and to monitor trends; these two data sources should be used for this purpose.
Given the dynamic nature of populations, of patients, of the health care system and of medical sciences; 
adaptable quality assessment and improvement programs are increasingly considered the foundation to 
reduce inequalities in cardiovascular health, Portugal is not an exception. Working groups in Portugal need 
to link the adjustment of international guidelines on the management of CHD to our national context, with 
quality assessment. The introduction of standardised quality indicators for management of ACS would 
improve quality of care and enable hospital benchmarking. Our results support that time dependent 
QIs for ACS should be selected and that appropriate risk adjustment is of particular relevance to study 
inequalities; the ESC/ACCA QIs for management of AMI proposal would be a good tool to start this work.
Health promotion strategies, at the population and individual levels, with focus on symptom awareness 
as well as on prompt and adequate health system seeking behaviours of patients with symptoms 
suggestive of ischemia should be evaluated through epidemiological research [288]. Eventually, it would 
also be useful to study the cost-effectiveness of implementing other models of organisation for evaluating 
patients with chest pain, namely the CPUs model, in Portugal.
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This thesis gave valuable insights about inequalities in CHD management and outcomes in Portugal. 
Focusing on sex/gender and region, we identified vulnerable groups of patients warranting intervention in 
Portugal, and also explored the dependence and interactions of factors that make the overall process of 
CHD management and outcomes complex to understand.
In Portugal, between 1981 and 2012, relative declines of CHD mortality indicators were different by 
geographic region, and greater declines in mortality rates were observed among women compared with 
men. Despite this encouraging result on mortality from CHD as a whole among women, we were able to 
identify targets to intervene to further reduce the sex/gender gap in management and outcomes from CHD, 
namely among women with STEMI, specifically in the reperfusion-invasive strategy; but also differences in 
the long term secondary prevention of AMI in general. The complexity of measuring clinical presentation of 
ACS is relevant, as our research underlined, and poses methodological challenges to include this variable 
in risk adjustment models. It is particularly relevant to understand inequalities in CHD management and 
outcomes by sex, considering the potential role of atypical ACS presentation in patient and system delays, 
and its impact on management, and consequently on outcomes. We identified opportunities to an earlier 
diagnosis and treatment of patients with CHD. Furthermore, we have found several determinants of the 
flow through the health system of patients with chest pain before the first ACS. Risk factors and subjective 
social class were associated with health care seeking behaviour; while gender, cognitive status, region, 
employment status and health subsystem coverage were associated with performance of ECG.
These findings strengthen that interpretation of health inequalities research results implies a profound 
clinical knowledge of the specific clinical condition, and also understanding of controversial issues related 
with measuring and analysis methodology. This thesis supports that CHD should be included as one of the 
target diseases in the “equity and adequate access to health care” goal, set by the Portuguese National 
Strategy for Quality in Health 2015–2020. Furthermore, our results support that interventions to promote 
equity and quality of CHD care should be directed not only to the health care system, but also to patients 
and to the general population.
5. CONCLUSION
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“The landmarks of political, economic and social history are the moments when some condition 
passed from the category of the given into the category of the intolerable. I believe that the history 
of public health might well be written as a record of successive re-definings of the unacceptable.” 
Sir Geoffrey Vickers, 1958
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